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 ABSTRACT 
Investigations into the metabolic requirements for lipoic acid and lipid species 
during the life cycle of the malarial parasite Plasmodium berghei. 
Brie Falkard 
 
Plasmodium, like many other pathogenic organisms, relies on a balance of synthesis and 
scavenging of lipid species for replication. How the parasite creates this balance is particularly 
important to successfully intervene in transmission of the disease and to generate new 
chemotherapies to cure infections. This study focuses on two specific aspects in the field of lipid 
biology of Plasmodium parasites and their hosts. Lipoic acid is a short eight-carbon chain that 
serves a number of different functions with the cell. By disrupting a key enzyme in the lipoic 
acid synthesis pathway in the rodent species of malaria, Plasmodium berghei, we sought to 
investigate its role during the parasite life-cycle. Deletion of the lipoyl-octanoyl transferase 
enzyme, LipB in P. berghei parasites demonstrate a liver-stage specific need for this metabolic 
pathway. In order to explore the impact of the fatty acid and triglyceride content on the 
pathogenesis of Plasmodium parasites, this study tests two methods to reduce lipid content in 
vivo and test the propagation of P. berghei parasite in these environments. Results from this 
study set forth new avenues of research with implications for the development of novel 
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I: Lipid metabolism is essential for the pathogenesis of malaria parasites, yet there is a limited 
understanding of the role of enzymes outside the canonical fatty acid synthesis pathway (Fatty 
Acid Synthase-II). Lipoic acid is an eight carbon chain that is a required cofactor of multi-
subunit complexes and has both synthesis and salvage pathways in Plasmodium. In parallel, a 
novel approach to malaria vaccine development is the generation of genetically attenuated 
parasites that arrest within the liver-stage of development and confers protection to subsequent 
challenges. Our specific aims include determining the essentiality of the lipoic acid synthesis 
pathway within the life-cycle of rodent malaria parasites, Plasmodium berghei. Additionally, we 
sought to test the hypothesis that lipoic acid synthesis is required for the completion of liver-
stage development and parasites disrupted for PbLipB could serve as genetically attenuated 
parasite (GAP) vaccine candidates.  
 
II: The nutrient conditions of the host are likely to play an important role in the pathogenesis of 
Plasmodium parasites and the severity of malaria as a disease. Our aim is to test how lowering 
the levels of fatty acid and triglycerides in mice will affect the rates of blood-stage and liver-
stage growth of Plasmodium berghei parasites. We are testing for any differences between two 
methods of lowering lipid species in mice. In our first method, we use clofibrate, a chemical 
agent that induces beta-oxidation of fatty acid species in the liver. In the second, we take 
advantage of the ΔXBP1 knock-out mouse that has a lower level of lipid synthesis in the liver. 
We seek to demonstrate that these model systems have reproducibly lower lipid species in vivo 





Malaria has been noted in human history for more than 10,000 years. The first evidence of 
malaria parasites in mosquitoes is from preserved amber from the Palaeogene period, 
approximately 30 million years ago 1. Human malaria likely originated in Africa and has 
coevolved with the mosquito vector and non-human primates, enabling its pathogenesis as a 
vector borne disease. The impact malaria on the human species can be traced back as early as the 
introduction of agriculture in human history. One consequence of its presence is the evolution of 
blood disorders that confer an advantage against infection, in particular sickle-cell disease and 
thalassemias 2. 
 
The name “malaria” comes from the Medieval Italian for “bad air,” because to the Ancient 
Romans this disease originated in the horrible fumes from the swamps. However the disease also 
affected populations beyond Europe. Medical writings dating from 2700 BC from ancient China 
describe characteristics of the disease. They noted the clinical symptoms as periodic fevers in 
addition to enlarged spleens and a pattern of epidemics. In a Sanskrit medical treatise dating back 
to the 6th century BC, the symptoms of malarial fever were described and attributed to the bites 
of certain insects. By the 4th century, malaria became widely recognized in Greece and was 
responsible for the decline of many of the city-state populations 
(http://www.cdc.gov/malaria/about/history/). 
 
However the identification of the causative agent of malaria, Plasmodium parasites, wasn’t made 
until 1880 by Charles Louis Alphonse Laveran, a French army surgeon stationed in Algeria. He 
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made the discovery from the blood of a patient suffering from the disease and his work was 
awarded the Nobel Prize for Medicine in 1907 2. Applying the principles of Louis Pasteur, that 
most infectious diseases are caused by microbial germs, Laveran studied the disease in order to 
identify its casual agent. Laveran called the organism he found, Oscillaria malariae, and 
hypothesized that it is the causal agent for the disease of malaria 3. 
 
PHYLOGENY 
Malaria is caused by Plasmodia protozoans, belonging to the phylum of Apicomplexa that 
consists of a large group of protists. The name refers to their apical complex that enables the 
parasite to invade host cells. The group of protists also contain a unique organelle called the 
apicoplast, a non-photosynthetic, plastid. The apicoplast organelle is essential for parasite 
survival and is thought to originate from a secondary endosymbiotic event that gave rise to its 
four-membrane structure 4. In the mosquito-specific infectious stage, sporozoite, the parasite 
contains three distinct structures for the apical complex. The apical complex consists of 
microtubules, a secretory body (the rhoptry) and one or more polar rings. Slender electron dense 
secretory bodies known as micronemes are also present. Structures pertaining to motility, such as 
the flagella, are only present in gamete stages of the disease 5. The literature annotates over 200 




Figure 1.1. The phylogenic lineage of Plasmodium species 
Schematic representation of the common lineage of Plasmodium parasite strains. (r) Refers to 
rodent infective malaria species; (h) human infective malaria species; (s) simian infective malaria 
species; (rp) reptile infective malaria species; (a) avian infective malaria species. The figure is 
adapted from 6.  
 
There are four species of Plasmodium that are known to be specific to humans, Plasmodium 
malariae, Plasmodium ovale, Plasmodium vivax and Plasmodium falciparum. Plasmodium vivax 
and Plasmodium ovale are distinguished by the formation of hypozoites, a dormant stage of the 
parasite that can remain in the liver for months to a year after the initial infection 7. Recently, 
Plasmodium knowlesi, a species known to infect macaques, has also been shown to infect human 
hosts 8. The human-infective species are remotely related to each other, suggesting that 
adaptation to humans has occurred several independent times 9. The last common ancestor of P. 
falciparum and the chimpanzee parasite P. reichenowi occurred around the time of the human-
chimpanzee divergence 10. However, recent studies place P. falciparum within the clade of 
gorilla-derived sequences, providing evidence that P. falciparum is of gorilla origin 11. 
Phylogenetic analyses of full-length mitochondrial sequences demonstrated that the human 
pathogen P. falciparum forms a monophyletic lineage with P. falciparum species that infect 
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gorillas, indicating that both parasite strains are descendants from a single common ancestor. It 
remains to be determined when P. falciparum entered the human population and whether 
present-day ape populations represent a source for recurring human infection 12. 
 
CLINICAL MANIFESTATIONS OF DISEASE 
As mentioned previously, the recurring clinical symptoms of regular cycles of fevers and chills 
has been documented in many civilizations, during infection with different Plasmodium strains. 
The key clinical symptoms of malaria are regular cycles of fevers and chills, anemia and an 
enlarged spleen. Mortality occurs in children under 18 months due to severe malarial anemia. 
These clinical manifestations of the disease typically begin approximately two weeks after the 
bite of an infectious mosquito, when the parasite has completed liver stage development. 
Synchronized invasion, development and lysis of the red blood cell, releasing daughter parasites, 
trigger the immune response to generate the cycles of fevers and chills.  
 
The clinical outcome of infection is dependent on the species of parasite, the host and geographic 
and social factors. These factors include the host age, previous exposures to the parasites and the 
general health of the patient. Access to health care and medications also greatly influences the 
clinical outcomes of an infection. An infection can develop into sever malaria or cerebral malaria 
depending on the patient. Severe malaria is considered to be much more complicated than 
originally thought 13. The clinical pattern of severe malaria differs between non-immune adults 
and semi-immune children. Cerebral malaria is a form of severe malaria, typically involving 
sequestration of the infected erythrocytes in the brain tissue 14. Cerebral malaria is the primary 
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Malarial infection of the mammalian host begins with a bite from an infected Anopheles 
mosquito, injecting sporozoites into the dermis 16 (Figure 1.2). The number of sporozoites that 
are inoculated by a mosquito on average is relatively low. The range of sporozoite inoculated is 
between 0 and 1,297, with a mean number of 123 and a median of 18 17. Sporozoites can remain 
in the skin for hours before entering the blood stream or being cleared by the local draining 
lymph node 18. Only a third of the transmitted sporozoites penetrate a blood vessel and 
potentially reach the liver 19. The parasites that end up in the draining lymph node induce a 
strong cell-mediated immune response. This immune response may contribute substantially to 
immune protection against subsequent challenges 18. Sporozoites that enter the blood stream will 
migrate to the liver where they can establish an infection in hepatocytes. At this point of 
development, the parasite loses its apical complex and surface coat and transforms into a 
trophozoite.  
 
Inside the hepatocyte, a single sporozoite can develop into tens of thousands of daughter cells 
known as merozoites. Development in the liver takes approximately 5 - 7 days for P. falciparum 
infections. Additional discussion of the process of sporozoite invasion of hepatocytes and liver 
stage development is provided below in the section entitled “Liver Stage.” Merozoites are 
released into the blood stream upon completion of liver-stage. Parasites begin the asexual blood 
stages of development following the initial invasion of erythrocytes. All Apicomplexa adopt a 
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common mode of host-cell entry, utilizing a specific set of ligand-receptor interactions. The 
adhesins connect to a parasite actin-based motor, enabling the parasite to invade the host cell 20. 
Inside the red blood cells (RBC), the parasites develop from the ring stage to the trophozoite and 
finally mature into a schizont. The eventual membrane rupture of the infected erythrocytes, 
achieved using orchestrated events of proteolysis, releases the daughter cells as well as 
erythrocyte debris and hemozoin pigment in the circulatory system of the human host. 
Erythrocyte lysis can lead to anemia and in cases of higher parasitemia (>4% red cells infected) 
leads to severe malarial anemia. The blood stage of development takes 48 hours for Plasmodium 
falciparum, P. vivax and P. ovale. The erythrocytic cycle last 72 hours for P. malariae. 
 
The life cycle of Plasmodium parasites inside the mosquito host begins with the ingestion of 
gametocytes from the mammalian host. Gametocytes, the sexual form of the blood-stage 
infection, develop as a subset of the asexually replicating population in the blood stream. These 
forms are ingested during a mosquito bite and therein begin a process of sexual reproduction 
within the mosquito host 21. 
 
After ingestion by the mosquito, the male and female gametocytes are released from their red 
blood cells in response to environmental changes including temperature and pH 22. Gametocytes 
quickly give rise to sexual gametes, which fertilize in the midget lumen to form zygotes. The 
zygote form develops into motile ookinetes, which invade and traverse the midget epithelium 
between 12 to 24 hours after blood ingestion. Ookinetes are diploid and undergo meiosis upon 




Figure 1.2. The Plasmodium life cycle 
Sporozoites are inoculated into a mammalian host through the bite of an infected mosquito. 
Sporozoites migrate into the liver of the host and begin to rapidly multiply and replicate, 
generating thousands of daughter cells. These merozoites escape the infected hepatocyte when 
the parasitophorous vacuole membrane begins to break down and are released into the 
circulation. Blood stage asexual replication begins when a merozoite invades a red blood cell. 
The parasite develops into the ring, trophozoite and schizont forms in the infected erythrocyte. A 
subset of the blood-stage parasites switch into the sexual gametocytes forms which when 
ingested by a mosquito develop inside that host. The gametes generate oocysts in the midget and 
sporozoites in the salivary glands. Image taken from 23.  
 
which undergo several rounds of mitosis as they mature. Each oocyst releases thousands of 
haploid sporozoites into the mosquito hemocoel. These sporozoites travel through the 
hemolymph and invade the salivary glands 24. The mosquito immune responses are important 
factors in determining sporozoite development 25. Sporozoites are transmitted to a new vertebrate 
host during an infective bite. One recent study predicted that if the approximately 10,000 
gametocytes were ingested in a blood meal, then on average only 1,000 ookinetes would 
successfully develop, and fewer than 5 would survive to develop into oocysts 25. Therefore this 
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stage of the life-cycle offers a bottle-neck during parasite replication when its numbers are 
relatively small.  
 
PARASITE SEQUESTRATION 
A key feature of the pathogenesis of Plasmodium falciparum is its ability to sequester the 
infected red blood cells in the microvasculature of the infected host, thereby preventing clearance 
into the spleen. The parasite adheres to tissues through the generation of electron-dense 
protuberances or ‘knobs’ that protrude from the infected red blood-cells and enable the infected 
cell to adhere to essential organs 26. Several complications occur due to the sequestration of 
infected erythrocytes in the microvasculature, such as cerebral malaria, acute renal failure and 
placental malaria 17. The obstruction caused by sequestered parasites causes the release of 
cytokines, nitric oxide and other host mediators 20. 
 
IMMUNE EVASION 
In addition to the pathogenic feature of sequestration in the human host, malaria parasites also 
have the ability to evade the immune system by their ability to undergo antigenic variation. 
Antigenic variation enables parasites to display a diversity of antigenically distinct Pf 
Erythrocyte Membrane Protein 1 (PfEMP1) proteins (encoded by the var gene family) on the 
surface of the infected red blood cell. The parasite will only express one var gene at any time. 
This process is known as antigenic or clonal variation. Switching its surface protein leads to 
evasion the immune response and subsequent expansion of the clone, causing a new wave of 
parasitemia 24. The large family of var genes is primarily located in subtelomeric regions of the 
P.f. chromosomes. Strains are thought to typically encode 60 var genes 27. PfEMP1 proteins are 
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trafficked from the parasite to Maurer’s clefts that enable expression on the surface of the 
erythrocyte membrane. Expression of the other variant gene families, including rifin, steavor and 
Pfmc-2Tm which all have stage specific expression. Rif genes are expressed during the 
trophozoite stage and steavor and Pfmc-2tm are expressed during the mature trophozoite stages 
27. Adhesion between infected and uninfected erythrocytes can form “rosettes” in the 
microvasculature 28. Expression of var, rifin and steavors also occurs in gametocytes 21. 
Gametocytes can also express variant genes other than those expressed by their asexual 
progenitors. Human antibodies that block binding of infected erythrocytes to host cells are 
important determinants of protective immunity to severe malaria. 
 
Parasitized red cell surface proteins bind to a set of host receptors. Host receptors CD36 and 
ICAM-1 are the major receptors in the adhesion of most P. falciparum-infected cells 29. These 
glycoproteins are expressed on vascular endothelial cells and are bound by certain forms of 
PfEMP1 30.  PfEMP1 adhesion to chondroitin sulfate A (CSA), a glycosaminoglycan on the 
placenta, is the likely interaction enabling the accumulation of infected erythrocytes in the 
placenta 31. Placental malaria is a severe condition that can cause substantial morbidity in women 
and will increase the risk of low birth weight or still-birth of the developing fetus. 
 
EPIDEMIOLOGY 
There are currently close to 3 billion people at risk of malaria infection, an entirely preventable 
and treatable disease. In 2010, there were an estimated 655,000 deaths due to malaria and 216 
million cases, the majority of are children under the age of 5 32. Most malaria cases and deaths 
occur in sub-Saharan Africa, yet many regions of Asia, Latin America, and to a lesser extent the 
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Middle East are also affected. In 2010, malaria was present in 106 countries and territories 
around the world. Of the five species of Plasmodium parasites that can cause malaria in humans, 
P. falciparum is the most predominant in Africa 33. 86% of deaths globally were children.  
 
The geographic and social factors that impact the clinical outcome of the disease include access 
to treatment, political stability of the country, transmission intensity of the Anopheles mosquito, 
including the season of the transmission and the number of infectious bites per year 12. In 
particular, the mosquito determinants of disease progression in the host include the mosquito 
lifespan, behavior, genetic susceptibility and degree of Victoria competence 34. Environmental 
factors, in particular the recent effect of climate change, have dramatically altered the landscape 
of malarial endemicity 35. Temperature, rainfall and humidity affect the replication, maturation 
and viability of Plasmodium in mosquitoes. Social factors that influence the health outcomes 
include attitudes and behaviors that affect whether they seek treatment or follow through with the 
treatment regime 36. 
 
The species of parasite also has an enormous impact on the clinical outcome of the disease. P. 
falciparum and P. vivax can cause severe anemia, but only P. falciparum can cause 
complications including cerebral malaria, hypoglycemia, metabolic acidosis and respiratory 
distress 23. P. falciparum can invade a large percentage of red blood cells, more likely to create 
anemia and is generally more lethal. P. vivax replication is limited to reticulocytes, immature red 
blood cells, that leads to lower levels of parasitemia. P. vivax is limited to cells that express 
Duffy antigens because of the way it invades red blood cells. In regions of the world where the 
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population is largely Duffy blood group negative, for instance, West Africa, P. vivax has 
essentially disappeared 37. 
 
There is also a close relationship between malnutrition and malaria. Because many malarial-
endemic areas suffer food shortages, the resulting malnutrition increases the risk of death from 
infectious diseases due to deficiencies in the immune system. Malnutrition is arguably the most 
common cause of immunodeficiency world-wide 38. Malnutrition leads to dysfunctions in the 
immune system, leaving the population very vulnerable to infections. Children with severe 
malnutrition (<70% normal weight/ height) have a markedly increased risk of mortality, often 
due to infection. Malnourished children with high parasitemias may show no common symptoms 
of infection, can develop severe malaria very quickly and may die without access treatment. 
 
In the case of Africa, the fact of a country being in a malarial endemic area lowers its gross 
domestic product (GDP) by an average of 1.3% annually 32. The economic costs of malaria 
endemicity to the growth of developing country are enormous. In addition to medical costs of 
treatment, loss of productivity including time away from school for children’s education and 
work for adults significantly contribute to the reduction in GDP 39. 
 
CONTROL, ELIMINATION, ERADICATION 
In 2007, the Bill and Melinda Gates Foundation called for a renewed effort at achieving global 
malaria eradication 40. Control of the disease implies that the number of malaria cases is 
manageable within the context of the local and regional population. Elimination of malaria is 
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particular to the country and population, however global eradication of malaria would mean 
permanent elimination of the parasite.  
 
The Roll Back Malaria partnership launched its goals for achieving malaria eradication as the 
Global Malaria Action Plan in 2010 (http://www.rollbackmalaria.org/gmap/index.html). Its main 
objective was the reduction of the number of preventable malaria deaths to nearly zero by 2015 
(http://www.who.int/malaria/world_malaria_report_2011/en/). These goals require the 
combination of several different strategies to reduce malaria infection and transmission.   
 
The major approaches for malaria control include the prevention of new infection and successful 
case management. This includes methods to block the transmission of parasites and prevent new 
infections. Intervention of malaria transmission is a combined effort, hitting several of the points 
of the Plasmodium life cycle. Vector control would both protect individual people against 
infective malaria mosquito bites and to reduce the intensity of local malaria transmission at the 
community level 32. 
 
The most powerful interventions are long-lasting insecticide-treated nets and indoor residual 
spraying using DDT 32. Indoor residual spraying involves the application of residual insecticides 
into the inner surfaces of dwellings, to effectively control malaria transmission, reducing the 
local burden of morbidity and mortality. Protection from people getting bitten by infected 
mosquitoes operates by preventing contact through the use of the insecticide-treated bed net. The 




Proper diagnosis and effective treatment are also important long-term strategies to reduce the 
burden of disease in communities. The use of diagnostics reduces the frequency and duration of 
malaria infection and can block mosquito transmission by reducing the human parasite reservoir 
41. Reliable diagnostic measures lead to improved care of parasite-positive patients and prevent 
the overuse of anti-malarials on parasite-negative patients.   
 
Preventive treatments aim to block malaria transmission by chemoprevention for vulnerable 
populations. These include the intermittent treatment for malaria in pregnancy through the 
administration of sulphadoxine/ pyrimethamine (SP) during the second and third trimesters. 
Women who are HIV-positive may require more frequent treatment 42. This treatment is also 
recommended for intermittent preventive treatment in infants; in countries in sub-Saharan Africa 
with moderate to high malaria transmission it is recommended that infants receive 3 doses of SP 
at the same time as their measles immunizations 32. 
 
CHEMOTHERAPIES FOR MALARIA INFECTION 
Chemotherapies are a critical component in reducing malaria morbidity and mortality. Drugs to 
kill the parasite target the various stages of its parasite life cycle. Drug treatments to malaria 
have been discovered throughout the course of human development. Quinine was discovered 
nearly 400 years ago. It is found within the class of quinolones that has been a major focus for 
the treatment of malaria. Chloroquine for decades was the first line of treatment for malaria 
worldwide. This weak base concentrates in the highly acidic digestive vacuoles of sensitive 
Plasmodium parasites, where it binds to heme and disrupts its sequestration 43. However, drug-




Antimalarial drugs can be classified based on their activities during the life cycle. They can also 
be classified by the way they are absorbed into the body, which can impact their effectiveness in 
treating the disease. There are three main classes of drugs. The first can act against the primary 
or latent liver stages. A second class is defined as drugs that are directed against the blood stages. 
A third class is effective against the liver stage and gametocytes. 
 
Quinolines are a class of drugs that are active against the blood stages of malaria. The 4-
aminoquinoline chloroquine was discovered in Germany in the 1930s and introduced in the 
United States after World War II. Chloroquine is inexpensive, safe and highly effective against 
the blood stages of malaria species. This drug was the foundation for the first campaign of 
malaria eradication in the 1950’s. The spread of chloroquine-resistant strains world-wide has 
diminished its use 45. Chloroquine is highly effective against erythrocytic forms of P. vivax, P. 
ovale, P. malariae, P. knowlesi and sensitive forms of P. falciparum. The spread of chloroquine 
drug-resistant P. falciparum species has led to this drug being replaced by artemisinin-based 
combination therapies 46. 
 
Chloroquine is still widely used to treat P. vivax although the drug has no activity against latent 
hyponozoite forms of P. vivax or P. ovale 47. Mefloquine is also a highly effective quinoline for 
the treatment for blood stage infections. It is an arylaminoalcohol analogue of quinine that was 
synthesized in the 1960s. Early work showed that mefloquine associates with intraerythrocytic 
hemozoin, suggesting similarities to the mode of action of chloroquine 48. The drug is rapidly 
absorbed, however with marked variability between individuals 49. The drug displays highly 
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potent schizonticidal activity against blood stage parasites. Mefloquine is no longer the first-line 
treatment of malaria in most clinical contexts 49. Primaquine acts on exoerythrocytic tissues in 
the liver to prevent and cure relapsing P. vivax. This drug belongs to the family of the 8-
aminoquinolines. Although primaquine does not exhibit any inhibitory activity against the blood 
stages, it is thought to be a powerful gametocytocidal compound. Tafenoquine has a longer 
plasma half-life and is thought to be less toxic than primaquine 50. Quinine is the main alkaloid 
of cinochona, the bark of the South American cinchona tree 49. Quinine acts against blood stage 
forms and has no significant effect on hepatic forms. This drug is more toxic and less effective 
than chloroquine.  
 
Artemisinin is a sesquiterpene (15-carbon) lactone endoperoxide derived from wormwood. 
Chinese have ascribed medicinal value to this plant for >2000 years. Artemisinins are very 
potent, fast-acting antimalarials, inducing a very rapid parasite clearance and fever resolution. 
Artemisinins caused a significant reduction in parasite burden. Three to four cycles (6-8 days) of 
treatment can remove essentially all the parasites from the blood 51. Artemisinins also possess 
gametocytocidal activity, leading to a decrease in malarial parasite transmission 52.  These drugs 
are valuable for the treatment of severe P. falciparum malaria. However, they cannot be used 
alone because of their very short half-life and limited ability to eradicate infection completely 53.  
Artemisinins should not be used for chemoprophylaxis because of their short half-life. Several 
derivatives of artemisinin have been synthesized and characterized. Dihydroartemisinin (DHA) 
is a reduced product and active metabolite of artemisinin, artemether is the lipophilic methyl 
ether of dihydroartemisinin, and artesunate is the water-soluble hemisuccinate ether of DHA 51. 
Artemisinins are active against nearly all the parasite blood stages, resulting in rapid parasite 
16 
 
clearance. They are also active against immature P. falciparum gametocytes 54.  Their mode of 
action remains uncertain, although it has been reported that the integrity of the endoperoxide 
bridge is necessary for antimalarial activity 55. 
 
The short plasma half-life of artemisinin (1-3 hours) and its derivatives translates into treatment 
failure rates when artemisinins are used as monotherapy 56.  They are now combined with partner 
drugs with a much longer half-life to ensure a continued antimalarial activity. The use of 
combination therapy also is a method of protecting artemisinins against the emergence of 
parasite resistance. Amodiaquine is a 4-aminoquinoline that is used as a partner drug in the 
ACTs.  In vivo, amodiaquine is rapidly converted into its metabolite, monodesethyl amodiaquine, 
which is characterized by a long plasma half-life of 9- 18 days 57. Piperaquine is a bisquinoline 
that is structurally related to chloroquine and other 4-aminoquinolines. It became the primary 
antimalarial in China during the 1970s and 1980s. Piperaquine has a large volume of distribution 
and reduced rates of excretion after multiple doses. The drug is rapidly absorbed, reaching its 
maximal concentration 2 hours after a single dose 58. Piperaquine has the longest plasma half-life 
(approx. 35 days) of all ACT partner drugs, suggesting that piperaquine-dihydroartemisinin 
might be effective in reducing rates of reinfection following treatment 59.  Pyronaridine is 
structurally related to amodiaqine, developed in the 1970s in China. The compound is highly 
effective against both P. falciparum and P. vivax blood stages 49. 
 
Lumefantrine is structurally related to quinine and mefloquine. It is thought to have the same 
mechanism of action, in which it is targeted to the parasite digestive vacuole in the blood stages 




Other anti-malarial agents include atovaquone and sulfadoxine-pyrimethamine and methylene 
blue. Atovaquone was developed as a synthetic derivative with activity against multiple 
Plasmodium species. It is highly active against P. falciparum blood stages, and against the liver 
stages of P. falciparum but not P. vivax hypnozoites. This drug targets the parasite mitochondrial 
cytochrome bcl complex and inhibits electron transport, collapsing the mitochondrial membrane 
potential 62. Atovaquone is now paired with the antifolate proguanil, to prevent the development 
of parasite resistance 63. The latter compound targets the parasite bifunctional enzyme 
dihydrofolate reductase-thymidylate synthase essential to parasite de novo synthesis of purines 
64.  
Sulfadoxine-pyrimethamine is a combination therapy of two antifolates: a sulfonamide (a p-
aminobenzoic acid analogue) that targets the Plasmodium dihydropteroate synthase involved in 
the synthesis of dihydrofolic acid, and diaminopyrimidine that inhibits the parasite dihydrofolate 
reductase. These slow-acting blood schizonticides are more active against P. falciparum than P. 
vivax. This drug combination is facing increased development of resistance due to mutations in 
both target enzymes 65. 
 
Methylene blue is a thiazine dye and was first introduced in 1891. The compound was earlier 
reported to inhibit the enzymatic activity of P. falciparum glutathione reductase in vitro 66. 
However, a recent study demonstrated that glutathione reductase-null blood stage parasites 
exhibited the same susceptibility to methylene blue as wild-type parasites, implying this agent 
has a different target 67. Clinical studies are ongoing to evaluate methylene blue as a new partner 
drug for the treatment of malaria. 
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The currently recommended treatment for malaria is Artemisinin-Based Combination Therapy 
(ACT). However, the 2008 World Malaria Report showed that only 3% of children suspected of 
having malaria were treated with an ACT. Artemisinins are effective against early-stage 
gametocytes and the symptomatic asexual blood stages 68. Recent evidence from the field 
indicates a reduced clearance time of Arteminisin in Western Cambodia 69. The emergence of 
artemisinin-resistant malaria on the western border of Thailand has brought the forefront a need 
for development of a malaria vaccine to prevent infections in the face of new drug resistant 
strains 70. 
 
The process of absorption depends on how it will pass through a barrier to enter a cell. If a 
process of lipid diffusion absorbs drugs, then the drug dissolves in the lipid components of the 
cell membrane. Certain antimalarials are classified as lipophilic drugs, such as atovaquone, and 
lumefantrine. It has been recently demonstrated that a doubled concentration of plasma 
triglycerides modifies the effectiveness of the drug. Studies with P. falciparum parasites in vitro 
required higher concentrations of both atovaquone and lumefantrine to kill the same percentage 
of parasites 71. Other drugs, such as chloroquine, which is hydrophilic, did not respond to 
changes in the triglyceride concentrations. This is an important finding, revealing a close 
relationship between the anti-malarial activity of lipophilic drugs and the nutritional status of the 
host. This area requires further investigation to optimize the use of these therapies in clinical 
settings. Also, proper administration of drug concentrations will prevent their overuse and 






As mentioned previously in the introduction, malaria vaccines have an important role to play in 
the long-term goals of malaria elimination and eradication 72. The different stages of the life-
cycle of Plasmodium parasites each provide a new opportunity in which to develop a vaccine. In 
addition, natural immunity to malaria infection occurs after many years of repeated exposure 73. 
However, maintenance of immunity requires a persistent subclinical infection because of 
immune evasion mechanisms such as antigenic variation 74. Natural immunity is only partial, 
strain specific and short-lived unless reinforced through frequent exposures. An ideal vaccine 
would protect the semi-immune as well as people with little or no immunity.  
 
Immunity to P. falciparum involves cellular and antibody mediated responses 75. The human host 
develops a repertoire of antibodies against the antigenically variable proteins expressed on the 
surface of infected erythrocytes. Cellular responses to malaria antigens include CD4+ T cells that 
proliferate and secrete interferon (IFN)- γ when stimulated 76. IFN-γ responses associate with 
protection against malaria amongst volunteers undergoing experimentally induced infections and 
naturally exposed human populations 77. Adaptive and innate lymphocytes contribute to the 
generation of IFN-γ 75. It is uncertain whether the clinically silent sporozoite and liver stages 
play a role in the development of natural immunity 78. However, targeting this stage of the life-
cycle, to generate protective immunity to preventing the onset of a blood-stage infection, remains 
attractive. A broad range of vaccine strategies have been developed to try to utilize the principles 
of naturally occurring immunity through exposure to different types of Plasmodium antigens.  
The most currently tested malarial vaccine is the RTS,S/AS01 vaccine. The RTS,S/AS01 vaccine 
is based on the fusion of the P. falciparum circumsporozoite (CSP) protein with the hepatitis B 
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virus surface antigen. RTS,S induces the production of antibodies and T cells that diminish the 
malaria parasite’s ability to infect, develop and survive in the human liver 75.  
 
In 2011, results from a large-scale phase 3 clinical trial of RTS,S showed 55% reduction in the 
frequency of malaria episodes after 12 months of follow-up 79. However, earlier reports for this 
vaccine were far less encouraging 80. Furthermore, RTS,S reduces the development of naturally 
acquired antibody responses to blood-stage antigens, leading many researchers in the field to 
continue searching for a vaccine with better efficacy 81.  
 
The majority of asexual blood-stage candidate vaccines that have been developed are based on a 
small number of antigens expressed on merozoites 82. Many of these vaccine candidates are 
based on just a few antigens, Merozoite Surface Protein-1 (MSP-1) and Apical Membrane 
Antigen-1 (AMA-1) in particular. Candidate vaccines have contained a protein given with an 
adjuvant designed to induce protective antibodies. Some approaches have focused on inducing 
antibodies that impair parasite invasion, while others have aimed to induce antibodies that impact 
parasite development in collaboration with effector cells 82. Although protection has been 
achieved in experimental animals, little clinical success has so far been achieved in humans with 
blood-stage vaccines 83.  
 
There are also major challenges to the development of blood-stage vaccines. A major hurdle to 
the development of a blood-stage vaccine is the antigenic variation of the surface proteins of 
Plasmodium parasites. The constant switching of epitopes, encoded by the var gene family, 
during blood-stage growth means every 48 hours the host needs to produce a new antibody to 
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combat the infection. Another challenge is the difficulty in expressing conformationally correct 
large antigens and scaling up the methods needed to do this to the extent that would allow large-
scale manufacture. Another challenge is the modest amount of antibody responses produced to 
the antigens currently tested 82. Another challenge is the allelic polymorphism observed in 
proteins, for example in the AMA-1 protein 84. AMA-1 is a polymorphic protein that contains 
different amino acid substitutions observed in P. falciparum isolates from various regions of the 
world.  
 
Vaccines that target the pre-erythrocytic stages of infection, encompassing the sporozoite stage 
and liver stages, constitute an attractive strategy. These pre-erythrocytic stages contain low 
numbers of parasites in comparison to blood stages, are completely asymptomatic, yet provide an 
opportunity for an effective immune response to eliminate the parasites (5-7 days for P. 
falciparum) 85.  
 
Vaccines that target the mosquito stages focus on antigens that are expressed during replication 
in the mosquito but not in the human host 86. Strategies to prevent transmission will greatly 
reduce the chance that the parasite will invade erythrocytes and be able to produce gametocytes 
for transmission of the infection. Immunization of mosquitoes with gametocyte or ookinete 
antigens could reduce or ablate oocyst development in the mosquito. This principle has been well 
established for decades 86. Efforts have been made to standardize membrane-feeding assays that 
allow sera from vaccinated animals or humans to be evaluated for their ability to reduce or 
prevent transmission. This approach has also been supplemented by the in vivo use of transgenic 
parasites to assess the efficacy of antibodies induced by P. falciparum and P. vivax antigens 87. 
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Another recent development has been the findings that antigens from the Anopheles midgut wall, 
in particular aminopeptidase APN1, appear to be a receptor for ookinetes and may act as suitable 
transmission-blocking vaccine components 87. The mosquito-stage vaccine also has the particular 
advantage that it may be effective against more than one species of Plasmodium.  
 
Another approach for vaccine development is the development of whole-cell attenuated forms of 
the parasite. Radiation-attentuated sporozoites have been used to inoculate mice, revealing that 
the ability of sporozoites to invade hepatocytes and arrest therein was correlated with the 
induction of protective immunity to subsequent challenge (Figure 1.3) 88. Irradiated sporozoites 
delivered by mosquito bite in human trials can induce very high levels of protective efficacy 89.  
 
More recent trials failed to achieve high levels of protection although they illustrated the 
feasibility of producing enough irradiated sporozoites for eventual use in humans as an 
optimized vaccine. However this recent study used a different method of inoculation of irradiated 
sporozoites; through needle inoculation of purified sporozoites 90. This method of inoculation of 
sporozoites into human patients resulted in suboptimal immunogenic protection. It is currently 
unknown how much immunity to Plasmodium infection occurs when mosquitoes bite the dermis 
and also inoculate mosquito antigens into the host. Irradiation of sporozoites is thought to 
introduce lethal double stranded breaks in the parasite DNA. When dosed adequately, 
sporozoites can invade liver cells, begin development to produce defective trophozoites that 
cannot mature and rupture to release merozoites that would normally invade red blood cells and 






Figure 1.3. Arrest during liver stages confers protection to subsequent challenges 
Sporozoites that are mutated by radiation (RAS) or genetic attenuation (GAS) arrest within the 
liver. Sporozoites that do not complete liver-stage development can provide protection to 
subsequent challenge. Schematic reproduced from 92.  
 
Immune protection during the liver stages is likely to be achieved through the action of CD8+ T 
cells that target the parasitized hepatocytes 93. Infected hepatocytes display parasite proteins on 
their surface through the Major Histone Compatibility Complex-II (MHC-II) protein, an antigen-
presenting molecule important for the immune response. The presentation of foreign peptides 
generates a response in T-cells 94. Antibodies to the sporozoites are thought to have a lesser 




Attenuation of sporozoites by chemical treatment can also induce sterilizing immunity. Studies 
with a DNA-binding drug, centanamycin, showed attenuation of sporozoites and when 
inoculated into naïve mice, provided protection to subsequent challenge 96. The protection was 
demonstrated across species: inoculation with P. berghei parasites and centanamycin treatment 
led to protection against challenge with P. yoelii parasites. High levels of CD8+ T cells and 
antibodies were generated in response to immunization with chemically-attenuated sporozoites 
(CAS), suggesting protection occurs through the same mechanisms as with radiation attenuated 
sporozoites.  
 
Attenuation can also be obtained by the deletion of genes essential for liver stages 85. These 
Genetically Attenuated Parasites (GAPs) therefore would not require irradiation to attenuate 
them and are potentially more efficacious if they are capable of progressing to a later liver stage 
of development 85. Genes, including, highly Up-regulated in Infectious Sporozoites (UISs) have 
been demonstrated to be essential for the completion of liver stages in both P. berghei and P. 
yoelii. UIS3 and UIS4 are proteins of the PVM and act at the host-parasite interface during liver-
stage development 97 98. Deletion of UIS3 led to a complete arrest in liver stage development, 
however deletion of UIS4 had occasional break-through when high numbers are used for 
immunization 98. Other genes that are critical for liver stage development have also demonstrated 
protection to challenge with wild-type parasites; including P52, SAP1 and SLARP. When P52 
was deleted in P. berghei strains of rodent malaria, the knock-out parasites arrested in the 
trophozoite stage in the liver. P52 encodes a putative GPI-anchored protein and is a member of 
the 6-Cys-protein super-family 99. This deletion strain was protective against subsequent 
challenge and no break-through occurred 100.  Deletion of SAP1 in P. yoelii also conferred 
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protection to subsequent challenge with no breakthrough 101. SAP1 is critical for post-
transcriptional regulation of infectivity during sporozoite stages. Deletion of SAP1 reduced 
expression of a number of sporozoite specific genes. A similar protein was disrupted in P. 
berghei, Sporozoite And Liver stage asparagine-Rich Protein, (SLARP) 16. Deletion of SLARP 
resulted in complete arrest during early liver stages 16. 
 
Double knock-outs can be highly effective experimental vaccines, with P. falciparum genetically 
attenuated parasites provide good protection in a humanized mouse model 102. Generation of a 
blood stage infection was abolished in the generation of double-knockouts in the rodent malaria 
parasites. Simultaneous deletion of p52/p36 genes resulted in complete attenuation with no 
breakthrough infections 99. P36 encodes a putative secreted protein. Also a double knock-out of 
UIS3 and UIS4 conferred protection with no break-through 103. However, ensuring a complete 
arrest during liver stage development in P. falciparum might be difficult, even if more than one 
mutation is introduced.  
 
GAPs involved in the synthesis of fatty acids have also demonstrated arrest in liver stages. 
Components of the FAS-II pathway were expressed the highest in liver stages when compared to 
other life cycle stages 104. The block within liver stage development for the FAS-II deleted genes 
was confined to the later stages of development, with no defect during the initiation of liver stage 
105 106. Since FAS-II knockouts develop significantly and form large liver-stage schizonts, they 




Many of these findings were made through the study of mouse forms of malaria, P. berghei, 
yoelii and chabaudi. Mouse models have served as a great source of information about the 
protective mechanisms the mammalian host has for controlling the infection 95. Additionally, the 
initial stage of vaccine evaluation takes place in the animal model. These studies can determine 
whether humoral or cellular immunogenicity is demonstrated with the vaccine candidate.  
 
Various murine model systems have been developed with parasites originally isolated from 
African wild rodents 108. These forms of malaria offer an advantage over simian models that they 
are more practical to study and the mouse immune system is well characterized. The four rodent 
species regularly used for scientific study are Plasmodium berghei, P. chabaudi, P. vinckei and 
P. yoelii. Although no one of the four species accurately reflects the infection in humans, 
together each rodent species offers a resource for studying the mechanisms of protective 
immunity. Even the host factors in eliminating parasites during blood-stage development have 
been discovered in mouse models 109. P. chabaudi chabaudi is the best murine model to study 
immune responses to blood stage malaria since it is similar to P. falciparum in several aspects: 
the blood stages infect normocytes and show synchrony in vivo. These parasites also undergo 
peripheral withdrawal of older parasitized RBC and in some mouse strains, recovery from the 
acute primary parasitemia is followed by one or more patent recrudescences by parasites of 
variant antigenicity 110. 
 
For liver stage examination, the use of human-infective Plasmodium species, P. falciparum and 
P. vivax sporozoites poses many safety concerns. Therefore more liver stage studies have been 
made in rodent and non-human primates. P. berghei and P. yoelii have been commonly used 
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rodent models for liver stages. The examination of liver stage development of sporozoites has 
been achieved during in vivo infections of rodents as well as in vitro studies in several cell lines. 
The advantage of studying Plasmodium in cell lines is that they are easy to maintain, have a 
well-defined genome and are amenable to genetic manipulation. The most commonly used cell 
lines are HepG2, Huh7 or Hepa1-6 cell lines for rodent Plasmodium parasites. P. vivax can infect 
HepG2 and HC04 cell lines 111whereas P. falciparum can only grow within the HC04 cell line 
112. A caveat to the use of cell lines is that they are immortalized and may have lost some of the 
features of the cells they were derived from. The possibility of using primary hepatocyte cultures 
for infections is an alternative approach. Primary hepatocytes retain more, although not all the 
characteristics of liver cells, and are more likely to replicate the natural infection. However they 
are difficult and time-consuming to produce for experimental use 113. 
 
Despite the knowledge gained through the study of rodent parasites, they are not natural mouse 
pathogens and much of the knowledge has been gained from infections initiated by unnatural 
routes. For instance, studies that determined the importance of CD8+ T cells in immunity to pre-
erythrocytic stages occurred with sporozoites administered through intravenous injection (I.V.), 
which bypasses the natural intradermal route of inoculation. Sporozoites administered through 
I.V. injection are less available for elimination by antibodies than sporozoites inoculated into the 
dermis and the sporozoites take minutes instead of hours to enter the liver 114.As mentioned 
earlier, the immune response is likely affected by the contents of the mosquito bite itself 115, 
making these types of experimental procedures less valuable to study the mechanisms of 
immunity. Although these caveats result in a reduced level of host immunity, the fact that we still 
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see protection observed with irradiated sporozoites offers great potential for vaccine 
development. 
 
An important tool to evaluate sporozoite vaccines in rodent models include humanized mouse 
models. Humanized mouse models that can support parasitized human erythrocytes or human 
liver stages provide a model that falls in between rodent models and human studies. The 
humanized mouse model for P. falciparum infection uses NOD/SCID mice inoculated 
intraperitoneally with human red blood cells 116. This model can be used to study the blood-stage 
replication of P. falciparum infections in vivo. Liver stage development of P. falciparum has also 
been demonstrated in immunodeficient mice that allow survival of differentiated human 
hepatocytes. One example is the knock-out mouse for the albumin-urokinase-type plasminogen 
activator (Alb-uPA) that confers a growth advantage to transplanted hepatocytes 117. By 
controlling nonadaptive immune defenses, macrophages and NK cells, there was increased 
survival of transplanted human hepatocytes to 3 months within the rodent host. Sporozoites 
injected intravenously into transplanted mice and showed P. falciparum liver forms by light 
microscopy.  
 
Finally, it is important consider how attenuated sporozoites might be able foster cross-species 
protection against other strains of malaria. This is an important factor when considering which 
strain of Plasmodium to use for inducing immunity. Cross-species protection has been 
demonstrated for chemically attenuated rodent malaria strains 96. The genetically attenuated P36-
p strain in Plasmodium berghei conferred partial cross-species protection to challenge with P. 
yoelii sporozoites 118. The genetically attenuated P. berghei strain demonstrated cross-species 
29 
 
protection to the P. yoelii challenge, although not as robustly as radiation attenuated P. berghei 
parasites. The cross-species protection had an impact on the level of liver infection, length of 
prepatent period and the peak parasitemia of challenge infections. This report demonstrates how 
cross-species protection is possible, although it was not complete. Although cross-species 
protection was not demonstrated with human malaria strains (immunization with radiation 
attenuated P. falciparum sporozoites with P. vivax challenge), this study only had a single 
volunteer 89.Further investigation into cross-species protection with human Plasmodium parasites 
is important for the practical value of translating these findings into an attenuated liver-stage 
sporozoite vaccine.  
 
LIVER-STAGE DEVELOPMENT 
The liver stage is an interesting stage to target for vaccines development because it can elicit an 
immune response while remaining clinically silent. Liver-stage enables the parasite to transition 
from sporozoite infection to active blood-borne disease. The liver stage produces new parasite 
forms that can enter and live inside red blood cells. The knowledge of the liver stage is relatively 
limited because the complete liver stage development of human Plasmodium species can 
generally only be studied in vitro in primary human hepatocytes 119 and rarely in vivo in 
immunocompromised non-human primates 120, 121. More recently, humanized mouse models 
have been developed that enable P. falciparum infections in the liver of rodents. Most of the 
knowledge about liver stages has been determined based on studies with rodent parasites. In the 
late 1940s, it was shown that sporozoites of mammal-infecting Plasmodium species initially 
invade hepatocytes, where they replicate asexually to form thousands of merozoites 122. 
Surprisingly, at least in the case of P. berghei, Plasmodium sporozoites can infect a wider range 
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of cells than originally thought, in particular they can develop in the skin tissues 123. However, it 
is generally thought that their main cell are hepatocytes types in which they complete 
development. To access them, the motile parasites need to cross the endothelium a second time 
after entering the bloodstream in the skin. In the liver sinusoids, the sporozoites bind to highly 
sulfated heparan sulfate proteoglycans (HSPGs) 124 present on the surface of the hepatocyte. 
Many cell types present hSPGs, but the sulfation level differs and is particularly high in liver 
tissue. Once inside the host cell, the parasite often localizes close to the host cell nucleus 125. It is 
likely that the vacuole attaches to the cytoskeleton of the host cell and is passively transported 
near the nucleus. There it is often in close proximity to the ER and the Golgi apparatus 126. After 
invasion of the host hepatocyte and formation of a PVM, the parasite undergoes an initial period 
of morphological changes. During the first 24 hours after infection, the parasite remodels its 
PVM and transforms from its elongated form to a small, round trophozoite. At 20 hours post 
invasion, the parasite nucleus begins dividing repeatedly, displaying one of the fastest replication 
rates known for eukaryotes. Up to 30,00 nuclei are generated, at the same time as the PV is 
expanding to accommodate the growing parasite. Apart from the host cell ER, which gathers 
around the parasite and a loose association with the Golgi apparatus, there appears to be no 
constant association between the PV and the host cell organelles 126. Nutrient uptake from the 
host is speculated to involve parasite-encoded transport channels inserted into the PVM, 
allowing molecules up to 850 Da to freely cross the membrane 126. Large molecules such as 
lipids and peptides need to be actively imported and again the parasite appears to be able to 




Figure 1.4. Plasmodium berghei liver-stage parasites.  
Several different markers are used to visualize liver-stage development of Plasmodium berghei 
parasites. Apicoplast-targeted GFP is shown during mid and late-liver stages on the left-hand 
panel in green. DAPI is a DNA stain, indicating the individual daughter nuclei. Anti-MSP 
antibodies mark the Parasite Plasma Membrane (PPM). Merged images show during cytomere 
stage the individual nuclei and apicoplast organelles surrounded by parasite plasma membrane 
for the generation of infectious merozoites. Image reproduced from 127 
 
must also dispose of metabolic waste. For liver-stage parasites, so far no food vacuole has been 
described. Thus, the question remains of how metabolically active liver-stage parasites deal with 
waste products. The massive quantity of membrane required for replication during this period 
would explain the reliance of the parasite on de novo fatty acid biosynthesis during the liver 
stage.  
 
Following the completion of nuclear division, at which point the single parasite can contain 
many thousands of nuclei, the parasite develops into a cytomere stage. The plasma membrane of 
the parasite invaginates to form what appear to be spheres of membrane, portioning the 
cytoplasm into between 5 to 20 units. During the cytomere stage, the individual units of plasma 
membrane are not fully separated and mitochondrial branches connect the segregating “clumps” 
32 
 
128. Once the formation of merozoites is complete, they must be transported into the bloodstream 
where they can infect red blood cells (RBCs) to continue the life cycle 128. The release of 
merozoites is a well-orchestrated, multi-step process. During merozoite formation parasite 
proteins begin to leak into the host cell, demonstrating that the membrane of the PV becomes 
increasingly permeable before it is completely disrupted 129. Parasite and host cell material mix 
freely in infected cells 130. Not much is known about the ultimate breakdown of the PVM in 
Plasmodium liver stages. This takes place within a short time and can be inhibited by E64, an 
inhibitor of cysteine proteases 131. LISP-1 in P. berghei is the only identified protein to be 
involved in PVM disruption. Deletion of LISP-1 prevents parasites from escaping the PV, 
however the protein has no functional protease domains. Once the PVM is dissolved, parasite-
dependent host cell death is initiated 128. It is unclear whether the host cell membrane remains 
intact after disintegration of the PVM, yet it has been demonstrated that the disruption of the 
PVM and the host cell membrane are differentially timed 125. Egress of intra-erythrocytic 
merozoites is known to involve specific sets of proteases that are activated in cascades 132. It is 
likely that similar mechanisms act during liver stage, although it remains unclear whether 
proteases are acting directly on the PVM or whether other effector molecules are involved. 
Merozoites remain surrounded by the hepatocyte-derived plasma membrane until they reach 
blood vessels where they can safely infect RBCs.  
 
During the liver-stage of Plasmodium development, the apicoplast and the mitochondria appear 
to be in even less contact with each other 133. In the liver stages of development, the apicoplast 
and the mitochondrion become extensively branched and intertwining structures. The organelles 
undergo impressive morphological and positional changes prior to cell division. The organelles 
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cannot be formed de novo by the parasites, so all daughter merozoites must contain a copy of 
these organelles and their genomes. Prior to the formation of daughter merozoites, fission of the 
apicoplast and mitochondrion occurs, with each new unit of apicoplast and mitochondrion 
containing one or more copy of the respective organellar genome 133. The apicoplast always 
divides before the mitochondrion, with the latter dividing only very shortly before cytokinesis 
133.  
It has been demonstrated that liver stage development requires the production of de novo fatty 
acids by the Plasmodium parasites. The liver stage of parasite development, in contrast to the 
blood stage, requires a functional FAS-II pathway 105. FAS-II is the biochemical pathway for the 
generation of fatty acids commonly found in bacterial and plant organisms. It is relatively highly 
expressed during this stage in Plasmodium parasites 104. Targeting the genes related to 
biosynthesis pathway for genetic deletion can lead to potential genetically attenuated whole 
organism vaccines, since many of these genes are highly expressed. Drugs such as ethionamide 
are also known to target enzymes particular to fatty acid biosynthesis; these could potentially 
provide new leads for drugs that inhibit liver stage. 
 
LIPIDS 
Understanding the dynamic relationship between the lipids of Plasmodium parasites and its host 
is a major focus of this work. The term lipid is a broad definition of a group of molecules that 
include fats, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides and 
phospholipids. A lipid contains a fatty chain of carbon atoms, usually of an even number and a 
polar head group. The fatty acid chain may be saturated or unsaturated. Fatty acids are 
unsaturated due to the presence of double bonds that are always configured in “cis.” The length 
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and degree of unsaturation of fatty acid chains significantly impacts membrane fluidity due to the 
kink that unsaturated fatty acids provide. Unsaturated fatty acids prevent the membrane from 
packing tightly together, therefore decreasing the melting temperature of cells. 
 
There are many molecules that are defined as lipids. Variation in head-groups and aliphatic 
chains allows for the existence of >1,000 different lipid species in any eukaryotic cell. Lipids, in 
contrast to proteins, DNA and carbohydrates, do not form polymers. This is a possible 
explanation for the wide diversity in lipid molecules.  
 
Lipids can be categorized into three different cellular functions. The first is their use in energy 
storage because of their relatively reduced state. Triacylglycerol and steryl esters in lipid droplets 
are primarily used for the function primarily as reservoirs for the efficient storage of caloric 
reserves as caches of fatty acid and sterol components needed for membrane biogenesis. 
Secondly, polar lipids form the matrix of cellular membranes. Using the bi-polar hydrophobic 
and hydrophilic nature of lipids in aqueous environments, drives the formation of membranes of 
lipid contents. The same principle also governs the formation of organelles within a cell, 
enabling the segregation of specific chemical reactions for increased efficiency and restricted 
dissemination of their products. Finally, lipids can act as first and second messengers in signal 
transduction and molecular recognition processes. A lipid messenger binds a protein target, such 
as a receptor, kinase or phosphatase, which in turn mediate the effects of these lipids on specific 
cellular responses. Lipid signaling is qualitatively different from other classical signaling 
paradigms because lipids can freely diffuse through membranes. A consequence of this is that 
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lipid messengers cannot be stored in vesicles prior to release and are often biosynthesized “on 
demand” at their intended site of action.  
 
Lipid droplets are also organelles within the cell that contain varying amounts of lipids. They are 
dynamic cytoplasmic organelles ubiquitously found in cells 134. They are linked to many cellular 
functions, including lipid storage for energy generation and membrane synthesis, viral 
replication and protein degradation.  
 
LIPIDS IN CELL MEMBRANES 
The solubility of a cell membrane is determined by its lipid components and these factors 
determine the ability of a substance to diffuse through membranes. It can determine the rate of 
absorption of chemical compounds and the extent of their potency. 
 
Lipids within the cell membrane provide the cell with many functions, including the potential for 
bidding, tabulation, fission and fusion. These processes enable the cell to divide, reproduce and 
allow intracellular membrane trafficking. The action of lipids can also define membrane domains 
that recruit proteins from the cytosol that subsequently organize secondary signaling or effector 
complexes. It has recently been described the presence of lipid rafts, that are defined as the 
organization of glycolipids and protein receptors organized in microdomains within the cellular 
membrane. These membrane microdomains enable to cell to compartmentalize cellular processes 
by serving as organizing centers for the assembly of signaling molecules, influencing membrane 
fluidity and membrane protein trafficking and regulating neurotransmission and receptor 
trafficking 135.Lipid rafts are more ordered and tightly packed than the surrounding bilayer but 
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float freely in the membrane bilayer 136. Lipid rafts contain 3 to 5-fold the amount of cholesterol 
than in the surrounding bilayer that confers the rigidness of the raft. The distribution of 
phospholipids and sterols throughout the organelles and the plasma membrane within eukaryotic 
cells can create microdomains for the specialized function of enzymes or biochemical 
intermediates.  
 
The major structural lipids in eukaryotic membranes are the glycerophospholipids, which contain 
a glycerol head group attached to a lipid base. Phosphatidylcholines (PtdCho) are the most 
abundant type of lipid species found within the plasma membrane of eukaryotes. Other 
components of eukaryotic membranes include the phosphatidylethanolamine, 
phosphatidylserine, phosphatidylinositol and phosphatidic acid. Their hydrophobic portion is a 
diacylglycerol (DAG) that contains saturated or cis-unsaturated fatty acyl chains of varying 
lengths. PtdCho accounts for over 50% of the phospholipids in most eukaryotic membranes. 
Most PtdCho molecules have on cis-unsaturated fatty acyl chain that enables them to be fluid in 
room temperature.  
 
The amount of cholesterol in cellular membranes is critical for its rigidity. Cholesterol is 
synthesized in the cell by a regulated feed-back loop that controls its level. The balance is 
maintained by membrane-bound transcription factors called sterol regulatory element-binding 
proteins (SREBPs) that activate genes encoding enzymes of cholesterol and fatty acid 
biosynthesis. The three SREBP proteins are bound to membranes of the endoplasmic reticulum 
(ER) and nuclear envelope. SREBPs are released by two sequential cleavages; the first catalyzed 
by Site-1 protease (S1P) and the second by Site-2 requires the action of S2P. When sterols build 
up within cells, the proteolytic release of SREBPs from membranes is blocked and domains that 
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have already entered the nucleus are rapidly degraded 137.These mechanisms of regulation 
maintain tight control over the cellular level of cholesterol. 
 
LIPIDS AND APICOMPLEXAN PARASITES  
Lipids have emerged as important pathogenesis factors in a variety of infectious diseases. Lipid 
and fatty acid metabolism has been studied in many areas of apicomplexan biology; including 
parasite adaptation, host-parasite interaction and targets for drug therapy. Parasites have their 
own unique methods of fatty acid synthesis that have major implications for disease 
pathogenesis. However, the large amount of lipid scavenging from the host demonstrates 
auxotrophies in parasite species that can be used in the development of new therapeutics. 
Although Apicomplexan parasites have methods for de novo fatty acid biosynthesis, they must 
balance the processes of synthesis and scavenge to remain pathogenic.  
 
Host lipids can have major impacts on disease pathogenesis. For example, intestinal infections 
with Giardia, a parasite that causes diarrhea, vomiting and malabsorpotion, host intestinal lipids 
and fatty acids influence the growth and encystation of the parasite 138Free fatty acids generated 
from phospholipids and triglycerides from the host are detrimental to the growth of Giardia 139.In 
particular, dodecanoic (C12:0) can accumulate inside the trophozoite and alter the membrane 
permeablility and integrity.  
 
Toxoplasma gondii, another Apicomplexan parasite, is known for scavenging a large variety of 
lipid precursors from host cytoplasm and modify them to generate complex lipids 
140.Toxoplasma, contains enzymes of the Fatty Acid Synthase-II (FAS-II) pathway within the 
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apicoplast organelle 141.However, unlike Plasmodium, Toxoplasma seems to express also the 
Fatty Acid Synthase type-I (FAS-I) enzymes within the parasite mitochondria 142.Toxoplasma 
parasites lacking the acyl carrier protein, a central component of FAS-II, are viable, suggesting 
that the FAS-I and FAS-II pathways serve complementary functions. The uptake of lipid and 
lipid precursors from its environment is also important for the pathogenesis of Toxoplasma 
gondii. Phosphatidylcholine is the most prevalent lipid of Toxoplasma. It is about 75% of the 
total phospholipids of the parasite is primarily scavenged from the host 143. Toxoplasma parasites 
are also capable of the scavenging choline 144. In order to scavenge cholesterol from the host, in 
Toxoplasma infected cells, cellular mechanism of cholesterol biogenesis (through the LDL 
receptors and the HMG-CoA reductase enzyme) are both augmented to increase the cell 
cholesterol levels 145.The particular need for T. gondii parasites for choline and cholesterol 
import may provide new avenues for intervention. This hypothesis is supported by an analogue 
for choline, N,N-dimethylethanolamine, when taken up by intracellular parasites demonstrates 
progressive arrest 143. Like the other Apicompleans, Plasmodium falciparum also demonstrates 
sensitivity to choline analogues.  
 
THE APICOPLAST ORGANELLE 
The apicoplast is a plastid organelle found in apicomplexan parasites. This organelle was 
discovered by Araxie Kilejian, who identified a circular, extrachromosomal DNA molecule in 
Plasmodium lophurae, a species of malaria that infects ducks 146. Similar circular DNA 
molecules were described in Toxoplasma gondii by Piet Borst 147. Identification of RNA 
polymerase genes that were homologous to plastid sequences in other organisms provided 
evidence that the apicoplast was a unique organelle with ancestral links to plant and algal 
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plastids 148. Sequencing of the apicoplast genome revealed a small 35kb genome principally 
dedicated to its own expression. Apicoplasts are found throughout the Apicomplexa and are an 
ancient feature of this group acquired by the process of endosymbiosis. The only exception is 
that of Cryptosporidium spp 149.  
 
The apicoplast was determined through the use of electron microscopy techniques to have four 
membranes bounding the organelle 150. The apicoplast is thought to be derived from an engulfed 
red alga and was acquired before dinoflagellates and Apicomplexa diverged 151. The function of 
the apicoplast remained a mystery after its discovery, especially since the photosynthetic 
capacity was lost from the organelle 152. Pharmacological or genetic perturbation of the 
apicoplast leads to parasite death 153.  
 
Genes for fatty acid biosynthesis in T. gondii and P. falciparum are targeted to the apicoplast 154. 
The apicoplast also contains the pathway to synthesize isopentenyl diphosphate, a precursor of 
isoprenoids, ubiquinone side chains and dolichols, and an essential component for the 
modification of tRNAs 155. Through data mining of genes targeted to the apicoplast, it was 
determined that malaria parasites make iron sulphur complexes and also cooperate with the 
mitochondrion in the synthesis of heme 156. The apicoplast thus harbors a collection of plastid-
like metabolic pathways that provide the organism with carbon, energy and reducing power in a 






THE APICOPLAST IS AN ANTIMALARIAL DRUG TARGET 
The apicoplast is an interesting target for the development of antimalarial compounds since it 
contains a range of metabolic pathways and housekeeping processes distinct from the host 156. 
Many of the cellular processes of the apicoplast, namely DNA replication, transcription, 
translation, post-translational modification, catabolism and anabolism, are bacterial-like and are 
sensitive to antibiotics that target these housekeeping pathways. Drugs targeting the apicoplast 
have been categorized for their targets: transcription, translation and genome replication. 
Ciprofloxacin is a gyrase inhibitor, that blocks prokaryotic DNA transcription. Ciprofloxacin 
inhibits apicoplast DNA replication but not nuclear replication in P. falciparum 153. Rifampin 
and thiostrepton-treated parasites display reduced expression of the apicoplast-specific RNA 
polymerase subunits and reveal an abnormal unbranched apicoplast morphology 158. Drugs that 
block the prokaryotic translation machinery include, doxycycline, clindamycin and spiramycin 
159. Lincosamides (lincomycin and clindamycin) block protein synthesis by interfering with 
peptidyl-transferase activity, blocking translocation of the peptidyl tRNAs 158, 159. Tetracyclines 
and doxycycline target the 70s ribosome, resulting in a lack of amino acid incorporation into 
cytosolic proteins 160. Macrolides (erythromycin and azithromycin) block peptide exit, 
preventing elongation of nascent peptides 161. The antibiotic fosmidomycin targets the isoprenoid 
synthesis pathway in the apicoplast 162. Fosmidomycin was demonstrated to inhibit growth of P. 
falciparum in culture as well as cure malaria in a mouse model. Mupirocin inhibits isoleucyl-
tRNA synthetase, which is required in the apicoplast but is encoded in the nucleus 163. . 
 
Parasites that are cured of their apicoplast do not die immediately. Instead they invade new host 
cells but develop poorly 164. Certain drugs targeting the apicoplast also demonstrate this “delayed 
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death” phenotype. Delayed death occurs when drug treatment does not show an impact on 
parasite viability until the next cell cycle. These drugs impact the viability of the progeny of 
treated parasites since they are inheriting non-functional apicoplasts 158.  
 
PROTEINS ARE SPECIFICALLY TARGETED TO THE APICOPLAST  
The four-membrane apicoplast organelle requires a unique set of tools for translocation of 
proteins encoded and synthesized by the parasite nucleus, to be incorporated into the organelle. 
An estimated 480 genes in the P. falciparum nucleus are targeted to the apicoplast 155. Similar to 
plant plastids, Plasmodium parasites used the translocons (Tic and Toc) residing in the inner and 
outer membranes to identify appropriately-tagged gene products synthesized and import them in 
an unfolded state across the membranes 165. Two components from plants, Tic 20 and Tic 22 
have been identified in the apicoplast with Tic22 residing in the innermost membrane 166. All 
known apicoplast-targeted proteins bear an N-terminal signal peptide, which directs the nascent 
protein to a specific translocon in the endoplasmic reticulum (ER) 167. Once within the lumen of 
the ER, the transit peptide is sufficient and necessary to direct proteins into the apicoplast 
organelle 168. The peptides of the apicoplast-target protein have properties that enable their 
predictions using the enable their predictions using the PlasmoAP algorithm 169. 
 
The apicoplast contains an ensemble of bacteria-like pathways to replicate and express its 
genome plus an anabolic capacity to generate fatty acids, heme and isoprenoid precursors. 
Apicoplasts are essential, making the components of apicoplast metabolism, attractive drug 
targets. Apicoplast type II fatty acid biosynthesis has been the focus of the development of 
chemotherapies since it was first discovered. Several putative inhibitors against the parasite have 
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focused on the fatty acid machinery. However gene knock-out studies revealed that the parasite 
can replicate without these enzymes in blood-stages105.  
 
MORPHOLOGY OF THE APICOPLAST 
The morphology of the apicoplast organelle evolves extensively during the stages of asexual 
replication and liver-stage development (Figure 1.5). The apicoplast first appears as a small 
circular organelle during the early ring stages of development, which then develops into a ring 
structure, followed by transformation into an extensive reticulated network as the parasite 
enlarges 170.  
 
Figure 1.5. Apicoplast morphology during P. falciparum blood-stage replication 
The apicoplast has a noticeable branched structure during the blood-stage of replication, which 




Both the apicoplast and mitochondrial organelles form highly branched structures in late-stage 
parasites, which undergo an ordered fission, first of the apicoplast and then by the mitochondria. 
These organelles are paired for packaging into daughter cells 170. The two organelles share some 
points of contact but they are not consistent throughout the stage of asexual development (Figure 
1.6). In general, the mitochondrion is slightly elongated in respect to the apicoplast. In the ring-
stage cells, apposition between mitochondria and apicoplast is maintained. In late trophozoite 
and early schizont stages, there is little association between the organelles. 
 
Figure 1.6. Contact between apicoplast and mitochondria organelles during P. falciparum 
blood-stage 
Morphology of the apicoplast and the mitochondria organelles in during blood-stage 
development shows close contact between the organelles. Image is replicated from 155.  
 
 
FATTY ACID METABOLISM IN PLASMODIUM 
Rapid growth and multiplication that occurs during both the blood and liver stages requires the 
synthesis of membranes to encapsulate all of the daughter cells. In addition, infection of a red 
blood cell by Plasmodium results in a marked increase in the phospholipid content and a 
significant change in the lipid composition of the infected erythrocyte 172.As mentioned 
previously, the machinery for fatty acid synthesis is contained within the apicoplast organelle. A 
major question in the field of parasite biology remains as to how these lipids are generated, 
through the process of de novo synthesis or scavenge from the host. It appears that both of these 
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pathways are needed, although to different extends depending on the conditions of the host and 
the stage of the life-cycle. Understanding the balance between synthesis and salvage of fatty 
acids and other lipid species has been a central focus of this project.  
 
Evidence for the uptake of scavenged fatty acids from the host has been shown with radio or 
fluorescence-labeled fatty acids that are incorporated into the parasite 173. Lipids in the parasite 
are primarily fueled by precursors supplied by the host; including serine, ethanolamine and 
choline. These are the major building blocks used by the parasite in the synthesis of its structural 
and regulatory phospholipids 172. Phosphatidylcholine and phosphatidylethanolamine are the 
predominant phospholipids in the P. falciparum membranes 174. P. falciparum is capable of 
normal growth when cultured in the absence of exogenous choline, indicative of biosynthesis by 
the parasite 175 176. The minimal requirement for blood-stage replication of P. falciparum during 
in vitro cultures was determined as a combination of palmitic acid and oleic or steric acid. This 
combination of free fatty acids could fully replace the need for serum in culture 177. Scavenged 
phospholipids can be incorporated without modification 178. 
 
The cellular mechanisms of fatty acid import remain to be biochemically elucidated for 
Plasmodium parasites. However, Apicomplexan parasites encode a variety of acyl-CoA 
synthases (ACS) and acyl-CoA binding proteins (ACBP) that likely act in salvage and 
incorporation of host lipids 179. In P. falciparum, these genes have been amplified by gene 
duplication and show considerable polymorphism, suggesting strong evolutionary selection 179. 
The ACS genes in P. falciparum are located in epigenetically controlled regions of the genome 




Plasmodium parasites modify fatty acids as needed by elongating or desaturating the lipids and 
incorporating them into phospholipids, such as diacylglycerols and tri-acylglycerols 177 181. In 
Trypanosoma brucei, elongase enzymes (ELO) are unique in generating the bulk of lipids for the 
parasite, since its ELO enzymes have adapted to use shorter carbon primers (C2) and elongate 
them to full length fatty acids (C10 or C14) 182. Three ELO genes have been identified in 
Plasmodium species and remain to be characterized. Fatty acids, which are taken up from the 
host are converted to triglycerides by the acyl-CoA:diacylglycerol acyltransferase located within 
the parasite ER 183. These triglycerides are stored in lipid bodies. P. falciparum generates oleic 
acid from radiolabeled stearic acid; this modification requires desaturation of scavenged fatty 
acids by the parasite. A delta-9 desaturase gene (PFE0555w) was recently identified in the P. 
falciparum genome and characterized in its expression during blood-stages, maximally in 
schizonts, and localizing to the ER 184. P. falciparum in vitro cultures were sensitive to sterculic 
acid, a D9-desaturase inhibitor, implicating the essentiality of desaturation of fatty acids during 
blood-stage growth.  
 
It was generally accepted in the scientific community that Plasmodium parasites do not 
synthesize their own fatty acids. However, analysis of the P. falciparum genome revealed the 
presence of the apicoplast-resident biosynthetic fatty acid synthesis type-II pathway, the 
biochemical pathway for the generation of fatty acids commonly found in bacterial and plant 
organisms (Figure 1.7). FAS-II enzymes are transcribed at a very low level in blood-stage 
parasites 185. However a clinical in vivo transcriptional data-set provided evidence that the FAS-




Figure 1.7. Genes hypothesized to be involved in lipid metabolism in Plasmodium 
Genes involved in fatty acid biosynthesis include the ACP, FabI, FabZ, FabB/F and FabG. 
Lipoic acid synthesis in the apicoplast is generated by proteins LipA and LipB. Acyl-CoA 
Synthetase enzymes are involved the import of fatty acids from the environment. Elongation 
enzymes and desaturation enzymes, modify synthesized or scavenged fatty acids, are located in 
the endoplasmic reticulum. Adapted from 187. 
 
Although the essential components for fatty acid biosynthesis have been demonstrated to be 
essential for liver-stage development, scavenge from the host is also important for development. 
Studies with obese Zucker rats, which had increased fatty acid synthesis and triglyceride content, 
supported the growth of four times the number of liver-stage schizonts than their leaner 
counterparts 188. Import of lipids must occur through the PVM, which encloses the developing 
parasite after invasion. The PVM itself contains cholesterol derived initially from the host 
plasma membrane. The PVM is porous, permitting the passive transfer of small soluble 
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molecules of < 855 Da 126. The pores are maintained during parasite cytokinesis until complete 
cellularisation. Host factors related to lipid transport impact parasite replication during liver 
stages. Decrease or loss of scavenger receptor class B type 1 (SR-BI) resulted in reduction in 
parasite invasion and growth in hepatocytes 189. SR-BI expression resulted in increase cell 
cholesterol levels and increased expression of liver fatty acid binding protein on the hepatocyte. 
One of the genes critical for liver stage development, UIS3, is likely to enable lipid absorption 
from the host. UIS3 binds the liver fatty acid binding-protein (L-FABP) of the host 190. This 
interaction is critical for liver stage, demonstrating that lipid import is essential for development.  
 
The FAS-II pathway generates octanoyl-ACP; a 6-carbon chain attached to the acyl-carrier 
protein. The synthesis of lipoic acid requires generation of this precursor for the post-
translational modification of certain enzymatic complexes. Lipoic acid is an essential cofactor 
for a number of oxidative decarboxylases, including pyruvate dehydrogenase (PDH), the glycine 
cleavage system, alpha-ketoglutarate dehydrogenase (KGDH) and branched-chain oxo-acid 
dehydrogenase (BCDH). It has been suggested that the critical function of apicoplast FASII 
might lie in lipoic acid production, as for the FASII pathway of plant mitochondria 187. In 
Plasmodium falciparum, disruption of LipB, a critical ligase for lipoic acid synthesis, parasites 
remained viable 191. Inhibition of lipoic acid scavenge pathway in Plasmodium falciparum is 
lethal to parasite replication . Plasmodium parasites must use a combination of the synthesis and 
scavenge pathways to optimize their replication in different host environments. This is the 





2. LIPOIC ACID SYNTHESIS DURING THE PLASMODIUM 
BERGHEI LIFE-CYCLE  
 
ABSTRACT 
Plasmodium parasites require the post-translational modification of several α-ketoacid 
dehydrogenases to regulate their activity through the attachment of lipoic acid, a short-chain fatty 
acid derivative. Lipoic acid can be synthesized de novo within the apicoplast of the parasite or it 
can be scavenged from the environment. Several of the important enzymes that are required for 
lipoic acid synthesis and attachment to target enzymes have been identified within the 
Plasmodium genome.  
 
Here, we report the generation of a P. berghei line disrupted in its apicoplast-targeted protein 
ligase LipB gene. The impact of deleting this gene was then assessed throughout the parasite life-
cycle. Although we observed no significant impact on mosquito stage development or asexual 
blood-stage growth, deletion of PbLipB resulted in a significantly decreased infectivity of 
sporozoites in vivo and in vitro. These parasites also demonstrated a very late liver-stage arrest. 
Disruption of PbLipB reduced the levels of lipoylated proteins in both asexual blood and liver 
stages, but the apicoplast morphology was only significantly impacted during the liver stage. 
ΔpbLipB parasites also have slower replication rates than wild-type controls during blood-stage 
growth after treatment with a lipoic acid analogue, 8-bromo-octanoate (8-BOA). These results 
demonstrate the importance of the LipB gene in the liver-stage of Plasmodium berghei
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development and an exchange between the synthesis and the scavenge pathways of lipoic acid, 






One of the metabolic products generated by fatty acid biosynthesis is lipoic acid (6,8-thioctic 
acid). This eight-carbon chain compound 192 is an essential cofactor for a number of multi-
enzyme complexes found in all eukaryotic cells that generate metabolic products including heme 
and fatty acids 193. In addition to being synthesized de novo, lipoic acid is also absorbed from 
dietary sources. Cells maintain active systems to import non-protein bound lipoic acid from their 
environment 192. Lipoic acid rapidly traverses cell monolayers in a pH-dependent manner 194. 
Lipoic acid is likely imported by transport system since its uptake can be inhibited by benzoic 
acid and medium-chain fatty acids. Studies have suggested a monocarboxylate transporter or 
Na+-dependent multivitamin transporter may be responsible for lipoic acid uptake into cells 195.  
 
Lipoic acid biosynthesis in all cell types begins with the generation of an octanoic acid precursor. 
Two carbons of octanoic acid are removed for their replacement with two sulfur atoms to 
generate a dithiolane ring (C6 and C8) (Figure 2.1). Lipoic acid has one chiral center and 
naturally exists in both R and S-enantiomeric forms. However, only the R form is attached as a 
cofactor to proteins 196. The dithiolane ring is critical for the function of lipoic acid, as it acts as 




                         
 
 
Figure 2.1. Different forms of lipoic acid intermediates 
A) The R stereoisomer of lipoate. B) Lipoamide, the oxidized cofactor, bound to the E2 subunit. 
C) Dihydrolipoamide, the reduced form of lipoic acid, also bound to the E2 subunit of a 
lipoylated complex. Schematic reproduced from 197. 
 
 
Oxidized (LA) and reduced (DHLA) forms create a potent redox couple. The dithiolane ring is 
the functional part of lipoic acid when it is attached to an enzymatic complex. The disulfur bond 
breaks and is attaches to the reaction intermediate to shuttle it between reaction subunits. After it 
transfers the product, the lipoate cofactor is regenerated through reduction of NAD+ by the E2 
subunit 197. Lipoic acid attachment always occurs on the N6 amino group of a lysine residue in a 
small protein domain (80-residues) 198 (Figure 2.2). The number of lipoyl acceptor domains on 





                              
Figure 2.2. The PDH enzyme complex 
Schematic shows how the lipoyl attachment to the E2 subunit of PDH is critical for function. The 
E1 subunit is responsible for the decarboxylation of the substrate that is then transferred to the 
lipoyl cofactor. The E2 subunit catalyzes the transfer of acyl to acyl-CoA The E3 subunit reduces 
NAD+ to regenerate the lipoyl domain. Schematic reproduced from 197.  
 
In Plasmodium, covalent attachment of lipoic acid is required for the function of four large 
multi-subunit enzyme complexes: pyruvate dehydrogenase (PDH), alpha-ketoglutarate 
dehydrogenase (KGDH), branched-chain alpha-ketoacid dehydrogenase (BCDH) and the glycine 
cleavage system (the H-protein) 199. PDH is located in the parasite apicoplast, a plastid-like 
organelle that performs a variety of metabolic functions including isoprenoid and fatty acid 
biosynthesis. In contrast to PDH, the other lipoylated complexes (KGDH, BCDH and the H-
protein) have been localized to the mitochondria 199. 
 
Lipoic acid also has a number of other biological functions. Lipoic acid has pharmacological 
properties as an anti-oxidant 193. Lipoic acid, like other anti-oxidants, protects tissue from 
oxidant damage. In addition, attached lipoic acid can also serve as an anti-oxidant, and oxidative 
stress near the dehydrogenase complex can lead to oxidative destruction and can decrease its 
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function as a cofactor. Lipoic acid in humans is typically bound  to proteins and free lipoic acid 
cannot be detected in the serum unless after the administration of a therapeutic dose 200. 
Oxidative damage is a normal process of living systems. During oxidation, electrons are 
removed from these molecules and subsequently transferred in a chain of reactions to other 
molecules until they reach their final electron acceptor of oxygen. Oxidative damage occurs 
when the normal pathways of oxidation are not controlled and reactive oxygen species damage 
biomolecules such as DNA, proteins and lipids. Anti-oxidants function to control the oxidative 
processes by absorbing these “free radicals.”   
 
Another metabolic event of lipoic acid is the beta-oxidation of its pentanoic acid side chain. In 
bacterial species, such as Pseudomonas putida, lipoic acid is a principal metabolite of beta-
oxidation 197, which produced carbon dioxide through the degradation of acetyl CoA in the citric 
acid cycle. In humans, the same beta-oxidation pathway degrades lipoic acid as for longer chain 
fatty-acids for energy production. However, seeing that the Plasmodium genome lacks the 
enzymes required for beta-oxidation of lipid species, lipoic acid is not used in these manner by 
the parasite. 
 
In certain conditions, lipoic acid has been demonstrated to have a pronounced effect on the cell 
cycle. Alpha-lipoic acid induces hyperacetylation of histones in vivo. Lipoic acid was 
demonstrated to induce a reversible G1/G0 cell cycle arrest in cell lines by inhibiting histone 
deacetylase activity in tumor cell lines. Lipoic acid has also been shown to be a factor in the cell 
survival of rat hepatocytes by remediating loss of function of the Akt serine/threonine kinase, 
involved in stress response and cell cycle 192. Lipoic acid supplementation of hepatocytes also 
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showed that two phosphatases that antagonize Akt, PTEN and PP2A, all components of the cell 
cycle, were inhibited by lipoic acid, demonstrating its ability to aid in the survival of liver cells.   
 
Plasmodium parasites synthesize lipoic acid within the apicoplast, where the Fatty Acid 
Synthesis-II (FAS-II) pathway generates an octanoic acid precursor attached to the acyl-carrier 
protein (ACP) 187 (Figure 2.4)  The derivation of lipoic acid from octanoyl-ACP requires two 
enzymes; Lipoate synthase (LipA) and Lipoyl octanoyl-transferase enzyme (LipB). LipA 
(MAL13P1.220) is responsible for catalyzing the introduction of two sulphurs at positions 6 and 
8, forming a lipoyl appendage. The lipoyl appendage is an 8-carbon fatty acid chain, which when 
covalently bound in an amide linkage to multienzyme complexes results in a “swinging arm” that 
shuttles intermediates among active sites 201. LipB (MAL8P1.37) transfers the octanoyl group 
from ACP to the conserved lysine residue on the PDH-E2 subunit in the apicoplast of 
Plasmodium parasites. LipA can work either before or after LipB has catalyzed this transfer. 
Both ligases have been identified in P. falciparum and are essential for the synthesis and 
attachment of lipoic acid to the E2 subunit of PDH in the apicoplast 202. In P. falciparum, LipB 
was shown to be responsible for maintaining normal levels of lipoylated PDH but was itself 
nonessential to blood stage replication 202.  ΔPflipb parasites were reported to have an increased 
growth rate during the asexual blood stages and a reduced level of lipoylation of PDH in the 
apicoplast. A second transferase enzyme, LplA2, was hypothesized to compensate for the loss of 
LipB and to be responsible for the remaining amount of lipoylation observed with the PDH E2 
subunit 202. LplA2 was demonstrated to localize to both the apicoplast and the mitochondria in P. 






Figure 2.3. Lipoic acid synthesis pathway  
Lipoic acid synthesis begins with the octanoyl-ACP precursor that is attached to the E2 subunit 
by LipB enzyme. LipA modifies octanoyl by introducing a dithiolane ring. Schematic 
reproduced from 197. 
 
The pyruvate dehydrogenase complex (PDH) catalyzes the oxidative decarboxylation of 
pyruvate to form acetyl coenzyme A (Acetyl-CoA), which is a carbon intermediate that feeds 
back into the FAS-II pathway. Since there is only one PDH enzyme annotated in the Plasmodium 
genome (unlike plant species) and it is located in the apicoplast, it is assumed its major role in 
acetyl-CoA generation is for the fatty acid biosynthesis pathway 155. 
 
In addition to the lipoic acid synthesis pathway, P. falciparum has an active scavenge pathway 
that is essential for both blood and liver stages and has been shown to lead to lipoylation of the 
mitochondrial enzyme complexes KGDH and BCDH. Scavenged radiolabeled lipoic acid is 
sequestered solely in the mitochondria where it is attached to these complexes 191. The lipoic acid 
analogue, 8-bromo-octanoate (8-BOA), prevents lipoic acid scavenging by irreversibly binding 





Figure 2.4. Lipoic acid synthesis and scavenge pathways in Plasmodium parasites 
Schematic representation of lipoic acid synthesis and scavenging in the Plasmodium apicoplast 
and mitochondrion respectively. Enzymes responsible for the synthesis or attachment of lipoic 
acid to its target proteins are represented in light blue. LipB and LipA synthesize lipoic acid from 
the octanoyl-acyl carrier protein (ACP) precursor generated through the fatty acid biosynthesis 
type II (FAS-II) pathway. LipB is responsible for the attachment of octanoyl-ACP to the E-2 
subunit of the pyruvate dehydrogenase (PDH) complex within the apicoplast. LipA is 
responsible for creating the thiosulfur bonds. PDH converts pyruvate into acetyl-CoA, which 
primes the FAS-II pathway. In the mitochondria, LplA1 attaches scavenged lipoic acid to α-
ketoglutarate dehydrogenase (KGDH) and branched-chain alpha-ketoacid dehydrogenase 
(BCDH), which both feed into the tricarboxylic acid (TCA) cycle, as well as the H-protein of the 
glycine cleavage system. Attachment of scavenged lipoic acid can be inhibited by the analog 8-
BOA that targets the ligase LplA1. A second lipoate ligase, LplA2, has been localized to both the 




8 BOA was transferred by P. falciparum LplA1 proteins in vitro to the H-protein acceptor 
domain 191. It acts as a competitive inhibitor to free lipoic acid since it binds irreversibly to 
acceptor proteins. Addition of 8-BOA to in vitro cultures of P. falciparum inhibited blood-stage 
growth in a dose-dependent manner 191. Recently, the essentiality of lipoic acid scavenging has 
been also been demonstrated for Plasmodium liver stages. 8-BOA treatment of parasites 
developing in vitro in hepatic cell lines prevented completion of liver stage development 203. 
Investigations into the lipoic acid metabolism pathway of Plasmodium currently evoke a 
complete separation in the pathways of synthesis and scavenge with no exchange of lipoic acid 
occurring between the mitochondria and the apicoplast 191, 204. The BCDH complex is involved in 
the degradation of branched-chain amino acids for the generation of acyl-CoA, which are 
intermediates of the tricarboxylic acid (TCA) cycle. The TCA cycle is commonly known in 
many cell types as the central process that allows them to metabolize carbon from glycolysis into 
a fully oxidized state to generate energy by oxidative phosphorylation and releasing carbon 
dioxide. The branched amino acids leucine, isoleucine and valine are deaminated to α-ketoacids 
that are decarboxylated and conjugated to CoA. In addition to contributing to the TCA cycle, 
these short chain primers can be used to generate longer branched fatty acid that can be 
important in modifying membrane fluidity. In certain organisms, BCDH activity is regulated by 
expression of the enzyme in response to accumulation of branched-chain ketoacids (prokaryotes) 
or phosphorylation of the enzyme complex (mammals). BCDH is expressed in both blood and 
liver-stages of Plasmodium parasites.  
 
 The KGDH complex converts α-ketoglutarate to succinyl-CoA, which also feeds into the TCA 
cycle. The TCA cycle enzyme succinyl-CoA synthetase consumes succinyl-CoA as a carbon 
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intermediate. It is regulated by the accumulation of metabolic intermediates like a high 
AMP/ATP ratio. While lipoic acid scavenging is sufficient to meet the metabolic needs of 
parasites during blood-stage growth, it has not been established if the synthesis pathway is 
necessary to meet the rigorous demands of liver-stage development. The observation that LipA 
expression is upregulated during early liver-stage development of P. yoelii nevertheless suggests 
an important role 104. Furthermore, disruption of PDH in P. yoelli produced a phenotype in liver-
stage forms, but did not affect the blood stage propagation in mice 205.  
 
We have disrupted the LipB gene in P. berghei parasites for the purpose of investigating its role 
throughout the parasite life cycle. Our studies reveal that parasites lacking LipB progress 
normally through the asexual and sexual blood stages and develop normally in the mosquito, but 
fail to develop properly during the liver stage, indicating that lipoylation plays a critical role 
shortly after sporozoites invade a new host. 
 
EXPERIMENTAL PROCEDURES 
PROPAGATION OF P. BERGHEI PARASITES 
P. berghei ANKA parasites (provided by MR4) were passaged in female Swiss-Webster mice 
(6–8 weeks of age purchased from Taconic Farms), via intraperitoneal injection. To determine 
pre-patent periods for parental ANKA vs. Δpblipb lines we used female C57/BL6 mice (Taconic 
Farms) as these are highly permissive and represent a sensitive model to detect low-level 
infections arising from the liver stage 105. All animal experimentation followed protocols 




PLASMID CONSTRUCTS AND PARASITE TRANSFECTIONS 
Deletion of the lipB gene in P. berghei ANKA parasites was achieved by double crossover 
replacement of the targeted coding sequence with the Toxoplasma gondii dhfr-ts selectable 
marker, as published previously 206. This marker mediates resistance to pyrimethamine that was 
added to the mouse drinking water at a concentration of 0.07 mg/ml in animal drinking water 206. 
The P. berghei ANKA strain was transfected with plasmid pL0001-Δpblipb, containing 5’ and 3’ 
untranslated regions (UTRs) of PbLipB as sites of homology. The cross-over event replaced the 
entire coding sequence with the Tgdhfr-ts selectable marker. The pL0001 vector was obtained 
from the MR4 organization (deposited by A. P. Waters, MRA-770). The pL0001-Δpblipb 
plasmid contains 680bp of the 5’ UTR, PCR amplified from the endogenous gene from P. 
berghei ANKA parasite genomic DNA. This fragment was sub-cloned between the EcoRV and 
the XbaI sites. 850bp of the LipB 3’UTR was also amplified from genomic DNA and sub-cloned 
between the Acc65I and HindIII sites. Plasmids were linearized by the XbaI, ScaI and Acc65I 
enzymes and verified by agarose gel electrophoresis prior to transfection. Transfection and with 
pyrimethamine selection were performed as previously described 206. Correct integration of 
constructs and absence of the endogenous LipB locus was confirmed by PCR. Clonal parasite 
populations were obtained by limited dilution 206.  
 
The plasmid designed to target GFP to the carboxyl-terminus of BCDH was generated from the 
GFP-containing pL0031 vector obtained from MR4 (MRA-800 pL0031) 207. 875bp of the 3’ end 
of the BCDH-E2 gene (PB001062.02.0) was amplified by PCR from P. berghei ANKA genomic 
DNA. Primers used were P2872 and P2873 (Table 2.1). The product was ligated into a Topo-
easy vector (Promega) where site-directed mutagenesis primers were used to generate a BsmBI 
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site within the cloned product for linearization prior to transfection. The product was then sub-
cloned between the restriction sites SacII and NcoI in the pL0031 vector, removing the 
endogenous stop codon and maintaining an open reading frame with the GFP coding sequence. 
This construct was linearized with BsmBI and transfected into P. berghei ANKA parasites to 
generate the tagged endogenous protein through a single cross-over recombination event. P. 
berghei ANKA parasites were transfected and selected with pyrimethamine as described above 
206. Correct integration into the BCDH-E2 endogenous gene was confirmed by PCR of the GFP-
positive parasite population using primers P2957 and P2873 (Table 2.1). Single digit names 
correspond to locations on (Figure 2.5).  
Primer 
Name Sequence Description 
9 (P23020 ATACCCATATATCGTATCAACAGAGG LipB gene F primer  
10 (P2303) ATTAATTTCAGTGATTAATGGATAATC LipB gene R primer  
7 (P2345) TGTGCTTCACTCCCAGCAGC Tgdhr gene F primer 
8 (P2346) GTCTCCACTGGAAGCCGTAGCC Tgdhr gene R primer 
2 (P2344) CATAAAATGGCTAGTATGAATAGCC LipB WT 5'utr R primer 
3 (P2343) GCATTATATGAGTTCATTTTACACAATCC LipB WT 3'utr F primer 
1 (P2448) CATAACAATGAATTTACACCTAACCC 
Recombinant locus 5' F 
primer 
5 (P2320) TGCATGCACATGCATGTAAATAGC 
Recombinant locus 5' R 
primer 
6 (P2317) TGTGATTAATTCATACACAAACATAC 
Recombinant locus 3' F 
primer 
4 (P2453) GACACAAATCAAACTATATTAATATGCG 
Recombinant locus 3' R 
primer 
P2304 AAGCATTAAATAAAATACATCCTTAC 18s rRNA subunit F primer 
P2305 GGAGATTGGTTTTGACGTTTATGTG 18s rRNA subunit R primer 
 P3081 AGATCAAATTGCAAGTGGTCAATCCG MSP1 gene F primer 
P3082 TGGTACTTAAATCTTTGAATAGATCC MSP1 gene R primer 
P2957 TATGGAATTTATGTCCTACAGG BCDH-GFP F primer 
P2873 
TGACCATGGATTTTCAAATCTTGAAGTGTCA
T BCDH-GFP R primer 
Table 2.1. Primers used in Chapter 2 
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IMMUNOBLOT ANALYSIS OF LIPOIC ACID-BOUND PROTEINS 
Cryopreserved P. berghei infected red blood cells were thawed on ice and then lysed in 1X PBS 
containing 0.2% saponin (1 mL for every 100 µl of packed iRBCs) for 3 min on ice.  Samples 
were immediately diluted with 10 mL ice-cold 1X PBS and centrifuged in a swing bucket rotor 
at 3,500 x g for 10 min at 4˚C.  The isolated parasites were washed twice with ice-cold 1X PBS 
and centrifuged as above.  Parasites were resuspended in ice-cold RIPA lysis buffer (Boston 
BioProducts) supplemented with 10 µg/mL pepstatin A, 2 mM orthophenantroline, 2 mM EDTA 
pH 8.0, and 2X Complete EDTA-free Protease Inhibitor cocktail (Roche Applied Science).  
Lysates were incubated at -80˚C for 10 min and thawed at room temperature followed by 
vortexing for 1 min.  This freeze/thaw/vortex cycle was repeated four times.  Next, lysates were 
diluted with an equal volume of 1 x PBS lysis buffer. Total protein content was determined using 
a Bio-Rad Protein Assay.  5X SDS loading buffer (250 mM Tris-HCl, pH 6.8, 50 mM EDTA, 
5% SDS (w/v), 25% glycerol (v/v), 0.02% bromophenol blue (w/v)) was added to each sample 
and boiled at 95˚C for 5 min.  Sixteen micrograms of total protein were subjected to SDS-PAGE 
on a NuPAGE 4-12% Bis-Tris gel (Invitrogen) and then transferred to a nitrocellulose 
membrane.  Membranes were incubated in a 1:1000 dilution of rabbit polyclonal anti-lipoic acid 
IgG (Calbiochem) overnight at 4˚ C and a 1:2500 dilution of secondary anti-rabbit IgG 
conjugated to HRP (GE Healthcare) for 45 min at room temperature (RT). This experiment was 
repeated three independent times.  
 
IMMUNOFLUORESCENCE ANALYSIS OF BLOOD STAGE PARASITES 
P. berghei wild-type ΔpbLipB, or pbbcdh-gfp asexual blood stage parasites were removed from 
infected mice, washed in complete schizont development media 206 and treated with 5nM 
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MitotrackerR CMXRos  (Invitrogen) for 20 minutes at 37ºC. Asexual blood-stage parasites were 
fixed with 4% formaldehyde and 0.0075% glutaraldehyde. Cells were incubated for 30 minutes 
at RT and washed with 1 x PBS. Cells were permeabilized with 0.1% Triton X-100 for 10 
minutes and washed with PBS. Cells were blocked in 3% BSA for 30 minutes. Anti-ACP 
antiserum was added at a 1:2000 dilution in 3% BSA for 1-2 hours (hr) at RT. Cells were washed 
3 times with 1 x PBS. Anti-rabbit 594 secondary antibodies were then added in 1:1000 dilution 
for 1 hr at RT. Cells were washed twice in PBS and resuspended in complete medium containing 
Hoechst 33342.  
 
P. BERGHEI INFECTIONS OF MOSQUITOES 
Anopheles stephensi mosquitoes, obtained from the NYU Department of Parasitology insectary, 
were fed on Swiss Webster mice infected with PbΔLipB or P. berghei ANKA parasites. 
Mosquitoes were maintained in incubators at 19ºC with 70-80% humidity until the time of 
dissection.  
 
IN VIVO LIVER-STAGE DEVELOPMENT ASSAYS 
To determine the pre-patent period of parasite lines, C57/BL6 mice were infected with 
sporozoites by intravenous injection. Mosquitoes infected with PbΔLipB or ANKA parasites 
were dissected on day 21-post blood meal and used for injection into naive mice. Mice were 
infected with either 1,000 or 10,000 sporozoites. Pre-patent periods were determined by blood 
smears and are defined as the number of days it took for blood-stage parasites to appear 




IN VITRO LIVER-STAGE DEVELOPMENT ASSAYS 
HepG2 cells (ATCC Company) were seeded at 2 x 106 per well in 8 well Lab-Tek culture dishes 
containing glass cover slips the day prior to sporozoite infection. Sporozoites were isolated from 
the salivary glands of infected female Anopheles stephensi mosquitoes and counted using a 
hemocytometer. HepG2 cultures were inoculated with 2 x 104 or 3 x 104 sporozoites per well. To 
quantify the size of the developing liver-stage parasites, developing exo-erythrocytic forms of 
GFP+ P. berghei (MRA-868) were visualized by fluorescence microscopy. Parasite size was 
completed using the Image-J program. In vitro cultures were also used for the generation of 
parasite cDNA after 48 hr of liver-stage development. RNA was harvested from infected HepG2 
cells in Trizol and purified with an RNeasy kit (Invitrogen). We used a SuperScript III kit 
(Invitrogen) to generate cDNA. To determine the absolute number of developing liver stage 
parasites, cover slips were fixed 24 and 48 hours post-invasion (hpi) and were stained using 
either an anti – RFP antibody (wild-type controls used expressed Pb mCherry) or anti –Hsp70 P. 
berghei serum (Δpblipb). Parasites were counted using a Leitz-DM RB fluorescence microscope 
(Leica). At 65 hpi parasites that have successfully finished liver-stage development detach from 
the coverslips and float in the culture supernatant. These “detached cells” were stained with 
Hoechst 33342 and were counted using an Axiovert 200 fluorescence microscope (Zeiss). 
Residual parasites on the cover slips were fixed, stained and counted as described above at 65 
hpi and 84 hpi. 
 
IMMUNOFLUORESCENCE ANALYSIS OF LIVER-STAGE PARASITES 
Liver-stage infections were prepared as described above. Infected cells were incubated for 15 
min at 37°C in 5% CO2 in the presence of 250 nM MitoTrackerRed CMXRos  (Invitrogen) and 
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washed twice with medium before fixation. For fixation, cells were washed three times with 1 x 
PBS before adding 4 % paraformaldehyde /PBS for 20 min at RT. Cells were washed three times 
with 1 x PBS and stored in methanol at –20°C until staining. For staining, cells were washed 
three times with 1 x PBS and incubated for 1hr at RT in 10% FCS/PBS. Primary antibodies 
(chicken α-Exp1 1:1000, rabbit α-lipoic acid (LA) 1:1000, rabbit α-ACP 1:1000) were applied 
for 2hr at RT in 10%FCS/PBS. Cells were washed three times with PBS and secondary 
antibodies (donkey α-chicken Cy2 1:250, goat α-rabbit Fluor647 1:1000) and DAPI (1 µg/ml) 
were applied in 10%FCS/PBS for 1hr at RT. Cover slips were washed three times with PBS, 
dipped once into ddH20 and mounted on glass slides. Microscopic analysis was done on a 
FluoView TM FV1000 confocal microscope. For visualizing co-localization of the mitotracker 
signal with the α-LA signal, false colors were assigned to the signals (mitotracker: red, α-LA: 
green, α-Exp1: cyan, DAPI: blue). To determine the apicoplast morphology during late liver 
stage development, infected cells were fixed and stored as described above at the indicated time 
points.  The same conditions were applied for the primary and secondary antibody staining as 
above. Microscopic analysis was done on a FluoView TM FV1000 confocal microscope. False 
colors were assigned to the signals: ACP: green; CSP, Exp1, MSP1: red.  
 
SEQUENTIAL STAINING OF LIVER-STAGE PARASITES WITH Α-LA AND Α-ACP ANTIBODIES 
Infected cells were fixed and permeabilized at the indicated time points with the same conditions 
as listed above. Cells were incubated with rabbit α-LA (1:2000 in 10% FCS/PBS) for 2hr at RT, 
washed three times with PBS and incubated with goat α-rabbit Hilyte647 (1:1000 in 10% 
FCS/PBS) for 1h at RT. Cells were washed three times with PBS. Following α-LA staining, cells 
were incubated with goat α-rabbit HRP (1:20 in 10% FCS/PBS) for 1hr at RT, washed three 
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times with 1 x PBS and incubated with 10% rabbit serum / 1x PBS for 1hr at RT. Cells were 
washed three times with PBS. Cells were incubated with rabbit α-ACP (1:500) and chicken α-
Exp1 (1:2000) in 10% FCS/ 1 x PBS overnight at 4°C. Cells were washed three times with PBS 
and incubated with goat α-rabbit Alexa594 (1:5000), donkey α-chicken Cy2 (1:250) and DAPI 
(final concentration 1 µg/ml) in 10% FCS/PBS for 1hr at RT. Cover slips were washed three 
times with PBS, dipped in H20 and mounted on glass slides using Daco Fluorescent Mounting 
Medium. 
 
8-BOA TREATMENT OF BLOOD-STAGE PARASITES 
In 3 independent experiments, blood-stage Plasmodium berghei parasites (ANKA or Δpblipb) 
were drawn from an infected mouse, washed in complete schizont development media 206 and 
incubated on overnight incubation at 37°C with gentle agitation in complete media with dilutions 
of 8-BOA or DMSO control. 100 µM, 200 µM and 400 µM dilutions of 8-BOA in DMSO were 
placed in the cultures and incubated for 12-16 hr. Parasite cultures were washed and inoculated 
at 10,000 infected red blood cells into naïve mice by intravenous-injection. Parasitemias were 
monitored for 8-days by thin-smear microscopy. 
 
RESULTS 
DISRUPTION OF THE LIPB GENE IN P. BERGHEI 
To disrupt lipB in P. berghei we replaced the entire coding sequence with the selectable marker, 
Toxoplasma gondii dihydrofolate reductase (TgDHFR) by double cross-over recombination 206. 
We transfected P. berghei ANKA parasites with a linearized plasmid, pL0001-∆pblipb using the 



























Figure 2.5. Generation of LipB knockout parasites in Plasmodium berghei 
A) Schematic representation of the targeted disruption of the wild-type genomic locus to 
generate ΔpbLipB parasites. The location and orientation of the different primer sets (1 through 
10) used for screening the transfectants are indicated. B) PCR confirmation of the modified locus 
of ΔpbLipB parasites. Primers used for screening are as listed in panel A. The top panel shows 
wild-type parasites have the LipB coding sequence. The bottom panel shows integration of the 
selectable marker into the LipB locus.  C) Confirmation of lack of LipB expression in KO cells 
in blood and liver-stages. pbLipB is not expressed from ΔpbLipB cDNA from blood (bs) and 
liver stages (ls). pbLipB is expressed in wild-type P.berghei cDNA. The lipB gene is expressed 




deposited by AP Waters. The targeting vector contained 680 bp of homology to the 5’ 
untranslated region (UTR) of LipB and 850bp of homology to the 3’ untranslated region. 
Transfected parasites were injected back into naïve mice and selected using pyrimethamine. 
Resistant parasites were cloned and integration was confirmed by PCR (Figure 2.5).  
 
In order to confirm the disruption of LipB, we performed an RT-PCR with primers specific to the 
coding sequence of the gene (Figure 2.5). Wild-type and cloned ∆pbLipB parasites were 
harvested at either blood or the liver stages (48 hours post-infection (hpi) of HepG2 cultures) and 
used to generate cDNA. HepG2 cells, a human liver carcinoma cells, were inoculated with wild-
type or ∆pbLipB sporozoites to generate a liver stage infection with in vitro conditions. We 
confirmed lack of expression of lipB during both blood and liver stages in our knock-out 
parasites.  
 
ASSESSMENT OF THE GROWTH RATE OF P. BERGHEI LIPB KNOCKOUT PARASITES DURING 
BLOOD STAGE 
To determine whether there was any difference in blood stage growth in ∆pblipb parasites, we 
inoculated either 10,000 or 1000 asexual blood-stage parasites of either wild-type P. berghei 
ANKA or ∆pblipb strains by intravenous injection into Swiss/Webster mice. The parasitemia of 
asexual replication was determined by blood smear in three independent experiments (Figure 
2.6A & B). Although 202, found a faster rate of asexual stage growth in P. falciparum parasites 
lacking lipB, our results indicate that in P. berghei disruption of the LipB gene does not impact 





Figure 2.6. ΔpbLipB parasites have no change in blood-stage growth kinetics 
(A & B) The blood-stage growth rate of Δpblipb parasites is shown in comparison to the growth 
rate of P. berghei wild-type parasites. In three independent experiments, either 103 or 102 asexual 
blood-stage parasites were injected by intravenous injection into 6 week old female Swiss-
Webster mice (n=5). Parasitemia was monitored by thin smear for 12 days or until death, shown 





ASSESSMENT OF LIPOYLATED PROTEINS IN BLOOD STAGE P. BERGHEI PARASITES 
 
To determine the effect of lipB deletion on the composition of lipoylated proteins in the parasite, 
we compared the lipoylation pattern in wild-type and ∆pblipb P. berghei protein extracts by 
Western blot. Blood-stage parasite lysates probed with an anti-lipoate antibody revealed 
significantly lower levels of lipoylated PDH in the ∆pblipb parasite extract compared to control 
parasite extracts (Figure 2.7). This result is consistent with a current working model that 
proposes that LipB is responsible for lipoylation of PDH within the apicoplast 202. LipB contains 
a predicted apicoplast targeting motif and PDH is the only protein within the apicoplast that is 
known to require lipoylation. Other lipoylated proteins identified in Plasmodium include BCDH, 
KDH and the H-protein, all demonstrated to be localized within the mitochondria 199. These 
proteins are not predicted to be lipoylated by LipB, but by the mitochondrial ligases LplA1 or 
LplA2 208. Surprisingly, we found a reduction in lipoylation of the BCDH protein in the ∆pblipb 
parasites compared to wild-type, suggesting that LipB might play a role in BCDH lipoylation in 
P. berghei. 
 
BCDH IS LOCALIZED TO THE MITOCHONDRIA IN P. BERGHEI 
Given the reduced level of lipoylation of BCDH in ∆pbLipB parasites, we sought to determine 
the localization of this protein. A BCDH-GFP fusion plasmid was transfected into parasites and 




Figure 2.7. ΔpbLipB parasites have less lipoylated BCDH and PDH proteins  
In three-independent experiments, antibodies specific for lipoylated proteins detected a different 
between wild-type and ΔpbLipB parasites. The three lipoylated proteins identified from top to 
bottom as pyruvate dehydrogenase E2 subunit (PDH-E2), branched-chain α-ketoacid 
dehydrogenase E2 subunit (BCDH-E2), and α-ketoglutarate dehydrogenase E2 subunit (KDH-
E2).  In the ΔpbLipB parasites, the level of PDH lipoylation is reduced to 16% of the level 
detected for the wild-type parasites. There is only 2% of lipoylated protein for the BCDH in the 
ΔpbLipB parasites versus the wild-type. The membrane was re-probed for P. falciparum Hsp70 





Co-staining of live parasites with the mitochondrial marker. Mitotracker red localized BCDH to 
this organelle (Figure 2.8A). In contrast, BCDH-GFP did not co-localize with the apicoplast 
marker, acyl-carrier protein (ACP), which was localized using anti-ACP antibodies (Figure 
2.8B). Approximately 50 - 80 BCDH-GFP cells were imaged with either mitotracker staining or 
with the anti-ACP antibodies on three separate occasions. We did not try to localize the BCDH 
protein by immunofluorescence because of a lack of protein specific antibody. Anti-lipoic acid 
antibodies would not be useful for immunofluorescence either. They would detect all lipoylated 
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proteins within the parasite and we wanted to find the organelle-specific location for BCDH. 
Given the results we obtained with the BCDH-GFP fusion line and the western-blot data of 
parasite extracts, it appears that LipB is responsible for the lipoylation of a mitochondrially-
targeted protein. We did not localize LipB itself because of its strong apicoplast targeting motif 
as predicted by PlasmoAP 169. These results suggest an exchange between the lipoic acid 
synthesis and scavenge pathways.  
 
 
Figure 2.8. The BCDH protein localizes to the mitochondria in blood stage  
A) Parasites expressing BCDH-GFP fusion proteins were stained with Mito-Tracker Red, 
revealing co-localization with the mitochondrial dye. B) The BCDH protein is not localized to 
the apicoplast. BCDH-GFP parasites were fixed and stained with anti-ACP antibodies to identify 
the location of the apicoplast. There was no co-localization of BCDH protein and the apicoplast 
during blood stages. 
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∆PBLIPB PARASITES DO NOT SHOW ANY DEFECTS IN APICOPLAST MORPHOLOGY  
To determine if apicoplast morphology was perturbed in the lipB knock-out parasites, we 
performed immunofluorescence microscopy with anti-ACP antibodies on fixed wild-type and 
∆pbLipB parasites (Figure 2.9). The apicoplast undergoes a striking morphological change over 
the course of blood-stage development, beginning as a compact dot in the ring stage and 
elaborating into a highly branched structure during schizogony in anticipation of subsequent cell 
division, ensuring inheritance to each daughter merozoite 170. ∆pbLipB parasites showed 
comparable amounts of dotted versus branched apicoplasts in comparison to wild-type parasites 
(∆pbLipB parasites: 61% branched, wild-type: 52% branched). In our P. berghei knock-out 
parasites, apicoplast development proceeded normally, suggesting that disruption of the lipoic 
acid synthesis pathway is not impacting the health of the apicoplast during blood stages. 
 
 
Figure 2.9. ΔpbLipB parasites show no defect in apicoplast morphology in blood-stages 
Blood stage ΔpbLipB and wild-type P. berghei parasites were fixed and stained with an anti-ACP 
antiserum to identify the apicoplast. No visible difference in apicoplast morphology between 





∆PBLIPB PARASITES DO NOT DEMONSTRATE A DISCERNIBLE PHENOTYPE DURING MOSQUITO 
STAGES  
We did not see a significant deficiency in the mosquito stages of development based on a 
comparison of the number of sporozoites isolated from mosquitoes infected with knock-out or 
wild-type parasites. In three independent experiments, infected mosquitoes were dissected 18-21  
days after feeding on infected mice with similar parasitemias dissected salivary glands and 
viewed midguts for the presence of oocysts on day 21 post blood-meal by phase-constrast 
microscopy. This experiment was performed three times and sporozoite numbers were calculated 
from groups of 5–30 mosquitoes per parasite strain (Table 2.2). We observed mean ± SD 
sporozoite loads of 15,313 ± 8,055 and 13,611 ± 6,286 for the WT and KO respectively. These 
assays indicate that the loss of LipB did not noticeably impair parasite development in the 
Anopheles mosquito vector, and provide evidence that normal levels of lipoylated protein are not 
required for P. berghei development within the mosquito host. 
 
                   
Experiment Parasite line # of Mosquitos Dissected     # of Sporozoites/ Mosquito 
I  WT    10        6667  
 ∆pbLipB   10     9375 
II  WT    10     22606 
  ∆pbLipB   32                20833 
III  WT    20                                      16667 
  ∆pbLipB   20                                      10625 
                         
Table 2.2. PbΔLipB sporozoites have normal sporozoite numbers 
 
∆PBLIPB PARASITES DO NOT COMPLETE LIVER-STAGE DEVELOPMENT IN VIVO 
To test whether disruption of LipB impacted the liver stage of Plasmodium development, mice 
were inoculated with sporozoites and the pre-patent period was determined. The pre-patent 
period, defined as the number of days until detection of parasites in the blood-stream, 
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demonstrates the infectivity of sporozoites to establish infection and complete liver-stage 
development in the mammalian host. 
 
                   
Experiment Parasite line   Sporozoites  Number of        Average Prepatent  
       Infected mice    Period    
I  WT    1,000     5 of 5   5.0 days 
 ∆pbLipB   1,000     1 of 5   9.0 days 
II  WT    1,000     4 of 4   5.0 days 
  ∆pbLipB   1,000     1 of 4              9.0 days 
III  WT    10,000    5 of 5                         3.0 days 
  ∆pbLipB   10,000    5 of 5                         7.6 days 
                                                 
Table 2.3. In vivo infectivity of ΔpbLipB in comparison to wild-type sporozoites 
 
Sporozoites were dissected from salivary glands of infected mosquitoes and injected 
intravenously into C57/BL6 mice, Using dosages of either 10,000 or 1,000 sporozoites, we 
consistently saw a delay in the pre-patent period with the ∆pbLipB sporozoites, which only 
generated a blood-stage infection in 1 of 5 and 1 of 4 mice at the 1,000 sporozoite inoculum 
(Table 2.3). In contrast, all of the mice inoculated with wild-type sporozoites developed a blood-
stage infection after a 5-day pre-patent period. At an inoculum of 10,000 sporozoites, all mice 
infected with ∆pbLipB sporozoites developed a blood-stage infection, but with a significantly 
increased pre-patent period, suggesting that lipB is important for normal liver-stage development 
in P. berghei. 1,000 or 10,000 infectious sporozoites were intravenously injected into mice and 
the pre-patent period was detected by thin-blood smears. Disruption of the LipB gene greatly 





∆PBLIPB PARASITES HAVE MAJOR DEFECTS DURING LATE LIVER-STAGES AND DO NOT 
PRODUCE DETACHED CELLS DURING IN VITRO CULTURE 
In order to investigate when the defect during liver stage development is occurring, equal 
numbers of P. berghei ANKA and ∆pbLipB sporozoites were plated onto HepG2 cells. From 
three independent experiments there was no significant difference between the absolute number 
of developing parasites 24 and 48 hpi (Figure 2.10B). In addition, the size of the exo-erythrocytic 
forms at 48 hpi was examined to determine whether the arrest seen during in vivo experiments is 
detectable early during in vitro development (Figure 2.10A). The area of the developing 
parasites, as delineated by Exp1 staining of the PVM, was measured and found to not differ 
significantly between the two parasite lines. Approximately 20-30% of wild-type ANKA 
parasites were capable of successfully finishing in vitro liver-stage development, resulting in the 
detachment of the hepatocytes from the culture surface. As the parasite develops within the host 
cell, the parasite blocks the apoptotic machinery and host cell does not demonstrate any signs of 
cell death 132. As the PVM begins to break down, merozoites mix with the host cell organelles 
and parasite proteases degrade host cell organelles 128. The parasite induction of host cell 
apoptosis is visualized during in vitro culture as detachment of infected hepatocyte cells from its 
neighboring cells. This typically occurs at 62-70 hpi. We counted the number of infected 
hepatocyte host cells floating in the supernatant of the culture at 65 hpi.  No detached cells were 
found for the ∆pbLipB parasites at 65 hpi, nor at the later time point of 84 hpi (Figure 2.10). 
Furthermore, we decided to detect expression of merozoite-surface protein-1. Msp-1 is a marker 
for the parasite plasma membrane (PPM), which at late time points invaginates around the 
individual daughter merozoites 132. Msp-1 is usually expressed at the later-stages of parasite 
development; i.e. 48hpi or later. We identified expression of Msp-1 at 48hpi in hepatocyte 
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cultures infected with wild-type parasites, but could not detect transcripts from ∆pbLipB infected 
cultures. P. berghei 18s ribosomal RNA was used as a control for proper isolation of RNA and 
cDNA synthesis from infected cultures. This result suggests that ∆pbLipB expression of msp-1 is 
abnormal; expressing later than wild-type. Therefore, although infectivity of knock-out parasites 








Figure 2.10. ΔpbLipB parasites fail to form detached cells in vitro 
A) ΔpbLipB parasites showed no defect in size at 48 hpi in comparison to wild-type parasites. 
The average sizes of the developing exo-erythrocytic forms were similar at this time point. Data 
represents two independent experiments in duplicate. Data presented as a box and whiskers plot 
that illustrates the mean, interquartile range (25-75%), <95% confidence interval. B) ΔpbLipB 
parasites do not complete liver stage development in vitro to form detached cells. In two 
independent experiments, HepG2 cells were infected with equal numbers of sporozoites. Parasite 
numbers were determined by counting fixed/ stained parasites at time points 24, 48, 65 and 84 
hpi and counting of live Hoechst stained detached cells at 65 hpi. No detached cells were ever 
detected. Error bars represent the standard error of the mean. C) Expression of 18s and msp-1 
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To further probe the timing of the developmental block in the lipB knockout parasites, HepG2 
liver cells were infected with either wild-type or ∆pbLipB parasites and assessed for parasite 
development by antibody staining for MSP1. Antibodies to MSP1 (PB000172.01.0) were used to 
recognize the morphology of the PPM at different time-points of development. Comparison of 
the staining of the wild-type and ∆pbLipB parasites revealed abnormal development of the 
knockout parasites at later time points (Figure 2.11). Wild-type ANKA parasites have well-
defined individual nuclei by 54 hpi. The PPM evenly invaginates around each of the individual 
merozoites at this and later time points during development. However the lipB knockout 
parasites, in contrast, demonstrate heterogeneous MSP1 staining that appears to clump and that is 
not well invaginated around the individual daughter cells. The abnormal MSP1 staining in the 
∆pbLipB parasites suggests that the plasma membrane is segregating improperly during the late 
time points of development. The images shown for ∆pbLipB parasites at the late schizont and 
cytomere stages of development show how the PPM staining is punctuated and does not 
surround the individual nuclei of the replicating parasite. Rarely were normal ∆pbLipB parasites 
found during in vitro cultures. These were only seen at very late time-points, around 84 hpi, 
when all normally developing parasites would have completed development and detached within 
their host cell membranes into the supernatant. The defect we are seeing in the MSP-1 staining 
clearly shows that the parasite plasma membrane is improperly segregating late in development 




Figure 2.11. ΔpbLipB parasites are defective in late liver-stage development 
Developing parasites were imaged over a liver stage time course by immunofluorescence for 
MSP1 (Green). The left panel shows wild-type (WT) cells at 54 hpi. The right three panels show 
ΔpbLipB parasites progressing through their liver stages of development within HepG2 cells. 
MSP1 staining of the parasite plasma membrane (PPM) appears to clump and is not evenly 
dispersed at late time points in the ΔpbLipB parasites.  
 
 
∆PBLIPB PARASITES HAVE REDUCED LEVELS OF LIPOYLATED PROTEINS IN THE APICOPLAST 
DURING LIVER-STAGE DEVELOPMENT  
To determine whether the defect in late liver stages was correlated with a lack of lipoylated 
proteins, we performed sequential staining with antibodies to the apicoplast marker, ACP, and an 
antibody that detects lipoylated proteins. The results demonstrate that the control wild-type 
parasites had extensive staining with the anti-lipoic acid antibody throughout the apicoplasts, 
whereas the ∆pbLipB parasites had more non-lipoylated structures (Figure 2.12). This phenotype 
was witnessed in 10-30 parasites per strain per time point. This result supports our hypothesis 
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lipoylated in the knock-out parasite lines. This is possibly due to the presence of other lipoic 
synthase enzymes in the apicoplast 204.  
 
 
Figure 2.12. ΔpbLipB parasites have less lipoylated protein in the apicoplast parasites 
ΔpbLipB sporozoites inoculated onto HepG2 cells were stained for lipoylated proteins (anti-LA) 
and apicoplast structure (anti-ACP) at  23 hpi and 48hpi. In comparison to wild-type parasites 




∆PBLIPB PARASITES SHOW LESS BRANCHING OF THEIR APICOPLAST DURING LIVER-STAGES  
Given the reduced lipoylation in the apicoplast described above, we examine the overall 
morphology of apicoplast development during the liver stage. We observed appreciably fewer 
branched structures during later time points, i.e. 48 hpi and 54 hpi (Figure 2.13). Unlike our 
results for the morphology of the apicoplast during the blood stages (Figure 2.13), these results 
demonstrate that blocking lipoic acid synthesis impacted the morphology of the apicoplast during 
liver stage development. ΔpbLipB sporozoites inoculated onto HepG2 cells showed slightly less 
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branching of the apicoplast over time points of development, as detected with anti-ACP 
antibodies (green). Red channel is as follows: anti-CSP at 6 hpi, anti-Exp1 for 24 and 48 hpi, and 
anti-MSP1 at 54 hpi and merozoites (WT at 62 hpi, ΔpbLipB at 72 hpi).  
 
To further examine this defect, we measured the size occupied by the ACP stained area by 
tracing the confines of the fluorescent images. This measurement is by the total parasite area to 
adjust for smaller growing parasites. This was measured by the total surface of the Exp1 staining. 
The data shows that in ΔpbLipB parasites, the apicoplast occupies a smaller total area of the 
parasite at the later time points, in comparison to the WT. However this analysis was not 
statistically significant.  
 
Additionally, we counted the number of ACP-positive branch points reaching into the periphery 
of the developing parasite and contacting the MSP-1 labeled parasite plasma membrane (PPM) 
for 40 parasites per time point, divided equally between WT and KO cultures. WT parasites 
yielded 7.4 ± 5.8 and 13.1 ± 4.3 (mean ± SD) “contact points” between branches of the 
apicoplast and the PPM, at 48 and 54 hpi, respectively. In comparison, KO parasites had an 
average of 4.4 ± 3.6 and 3.9 ± 2.1 contact points at 48 and 54 hpi (the latter time point was 
significantly different between the WT and KO lines; P<0.0001 based on Mann-Whitney U test). 





        
 
Figure 2.13. ΔpbLipB parasites have a less branched apicoplast in liver-stage 
A) Morphology of the apicoplast during different time points of development by staining with 
anti-ACP antibodies. The top panel shows wild-type parasites with the corresponding markers to 
identify parasite structure at the stages of development. The bottom panel shows the knock-out 
parasites at the same time-points. B) Quantification of the branching of the apicoplast between 
the wild-type and knock-out parasites at 48 and 54 hours post-infection. Data is represented as a 
percentage of the  area occupied by the anti-ACP fluorescence of the total parasite area (marked 
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8-BOA TREATMENT INHIBITS SCAVENGING OF EXOGENOUS LIPOIC ACID IN ∆PBLIPB 
PARASITES  
In order to determine whether the scavenge pathway is active in our knockout cell lines, liver 
stage ∆pbLipB parasites were treated with 8-BOA (Figure 2.14). The developing parasites at 48 
hpi were then stained with Mitotracker red was used to distinguish the mitochondria and the anti-
Lipoic acid antibody, to find the lipoylated proteins.  
 
 
Figure 2.14. 8-BOA inhibits scavenging of lipoic acid species into the mitochondria 
A) HepG2 cells infected with wild-type parasites at 48 hpi were stained with anti-LA to identify 
the lipoylated structures, in the presence of DMSO treatment as a control. B) ΔpbLipB parasites 
after 48 hours grown in the presence of 200 µM 8-BOA showed reduced levels of lipoylated 
protein in the developing parasites.  
 
In comparison to wild-type ANKA parasites ∆pbLipB parasites treated with 8-BOA show less 












































scavenge pathway brings exogenous lipoic acid into the mitochondria of P. berghei liver stages 
for attachment to the dehydrogenases. ∆pbLipB parasites showed very few lipoylated structures 
outside of the mitochondria. Therefore after treatment with 8-BOA, the developing parasites 
showed almost no residual lipoylation during liver stage development.  
 
In a similar set of experiments, we inhibited scavenging of lipoic acid during the asexual blood 
stage cycle with the 8-BOA inhibitor. In these experiments, P. berghei parasites were incubated 
overnight at different concentrations of 8-BOA and then counted for the number of nuclei per 
infected red blood cell (Figure 2.15). We wanted to determine whether 8-BOA would reduce the 
replication of Plasmodium parasites during an overnight incubation period. This experiment was 
repeated three times, counting between 100 - 200 infected red blood cells per parasite line.  
 
 
Figure 2.15. No significant different in schizont development between ΔpbLipB and wild-
type blood-stage parasites treated with 8-BOA over-night  
Parasites were counted for the number of nuclei per parasite, incubated with different 
concentrations of 8-BOA or DMSO control. In three experiments, equal numbers of infected red 
blood cells were incubated and counted by DAPI-staining for nuclei. Results demonstrate the 
percentage of total number of parasites counted (100-200 per experiment) as grouped by number 
of nuclei per RBC. Data represents the average of the percentages calculated in three 
experiments. There was a reduction in the amount of multi-nucleated, fully mature schizonts in 
culture, however no significant difference between the wild-type and the knock-out parasites.  
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We identified fewer fully formed schizonts after over-night development, in a dose dependent 
manner with 8-BOA treatment. This confirms that 8-BOA is a toxic inhibitor to parasite 
replication, as previously demonstrated in P. falciparum parasites 191. However, there was no 
significant difference between the wild-type and the knock-out parasites.  
 
In parallel, these 8-BOA treated parasites were injected back into naïve mice to determine the 
blood-stage growth kinetics. 8-BOA treatment increased the recovery time for both P. berghei 
ANKA and ΔpbLipB parasites in a dose-dependent manner. We observed a more significant 
impact of the 8-BOA treatment on the ΔpbLipB parasites than the wild-type ANKA cells (Figure 
2.16). The ΔpbLipB parasites required a longer recovery time to reach the same levels of 
parasitemia as the untreated control. These results suggest that although we don’t see a 
difference between the impact of 8-BOA between the wild-type and the knock-out after the 
overnight incubation period, there is a difference in their processes of lipoic acid attachment. By 
disrupting LipB gene, we have inhibited the way parasites are repopulating their lipoylated 
proteins. This implies that a degree of exchange between the scavenge and synthesis pathways 











Figure 2.16. Blood-stage ΔpbLipB parasites are more sensitive to lipoic acid scavenge 
inhibitor 8-BOA 
A) P. berghei wild-type or B) ΔpbLipB parasites were treated with concentrations of 100, 200 
and 400 µM 8-BOA or DMSO control during overnight incubations. Resuspended cultures of 
10,000 parasites were inoculated into naïve mice by intravenous injection. Parasitemia was 
tracked by thin smear microscopy. The 8-BOA treatments showed a dose-dependent effect and a 
stronger impact on the ΔpbLipB parasites than on wild-type control. Statistics were generated 




Since lipoic acid is an essential cofactor used to covalently modify a number of enzymatic 
complexes, we decided to disrupt pbLipB to determine the essentiality of lipoic acid synthesis 
during the Plasmodium life-cycle. Our studies reveal that while lipoic acid synthesis is not 
required for mosquito stage development or blood-stage, it is critical for normal liver stage 
development.  
 
∆pbLipB parasites arrest during liver-stage development in vitro and have reduced infectivity in 
vivo as evidenced by a significantly extended pre-patent period. Additional experiments 
suggested that the developmental defect occurs late during liver stage growth. ∆pbLipB parasites 
in early liver-stage development have the same parasite size and absolute number as wild-type 
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controls. ∆pbLipB parasites had abnormal MSP-1 staining. This staining showed that ∆pbLipB 
parasites do not have normal development of the PPM. This membrane appeared to be unable to 
invaginate around each of the developing merozoites. This suggests that disruption of LipB had 
an impact on membrane biogenesis. Disruption of LipB leads to a reduced levels of lipoylation of 
PDH in the apicoplast and its main role in Plasmodium parasites is considered to be the 
generation of acyl-CoA for fatty acid biosynthesis. Perhaps ∆pbLipB parasites show 
abnormalities in the PPM because it is not synthesizing adequate amounts of fatty acids.  
Although we did not observe any detached cells, ∆pbLipB parasites were nonetheless capable of 
establishing a blood-stage infection in vivo, albeit at a reduced rate. These results indicate that 
synthesis of lipoic acid synthesis plays an important role during liver stages development 
although it is not absolutely required.  
 
Liver stage ∆pbLipB parasites demonstrated reduced levels of lipoylated proteins in the 
apicoplast. In addition these parasites developed apicoplasts with an abnormal size and 
morphology. This phenotype is likely due to the lack of lipoylation of PDH within the apicoplast. 
A similar defect in the apicoplast morphology during liver-stage development was found when P. 
yoelii parasites were disrupted for the PDH-E1 and E3 subunits 205. 
 
In an earlier study, P. falciparum ∆pbLipB lines demonstrated a residual amount of lipoylated 
PDH-E2 subunit and attributed it to the action of the LplA2 ligase that localizes to both the 
apicoplast and the mitochondria 202. It is possible that the residual amount of lipoic acid on the 
apicoplast in our knock-outs is because of lipoylation by LplA2 in P. berghei. RT-PCR studies 
with P. berghei confirmed the expression of pblplA2 during both blood and liver stages (data not 
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shown). The residual amount of lipoylation of PDH, due to LplA2, could also be the reason why 
we do not have a complete arrest during in vivo infections. Disruption of LplA2 would be an 
interesting follow-up experiment to determine whether it has an essential role during liver-stages. 
 
While pbLipB was not essential for development during the blood-stages, we did find that it is 
required for normal levels of lipoylation of the PDH and BCDH proteins. There was no 
significant change in the growth rate of parasites and we also saw no impact on development of 
the apicoplast organelle. Our results are contrary to the phenotype found upon disruption of lipB 
in P. falciparum, in which knock-out parasites replicated faster than the control lines 202. Lipoic 
acid can act as a mediator of histone hyperacetylation and cell cycle arrest. Changes in the levels 
of lipoylation of proteins within the mitochondria could impact the histone acetylation  and 
Plasmodium has a unique TCA cycle in which acetyl-CoA generated in the mitochondria is 
exclusively used for histone modification 209.Lipoic acid can also inhibit histone deacetylase in 
other cell types 210.These other functions of lipoic acid, beyond its role as a post-translational 
modification, could explain the changes in growth kinetics of ∆PfLipB lines. However, we did 
not see any change in growth kinetics in vivo in ∆pbLipB parasites. Explanation for this 
difference could be the different types of environments used to measure blood-stage growth. Or 
else, it could mean that the lipoic acid synthesis pathway has a different function in P. 
falciparum parasites versus P. berghei. Authors of the study did not propose an explanation as to 
why their knock-out parasites replicated faster in P. falciparum than control lines. However, in 
both studies, disruption of LipB did not hinder parasite replication in blood-stage. Several 
phenotypes presented in this chapter were not studied in the ∆PfLipB study; i.e. morphology of 




Our results demonstrate that while lipb, pdh and bcdh are expressed during blood-stages in 
Plasmodium berghei, they are not critical for development and can be inactivated in vivo without 
an impact on pathogenesis. However, under conditions in which parasites were treated with the 
lipoic acid analog, 8-BOA that competitively inhibits lipoic acid scavenging, ∆pbLipB parasites 
required a longer time to reach the same parasitemias as wild-type. This suggests that lipoic acid 
synthesis might be needed for pathogenesis under lipoic acid limited conditions.  
 
The central components of the FAS-II pathway (FabI, FabB/G, FabZ) and PDH are unessential 
for blood-stage but critical for liver stage development 105, 106, 205. ∆pbFabI parasites, like 
∆pbLipB, also failed to form detached cells during in vitro culture, however most of the late 
liver-stage parasites were not MSP1 positive 105. ∆pyPDH parasites also lacked MSP-1 staining 
in the mature late liver-stages and had abnormal apicoplast morphology 205. A unique feature of 
the phenotype of ∆pbLipB parasites was that it arrested later than other knock-outs related to 
lipid metabolism in liver stages. This is likely due to the residual amount of lipoylation of PDH, 
which could enable parasites to develop until very late time points with a limited amount of 
functional PDH proteins. Although we created a P. berghei line stably deleted for the lipB, it is 
not a complete knock-out in terms of PDH and BCDH protein function. Our western-blot data 
showed 16% of signal intensity for the PDH protein and 2% for BCDH protein in comparison to 
the wild-type parasite extracts. As mentioned above, BCDH protein becomes more visible at 
longer exposures. We have not completely abolished the enzymatic function of these complexes, 
but instead decreased the amount of functional protein per cell. This is one explanation for why 




Other explanations for the phenotype of ∆pbLipB parasites could be related to its functions 
outside of fatty acid generation. Lipoic acid is unique to other carbon chain fatty acid since it is 
known for its potent antioxidant properties. It is unknown whether the parasite would require 
more antioxidation during liver-stage of development, but it definitely an interesting avenue to 
consider.   
 
A third explanation is whether the reduction of BCDH lipoylation is responsible for the arrest we 
see during liver stages. BCDH degrades branched chain amino acids, valine, leucine, isoleucine, 
to generate acetyl-CoA or succinyl-CoA, intermediates for the TCA cycle 199. TCA-cycle 
intermediates have been detected in the blood stage of Plasmodium 209. Since we have greatly 
reduced the amount of lipoylated BCDH, we can conclude that it is non-essential for blood 
stages. BCDH is overexpressed during liver-stage in comparison to blood-stage 104, however its 
role and a general understanding of the importance of the TCA-cycle during liver-stage remains 
to be clarified. Plasmodium liver-stage parasites replicate at an enormously abundant rate, which 
might require the energy generated from the TCA-cycle. However, we are not certain that BCDH 
is unlipoylated in ∆pbLipB liver-stage parasites since our western-blot data used parasite extracts 
from blood-stage parasites. In addition, the apicoplast and the mitochondria are not in close 
proximity during liver-stages of development like during blood-stage 133. It is possible that LipB 
is only responsible for the lipoylation of BCDH during blood-stage replication.  
 
Our data suggest that some amount of lipoic acid exchange is occurring between the synthesis 
and the salvage pathways located in the apicoplast and the mitochondria,  respectively. Recently, 
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it has been shown that scavenging of lipoic acid is essential to complete liver-stage development 
in rodent Plasmodium species 191. Treatment with 8-BOA did not completely arrest liver-stage 
development in vitro, since some parasites were capable of forming full merozoites 203. Studies 
in P. falciparum blood stages showed no effect of 8-BOA treatment on lipoylation of apicoplast 
proteins 191. However, it is possible that exchange is occurring in a small and unidirectional 
manner; such that lipoic acid generated in the apicoplast is exported into the mitochondria, 
explaining our result of reduced lipolyation of BCDH and increased sensitivity to 8-BOA. A 
close physical association between the mitochondria and the apicoplast has been demonstrated 
during the blood stages and these organelles are known to share some metabolic pathways such 
as heme biosynthesis 211. However, the two organelles do not share such close proximity 
throughout the liver stages 133, suggesting less exchange of metabolites during this stage. The 
uptake of lipoic acid into human cells is an energy-dependent reaction, mediated by a sodium-
dependent vitamin transporter 195 and 8-BOA is likely actively transported into Plasmodium 191. 
However, the mechanisms of lipoic acid uptake into the parasite or the processes that could 
regulate its movement between the organelles remain to be determined.  
 
The results from this study advance our understanding of the importance of lipoic acid 
metabolism throughout the parasite life cycle. As mentioned, ∆pbLipB parasites arrested even 
later than other related knock-outs 205, 105, 106. This is an important finding since parasites that 
arrest late during liver stage development confer the strongest amount of protection to 
subsequent challenge 107. LipB is a very viable candidate for the development of a whole 
attenuated sporozoite vaccine. Testing these resulting in P. falciparum knock-out parasites would 






































































































































































































































































3. THE ROLE OF HOST LIPIDS 
 DURING PLASMODIUM PATHOGENESIS 
 
ABSTRACT 
Plasmodium parasites require the import of exogenous fatty acids for replication during the 
blood and liver-stages. The parasite uses these fatty acids for a number of functions, including 
membrane formation and metabolic co-factors. We wanted to assess how modifications to the 
fatty acid content the host would impact the replication of Plasmodium parasites. To 
understanding how Plasmodium parasites scavenge nutrients from their environment, we decided 
to examine their replication in mice that have decreased levels of circulating fatty acids in the 
blood-stream and fatty acid content in the liver. Using two methods to reduce the levels of 
circulating fatty acids in mice, we have monitored the replication rates of parasites in vivo. In the 
first, we have administered a fatty acid-lowering agent, clofibrate, which chemically stimulates 
beta-oxidation of fatty acid. In a second method, we used a genetic approach to block lipid 
synthesis in the host. ΔXBP1 mice are disrupted for a transcription factor that plays a key role in 
fatty acid synthesis in the liver. Both of these animal models demonstrated significant decreases 
in blood-stage growth kinetics of P. berghei ANKA parasites. We found an even greater impact 
on the blood-stage growth kinetics of ΔpbLipB parasites versus the wild-type control parasites. 
We examined the impact of reduced fatty acid content in the liver through the inoculation of P. 
berghei ANKA sporozoites and determination of the pre-patent period. There were modest 







Plasmodium requires a critical amount of fatty acid scavenging from the host to complete its life-
cycle. During the blood stage, Plasmodium falciparum metabolizes a broad range of serum-
derived fatty acids into the major lipid species of the parasite membrane and lipid bodies 177. It 
has been demonstrated through in vitro experiments that the minimal serum components required 
for Plasmodium falciparum blood-stage growth are palmitic and oleic or steric acids. These 
serum components are metabolized into the major constituents of membranes and lipid bodies of 
the parasite; phosphatidylcholine, phosphatidylethanolamine, diacylglycerol and triacylglycerol 
181. The reliance on host lipids for parasite metabolism during intracellular growth is further 
supported by studies on parasites disrupted in genes for fatty acid synthesis. FabI, of the FAS-II 
pathway of fatty acid synthesis, is not-essential during blood-stages of P. falciparum 105. The 
same result was found by disrupting fab B/F in P. yoelii 212. These studies demonstrate that 
during blood stage replication Plasmodium derives all of its fatty acid needs, likely through 
scavenging from the host serum. 
 
Conversely, in the liver stage, the Plasmodium parasite might meet the majority of its demands 
for fatty acids via de novo synthesis by the FAS-II pathway. Deletion of FabI decreases 
infectivity of the liver stages of P. falciparum and P. berghei 105. The requirement for 
Plasmodium parasites to generate their own lipids during liver stage development is likely due to 
a greater need for fatty acids for membrane biogenesis in this life-cycle stage. The liver is also 
the key organ for fatty acids generated in the human host. In addition to its functions in 
detoxification of the blood-stream, protein synthesis, and production of chemicals necessary for 
digestion, the bulk of lipoproteins for the body are produced in the liver. Therefore, any 
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modifications in liver function could lead to abnormalities in the level of lipid species in the 
bloodstream 213. 
 
Scavenging of lipid-species by Plasmodium parasites from the host during liver-stage 
development has not been well characterized. Only cholesterol and lipoic acid scavenging have 
been demonstrated during liver-stage infection. Cholesterol is scavenged from the host to enrich 
in the parasite PVM for rigidity and fluidity [138, 226]. Scavenged lipoic acid is essential in 
liver-stage for its attachment to multi-enzymatic complexes within the parasite mitochondria 203. 
It has been hypothesized that parasites maximize their potential to scavenge host nutrient through 
association with hepatocyte organelles, such as the host endoplasmic reticulum (ER) 126. A close 
proximity between the PVM and the host mitochondria has also been described, which might 
enable the uptake of other nutrient needs. 
 
New insights into the metabolic processes of Plasmodium parasites were found by a 
transcriptional profiling study of P. falciparum parasites isolated from human patients 186. 
Contrary to the transcriptome data set for P. falciparum replication during in vitro culture, 
samples from patients demonstrated three unique transcriptional states, suggesting that the 
parasite has the capacity to transcriptionally respond to varying host metabolic conditions in 
which it propagates. The first state, which represents active growth based on glycolytic 
metabolism, is similar to the transcriptional profile observed with in vitro cultures. The second 
and third states resemble a starvation response, in which the parasites metabolize alternative 
carbon sources to support growth. These latter stages are often indicative of an environmental 
stress response, which involves the induction of gene sets associated with glycolysis, amino-acid 
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metabolism and nitrogen metabolism and general growth processes such as nuclear transcription 
and cytoplasmic translation. The up-regulation of metabolic pathways during P. falciparum 
propagation in vivo implies that lipid metabolism of parasites is enhanced as required during low 
lipid conditions. Similarly, our findings from Chapter 2 demonstrated an increased sensitivity to 
the lipoic acid scavenge inhibitor, 8-BOA, in the ΔpbLipB parasites we generated. In order to 
follow-up this finding in a broader context, we set out to determine whether parasites would 
require lipoic acid or fatty acid synthesis during in vivo replication in a fatty acid depleted 
environment.  
 
In our study, we have used two independent approaches to determine the role of host fatty acids 
during Plasmodium blood and liver stage development in vivo. In the first approach, we 
decreased host fatty-acid levels by stimulating beta-oxidation of lipid species with the drug, 
clofibrate. Fibrates have been demonstrated to lower fatty acids and triglycerides 214. Fibrates 
function by stimulating the peroxisomal beta-oxidation pathway in the liver. Clofibrate acts by 
binding to Peroxisome Proliferator Activated Receptor-alpha (PPAR-α), which is predominantly 
expressed in the liver, kidney, heart and adipose tissue. Activation of the PPAR-alpha receptor, 
in hepatocytes leads to the proliferation of peroxisome organelles that are the site of beta-
oxidation in the liver. The resulting increased beta oxidation causes decreases in the levels of 
circulating triglycerides and fatty acids and liver total lipid content 214. PPAR-α is normally 
activated under nutrient-deficient conditions as an adaptive response to prolonged fasting. Beta-
oxidation is the process of breaking down fatty acids to generate acetyl-CoA to enter the citric 
acid cycle. The three steps of the beta-oxidation pathway include, activation of fatty acids in the 
cytosol, transport of activated fatty acids into the mitochondria or peroxisomes and beta-
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oxidation of the fatty acid. In peroxisome beta-oxidation, fatty acids oxidation ceases at 
octanoyl-CoA. Unlike beta-oxidation in the mitochondria, in the peroxisomes it is not coupled to 
ATP synthesis. It also requires other enzymes for beta-oxidation than the mitochondrial pathway; 
the carnitine acyltransferase enzyme (for the transport of the activated acyl group into the 
peroxisome), the acyl-CoA oxidase (the first step of oxidation) and the peroxisomal beta-
ketothiolase (different substrate specificity than the mitochondrial beta-ketothiolase). Clofibrate 
administration does not decrease fatty acid synthesis, it reduces fatty acid levels in the serum and 
in the liver content. A previous study demonstrated that clofibrate-treated mice showed a reduced 
level of P. berghei blood-stage growth 215. 
 
Figure 3.1. Chemical structure of clofibrate 
 
 
In our second approach, we used the XBP1 liver-specific conditional knock-out mouse in order 
to decrease de novo fatty acid synthesis in the liver 216. This transcription factor is ubiquitously 
found in adult tissues, with its highest expression in the fetal exocrine glands, osteoblasts and 
liver tissue. XBP1 is essential for hepatocyte differentiation as XBP1-deficient embryos die in 
utero217. In the liver, XBP1 expression is induced by glucose and it directly regulates the 
expression of critical genes involved in fatty acid synthesis 216. XBP1 is activated by inositol 
requiring enzyme 1 (IRE1), a proximal sensor of ER stress, which splices the XBP1 mRNA into 
a functional transcript 218. The splicing by IRE-1 removes 26 bp from XBP1 mRNA and the 
spliced 267 amino acid XBP1 protein becomes a transcriptional activator once it translocates into 
the nucleus. XBP1 is a key factor in the unfolded protein response (UPR) in the endoplasmic 
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reticulum (ER) 219. XBP1 also regulates genes involved in ER-associated degradation (ERAD), 
redox metabolism, autophagy, vesicular trafficking, glycosylation and protein entry into the ER. 
The UPR ensures correct folding, processing, export and degradation of proteins that emerge 
from the ER during both stressed and normal conditions.  
 
Fatty acid biogenesis occurs in the ER within mammalian cells. XBP1’s role in controlling fatty 
acid biosynthesis is relates back to the cell’s need to regulate activity within this organelle and 
avoiding ER stress. Similarly, XBP1 is also known to be important for the development of B 
cells 219. XBP1 expression is critical during B lineage development from pro-B to plasma cells, 
where its high transcript level is found in plasma cells. XBP1 plays a critical role as a regulator 
of the ER stress response, particularly in B cells during high levels of protein synthesis that are 
required for plasma cells to secrete anti-bodies 
 
Deficiency of XBP1 in the liver, using a conditional knock-out approach, leads to a significant 
decrease in serum triglycerides, cholesterol and free fatty acids while retaining normal liver lipid 
content in the liver 216. XBP1 exon 2 is floxed on either side and an inducible Mx1-CRE is 
introduced on a separate chromosome. Poly-IC injections stimulate CRE expression and create a 
stable knock-out in homozygous-floxed mice. We used this conditional knock-out mouse to test 





Figure 3.2. The role of XBP1 during hepatic lipogenesis 
The XBP1 transcription factor has a unique role for fatty acid metabolism by promoting the 
expression of both sterol and glycolysis lipogenesis in the liver. Glucose stimulates the 
processing of the XBP1 mRNA. Schematic is reproduced from 219. 
 
In this study, we have used these two independent models to study the impact of a reduction in 
lipids on the pathogenesis of malaria. We have found that blood stage parasites when inoculated 
into clofibrate-treated mice or XBP1 KO mice had decreased growth kinetics. Both models 
demonstrated modest changes during liver stage infection.  
 
METHODS 
ANIMAL USE AND CARE 
XBP1Δ mice were generated as previously described 216. The mice were generated on the 
C57/BL6 background at Harvard University, Cambridge Massachusetts. Mice were imported 
into Columbia University facilities and cared for according to University standards under a 
protocol approved from the Institute for Animal Care and Use Committee. Mice over 5 weeks 
Glimcher & Lee: XBP1 and Lipogenesis E3
Figure 1. Schema of XBP1 in hepatic lipogenesis.
stimulates fatty acid synthes s a d very low
density lipoprotein (VLDL) secretion, as ob-
served in genetically modified obese (ob/ob)
mice, aggravating insulin resistance.7 Control
of dyslipidemia in patients with coronary artery
disease with the statins, agents that target 3-
methylglutaryl-coenzyme A (HMG CoA) re-
ductase, and with triglyceride-lowering agents
has resulted in measurable improvements in
cardiovascular morbidity and mortality, sug-
gesting clinical benefits of lowering hepatic de
novo lipid synthesis.8
The Transcription Factor XBP1
The transcription factor XBP1 has been
identified as a key regulator of the mammalian
unfolded protein response (UPR) or endoplas-
mic reticulum (ER) stress response, which is
activated by environmental stressors such as
protein overload that require increased ER
capacity.9 XBP1 is activated by a post-
transcriptional modification of its mRNA by
inositol requiring enzyme 1 (IRE1), an ER-
localizing proximal sensor of ER stress that is
a Ser/Thr protein kinase and endoribonucle-
ase.10–13 Upon ER stress, IRE1 induces an un-
conventional splicing of XBP1mRNA by using
its endoribonuclease activity to generate a ma-
ture mRNA encoding an act ve transcription
factor,10–14 XBP1s, which directly binds to the
promoter region of its target genes to promote
transcription.15–17 In mammalian cells, a 26-
nucleotide intron of XBP1 mRNA is spliced
out by activated IRE1, leading to a shift in
th co o rea ing frame. Transl tion of the
new reading frame results in the conversion
of XBP1 from an unspliced form of 261 amino
acids (in human) to a spliced form of 376 amino
acids that comprises the original N-terminal
DNA binding domain plus an additional, po-
tent transactivation domain in the C termi-
nus.10–12,14 XBP1 mRNA is the only known
substrate of the ribonuclease activity of IRE1
in metazoans, as is the case in yeast, in which
a genome-wide search failed to identify any
additional substrates.18 While the function of
XBP1 in hepatic lipogenesis is unrelated to its
function in the UPR (see below), it neverthe-
less requires splicing by IRE1α. Although IRE1
is the most evolutionarily conserved branch
of the UPR, little is known about the regula-
tion of its ctivity or about it function in vivo.
IRE1α–/– mice have defects in embryonic liver
development but die earlier in embryogenesis
than XBP1–/– embryos.19 In insect cells, ac-
tive IRE1 was recently proposed to control
the degradation of mRNAs encoding certain
ER proteins that were predicted to be difficult
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old were injected with 250 µg of poly(I:C) (Amhersham) every two days, for a total of three 
times, to induce CRE recombinase-mediated deletion of exon 2. This deletion results in a 
frameshift of the open reading frame, producing a truncated and non-functional product. Primers 
specific to exon 2 were used for PCR confirmation of excision of exon 2 post-poly I:C injections 
(Figure 3.8).  
 
CLOFIBRATE DOSAGES IN MICE 
Female Swiss-Webster mice of 6 weeks of age were purchased from Taconic and housed in 
Columbia University mouse facilities. Groups of five mice for each independent experiment 
were injected with dosages of 0.5 mg/kg or 5.0 mg/kg of clofibrate resuspended in DMSO or a 
control volume of DMSO by intraperitoneal injection for 9 days. Volume injected was < 0.1ml 
per mouse of <10% DMSO to avoid toxicity. We confirmed the reduction of levels of circulating 
lipids five and ten days after the completion of treatment (also represented as day 0 and day 5 of 
parasite inoculation). WAKO enzymatic kits were used to determine the levels of non-esterified 
fatty acids (NEFA) and triglycerides (TG) in treated and untreated mice. The lipid levels are 
represented as the average percent reduction of lipid levels for treated versus untreated control 
mice, for three independent experiments.  
 
PARASITE PROPAGATION 
Plasmodium berghei ANKA, ΔpbLipB and ΔpbFabI parasites were inoculated into mice from 
cryopreserved stocks. Parasites were diluted to inoculums of 10,000 or 1,000 parasites per 0.1ml 
of media. Clofibrate treated mice with infected with parasites 5 days after the completion of drug 
treatment. Blood-stage parasites were inoculated into mice by intravenous (IV) tail vein 
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injection. Sporozoites were obtained from mosquitoes (reared at NYU Medical Center) dissected 
on day 18 - 20 post-feeding and injected by IV into mice at inoculums of 10,000 or 1,000. 
Parasite growth in mice was determined by thin-smear microscopy of mouse blood. 
 
ALBUMIN DETECTION IN MOUSE PLASMA 
Groups of five mice were tested for their circulating levels of albumin in the plasma. 
Approximately 30-50υl of blood was drawn with an anti-coagulant every other day from the tail-
vein during a 9-day clofibrate treatment. Blood was diluted 1:30,000, according to the protocol 
of the AbCAM Mouse Albumin ELISA kit. The clorometric read-out values generated from the 
ELISA were converted into gram per deciliter (g/dL) with the slope generated by the standard 
curve processed on the same day. Data is represented as the average value of five mice and error 
bars represent the standard deviation of all values. 
 
Name   Nucleotide Sequence Description 
P2656  ACTTGCACCAACACTTGCCATTTC F flox primer 
P2657  CAAGGTGGTTCACTGCCTGTAATG R flox primer 
P2658  GCGGTCTGGCAGTAAAAACTATC F cre primer 
P2659  GTGAAACAGCATTGCTGTCACTT R cre primer 
P2660  CTAGGCCACAGAATTGAAAGATCT F IL-2 control primer 





F primer to verify excision of 





R primer to verify excision of 






F primer that only detects the 






R primer that only detects the 
WT non-excised XBP1 locus 





 All stats analyses were performed using the Prism 4 software. Analysis of the significant 




BLOOD-STAGE PARASITE REPLICATION RATES ARE REDUCED IN CLOFIBRATE-TREATED MICE 
A previous study showed that clofibrate treatment decreased Plasmodium blood stage growth. In 
this study, we inoculated parasites into the dosed mice after completion of the treatments and did 
not continue dosing during the stages of infection. The impact of clofibrate treatment on host 
lipids mice was confirmed through the use of WAKO enzymatic kit for the values of NEFA and 
TG in the serum.  Values from both days 0 and 5 post-parasite inoculation of treated mice show a 
reduction in the serum lipid levels (Figure 3.3). The absolute values of the nonesterified fatty 
acid and triglycerides for the 3 independent clofibrate experiments are also shown in Table 3.2. 
In three independent experiments, mice were treated with clofibrate over the course of 9 days. In 
all three experiments, the NEFA values were detected by WAKO enzymatic kit and represented 
as the average mEq/L of the 5 mice per treatment group. In two experiments, the TG values were 
detected, also by WAKO kit and shown above as the average mEq/L. Values were determined on 







                   
Experiment Lipid         Day Post Average Value SEM   Percent   
Group  Species   Treatment (mEq/L)                 Reduction  
I  Non-esterified     
  Fatty Acids 
Untreated       5 0.7024   0.198   
0.5mg/kg    5 0.505   0.074  28% 
Untreated       10 0.996   0.142   
0.5mg/kg    10 0.427   0.329  57% 
 
II  Non-esterified     
  Fatty Acids 
Untreated       5 0.164   0.085   
0.5 mg/kg    5 0.130   0.039  21% 
5.0 mg/kg    5 0.102   0.039  22% 
Untreated       10 0.338   0.158 
0.5mg/kg    10 0.220   0.037  35% 
5.0 mg/kg    10 0.112   0.086  66% 
 
II  Triglycerides 
Untreated       5 0.267   0.145   
0.5 mg/kg    5 0.206   0.062  23% 
5.0 mg/kg    5 0.204   0.062  24% 
Untreated       10 0.234   0.068 
0.5mg/kg    10 0.205   0.086  12.5% 
5.0 mg/kg    10 0.204   0.081  13% 
 
 
III  Non-esterified     
  Fatty Acids 
Untreated       5 0.148   0.060   
0.5 mg/kg    5 0.125   0.007  15.5% 
5.0 mg/kg    5 0.121   0.002  18.3% 
Untreated       10 0.156   0.060 
0.5mg/kg    10 0.105   0.108  33% 
5.0 mg/kg    10 0.072   0.011  54% 
 
III  Triglycerides 
Untreated       5 0.132   0.019   
0.5 mg/kg    5 0.110   0.017  16.5% 
5.0 mg/kg    5 0.090   0.008  31% 
Untreated       10 0.491   0.088    
0.5mg/kg    10 0.449   0.086  9% 
5.0 mg/kg    10 0.436   0.076  12%  
                                                                                       





     
 
Figure 3.3. Triglyceride (TG) and non-esterified fatty acid (NEFA) in the serum in 
clofibrate-treated mice as a percentage of control 
The data represent the average of the percentage of three experiments when TG and NEFA levels 
were measured on days 0 and 5 post infection with parasites. For each experiment, 5 mice from 
each group were measured. The percent reduction represents the average of the treated groups 
divided by the average of the untreated groups, subtracted from 100. Error bars represent 
standard error of the mean. 
 
To investigate the impact of reducing the lipid levels on malaria blood-stage growth, P. berghei 
wild-type, Δpblipb and ΔpbFabI, parasites were inoculated into clofibrate-treated mice 5 days 
after the completion of the clofibrate dosing (i.e. Day 0 as annotated in Figures 3.4, 3.5 and 3.6). 
All inoculations were performed at 10,000 parasites per mouse and comparison of the blood-
stage growth kinetics of the different parasite strains was completed in parallel. Parasitemias 
were tracked over the course of 10 days or until parasites reached lethal levels of parasitemia; i.e. 
mice were sacrificed as they demonstrated severe illness due to the parasite infections. Infections 
are always lethal, therefore in our experiments no mice ever recovered from infection after 
TG Levels









































































viewing detectable levels of parasitemia. We found that clofibrate treatment dramatically 
reduced the rate of blood-stage growth kinetics for all parasite lines (Figures 3.4 – 3.6).  
 
Additionally, we also observed that a decrease in the rate of blood-stage development correlated 
with the decrease in lipid levels. Mice treated with a ten-fold higher dosage of clofibrate 
treatment showed greater impact on blood-stage replication for all parasite lines. In addition to 
reducing the rate of blood-stage replication, clofibrate treatment was found to have an even 
greater impact on the Δpblipb parasite rate of replication in comparison to wild-type or the 
ΔpbFabI parasites (Figure 3.5). These results show that changing the lipid levels of the host, by 






Figure 3.4. Kinetics of blood-stage growth of wild-type parasites in clofibrate-treated mice 
Data represent the average parasitemias tracked for three independent experiments: 3 
experiments with the dosages of 0.5 mg/kg and 2 experiments with the dosages of 5.0 mg/kg of 
clofibrate. Each independent experiment contained five mice per group. Error bars represent 






Figure 3.5. Kinetics of blood-stage growth for Δpblipb parasites in clofibrate-treated mice 
Data represent the average parasitemias tracked for three independent experiments: 3 with 0.5 
mg/kg dosage and 2 with 5.0 mg/kg dosage of clofibrate. Each independent experiment 






Figure 3.6. Kinetics of blood-stage growth for ΔpbFabI parasites in clofibrate-treated mice 
Data represents the average parasitemias tracked for two independent experiments; both with the 
dosages of 0.5 mg/kg and 5.0 mg/kg. Each independent experiment contained five mice per 
group. Error bars represent standard error of the mean. Significance was determined using a 




SPOROZOITE INFECTIONS OF CLOFIBRATE-TREATED MICE SHOW AN INCREASED PRE-PATENT 
PERIOD  
To determine whether host liver lipid levels impact liver-stage development of P. berghei, mice 
that were dosed with 0.5 mg/kg  or 5.0  mg/kg clofibrate were infected with sporozoites. In two 
independent experiments, the pre-patent period was determined by thin-smear microscopy and is 
defined as the number of days it takes after sporozoite inoculation to a detectable blood-stage 
infection. This experiment revealed an increase in the average pre-patent period for the 
clofibrate-treated mice in comparison to the control, ranging from 0.5 days to 2.0 days (Table 
3.3).  
 
                   
Experiment Clofibrate  Sporozoites  Percent of        Average Prepatent  
  Dose     Inoculated Infected mice    Period    
I  Control    1,000  100%    4.0 days 
 0.5 mg/ kg  1,000   66%    4.0 days 
 5.0 mg/ kg  1,000  100%   4.5 days 
 
II  Control    1,000  100%    4.0 days 
 0.5 mg/ kg  1,000  100%    4.0 days 
 5.0 mg/ kg       1,000  100%   4.5 days 
 
III  Control    10,000  100%    4.0 days 
 0.5 mg/ kg  10,000  100%    4.0 days 
 5.0 mg/ kg 10,000  100%   4.5 days 
 
IV  Control    10,000  100%    4.0 days 
 0.5 mg/ kg 10,000  100%    4.0 days 
 5.0 mg/ kg 10,000  100%   4.5 days 
 
                          
Table 3.3. Pre-patent period of P. berghei ANKA sporozoites in clofibrate-treated mice 
Mice dosed with clofibrate were inoculated with 1,000 or 10,000 P. berghei ANKA wild-type 
sporozoites, administered intravenously. Detection of blood-stage parasites and determination of 
the pre-patent period was conducted by daily thin-smear microscopy. The lower lipid of 




A greater difference in the pre-patent period was seen in mice treated with higher doses of 
clofibrate-treatment. While the phenotype we are seeing is subtle, the pre-patent period is longer 
at the clofibrate dose of 5.0 mg/kg, implying a dose-response.  
 
CLOFIBRATE TREATMENTS REDUCE THE AMOUNT OF CIRCULATING ALBUMIN IN MICE 
Although there is no published information relating clofibrate treatment to a physical reduction 
in circulating albumin levels, we were interested in determining whether albumin levels changed 
over the course of clofibrate treatments. We found that clofibrate treated mice had reproducibly 
lower levels of albumin in comparison to the untreated controls. Although there was a high 
degree in variability between the groups of the untreated control mice and the treated mice, we 
found reproducibly lower levels versus the untreated control mice.  
 
 
                   
Treatment Lipid         Days of Average Value SEM   Percent   
Group  Species   Treatment (g/dL)                 Reduction  
  Albumin 
Untreated       2 5.50   2.40   
5.0 mg/kg    2 3.20   0.78  26% 
Untreated       4 5.30   2.50   
5.0 mg/kg    4 2.59   1.57  47% 
Untreated       6 4.98   23.6   
5.0 mg/kg    6 2.50   1.20  50% 
Untreated       8 4.80   3.30   
5.0 mg/kg    8 3.50   2.80  27% 
 
                                                 






Figure 3.7. Albumin levels in mouse plasma during clofibrate treatment 
Albumin was tested by ELISA-Abcam enzymatic kit. Data represents the average of 5 mice 
tested over the course of one clofibrate treatment regimen. 
 
 
WILD-TYPE P. BERGHEI PARASITES HAVE A SLOWER RATE OF BLOOD-STAGE REPLICATION IN 
XBP1 KNOCK-OUT MICE  
XBP1 KO mice have decreased levels of circulating lipids. We assessed a decrease in the levels 
of circulating lipids in the XBP1 KO mice. Similarly to the clofibrate-treated mice, we confirmed 
a reduction in the non-esterified fatty acid (NEFA) and triglyceride (TG) levels for the XBP1-
KO mice after poly-IC mediated excision of exon 2 (Figures 3.8 and 3.9). The data is presented 
in the same manner as Figure 3.3; as a percent reduction of lipid levels measured as compared 
values to the control mice. The data is the average from two experiments with 4-6 mice per 
group. We saw between a 10-50% reduction in the levels of NEFA and between a 20-80% 
reduction in the levels of TG for XBP1 KO mice. These values are similar to the levels of lipid 









Figure 3.8. Confirmation of XBP1 exon 2  excision by RT-PCR 
Excision of XBP1 was determined by locus specific primers. Data represents 5 mice from 
experiment I in which cDNA was generated from homogenized liver tissue after the experiment 
was completed. The top panel shows 2 mice with expression of the longer delta-XBP1 product 
(deltaXBP-F + deltaXBP-R, product 120 bp) and is absent for the shorter WT product. The 
bottom panel shows 3 XBP1 CRE- control mice were and show only detectable levels of 
expression of the WT-control gene (primers XBP1WT205 F + XBP1WT272, product 70bp) and 
absence of the delta-XBP1 product. These results confirm proper excision of the XBP1 locus 
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Experiment Lipid     Average Value SEM   Percent   
Group  Species    (mEq/L)                 Reduction  
I  Non-esterified     
  Fatty Acids 
Control (Cre-)        0.462   0.029   
ΔXBP1 (Cre+)    0.641   0.042  28%   
 
I  Triglycerides 
Control (Cre-)        0.135   0.014   
ΔXBP1 (Cre+)    0.092   0.011  32% 
 
II  Non-esterified     
  Fatty Acids 
Control (Cre-)        0.188   0.050   
ΔXBP1 (Cre+)    0.094   0.042  50%   
 
II  Triglycerides 
Control (Cre-)        0.280	     0.019   
ΔXBP1 (Cre+)    0.071   0.034  75% 
 
                          
Table 3.5. XBP1 KO mice have lowered lipid levels as compared to littermate controls 
The absolute values of the non-esterified fatty acids (NEFA) and triglycerides (TG) as 
determined in the serum for CRE positive and CRE negative control mice. Lipids were 
determined 2-3 weeks after poly-IC injections to induce excision. Serum lipids levels were 
determined for all mice per group for each experiment.  
 
 
. Representation of the NEFA and TG values of XBP1 KO mice 
Graphs represent the average value of the two experiments, as a percentage of the control mice. 











































In order to assess Plasmodium blood stage growth kinetics in XBP1 KO mice, we inoculated 
these mice wild-type blood-stage parasites 2 to 3 weeks after the final poly-IC injection. We 
found a greater than two-fold reduction in the blood-stage growth kinetics in the KO mice as 
compared to wild type control (Figure 3.10).  These findings confirm our results with the 
clofibrate treated mice, that blood-stage P. berghei parasites are sensitive to changes in the fatty 
acid content of the mouse serum and will replicate with slower blood-stage growth kinetics..  
 
 
Figure 3.10. Blood-stage growth kinetics of P. berghei ANKA in XBP1 KO mice 
In two experiments, 6-8 mice per group were inoculated with 10,000 blood-stage parasites by 
I.V. injection into XBP1 flox/flox CRE positive mice and control CRE negative mice. Blood-
stage parasitemia was tracked by thin-smear microscopy over the course of 8 days. Statistics 
















SPOROZOITE INFECTIONS IN XBP1 KNOCK-OUT MICE DO NOT HAVE SIGNIFICANTLY INCREASED 
PRE-PATENT PERIODS 
   
In two independent experiments, XBP1 KO mice were inoculated with 1,000 sporozoites and the 
pre-patent period was determined by thin-smear microscopy. Mice used were litter-mates (age-
matched) and were also the same sex. In comparison to control mice there was a modest increase 
(0.25 days) in the number of days for the parasites to complete liver-stage development in XBP1 
KO mice (Table 3.6). Our results demonstrate that XBP1 KO has no significant impact on liver 
stage development, illustrating that in these mice the quantities of lipids for parasite proliferation 
is not limiting. 
                   
Experiment Clofibrate  Sporozoites  Percent of        Average Prepatent  
       Inoculated  Infected mice    Period    
I  Control (Cre-)    1,000 100%    5.2 days 
                        ΔXBP1 (Cre+)   1,000   100%    4.8 days 
 
II  Control (Cre-)    1,000 100%    5.0 days 
                        ΔXBP1 (Cre+)   1,000 100%   5.2 days  
                              




Lipid scavenging from the host is critical for pathogenesis of Plasmodium falciparum. In our 
studies, we utilized two independent animal models enabled us to study how changes in serum 
and liver lipids impact malaria progression. In one model we treated mice with clofibrate, which 
reduces the fatty acid and triglyceride levels in the serum by inducing beta-oxidation of fatty 
acids in the liver. In our second model we utilized XBP1 KO mice, which have a reduced level 
of fatty acid synthesis in the liver. With both of these models we demonstrated that changes in 




Using these animal models, we tested the impact decreasing lipid levels has on the development 
of liver stages. We demonstrated an impact on liver-stage development for both the clofibrate-
treated and the XBP1 KO mice. For the XBP1-KO mice, there was a slight increase (0.25 to 0.5 
days) in the pre-patent period in comparison to control mice. XBP1 KO mice are not reported to 
have changes in the lipid content within the liver 216. Conversely, there was a more substantial 
change in the pre-patent period for the clofibrate-treated mice. The increased pre-patent period 
varied from 0.5 to 2.0 days in the clofibrate treated mice in comparison to control treated mice. 
At both inoculums we are seeing an increase in the average pre-patent period in the treated mice 
versus the mock-treated controls. Clofibrate treatment impacts the lipid content of the liver 220 by 
a reduction in triglycerides by 30%, and phospholipid content by 30% when administered within 
the food as 0.5% of total food content 221. Results from the clofibrate-treated mice demonstrate 
that decreasing the lipid content of the liver slows the pathogenesis of malaria parasites. A 
corresponding experiment with obese mice showed an accelerated rate of sporozoite 
development in fatty livers188.  The studies we performed were with 5 mice per dosage of 
clofibrate in two experiments. To definitively prove such a small change in the pre-patent period, 
we would need to at least double the size of the experiment and use at least 20 mice per group. A 
relevant future experiment to conduct is to inoculate clofibrate treated mice with ΔpbLipB 
sporozoites and monitor the pre-patent period. We hypothesize that these parasites would be 
blocked in treated mice. This hypothesis assumes that the parasite is unable to scavenge enough 
lipoic acid from its host environment under the treated conditions to compensate for the 
disruption in the synthesis pathway in knock-out parasites. These studies demonstrate initial 
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findings of how liver lipid content could be an important factor in determining malaria 
pathogenesis, but require several follow-up experiments.  
 
The statistically significant impact that clofibrate treatment has on Δpblipb blood-stages is 
intriguing. These findings imply that certain genes of the fatty acid synthesis or lipid metabolism 
pathway of the parasite are necessary for normal blood-stage development in lowered lipid 
conditions. This is an interesting finding, since we previously did not see any phenotype for the 
ΔpbLipB parasites during blood-stage growth in normal mice (Figure 2.6). This is also intriguing 
because we do not see the same impact on blood-stage growth kinetics for P. berghei wild-type 
or ΔpbFabI parasites in the clofibrate treated mice, especially since LipB and FabI are both 
involved in the lipoic acid synthesis pathway in the apicoplast. This finding could be explained 
by how LipB has a role in the lipoylation of mitochondrial proteins, as demonstrated in Chapter 
2. FabI is currently known to only function within the apicoplast and impact fatty acid 
biosynthesis. The reduction in BCDH E2-lipoylation within the mitochondria , a protein that is 
assumed to be lipoylated through the scavenge pathway, would have increased sensitivity to 
changes in the levels of circulating lipoic acid for attachment. The currently unclear role LipB 
has on BCDH-E2 lipoylation is likely the reason we are seeing a more significant impact in 
blood-stage growth kinetics of ΔpbLipB parasites versus in the ΔpbFabI parasites in clofibrate 
treated mice.  
 
While there is no published data whether clofibrate modulates the levels of lipoic acid in the 
serum of treated mice, it has been demonstrated that clofibrate binds to albumin, displacing 
thyroxine, a thyroid hormone222. Lipoic acid similarly circulates in the serum of mammals 
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attached to albumin223. Clofibrate treatment of mice is thus likely displacing lipoic acid from 
albumin in a similar manner to thryoxine, reducing the likelihood of infected red blood cells 
scavenging albumin-bound lipoic acid attached albumin into the parasite cytosol. Our data also 
showed an overall reduction in the total content of albumin in the circulation during the course of 
clofibrate treatment. Lipoic acid can also be reduced by beta-oxidation in the same pathway as 
longer chain fatty acids, suggesting that free circulating lipoic acid could be degraded in 
peroxisomes as well. These are three possible ways clofibrate is acting to decrease either the total 
lipoic acid content within the serum or its availability for uptake into the parasite by reducing its 
transportation in the circulation as attached to albumin. 
 
These results raise an interesting point on whether genes involved in fatty acid or lipoic acid 
metabolism are up-regulated during low lipid conditions. As mentioned earlier, a study 
examining P. falciparum infections from patients demonstrated new transcriptional profiles, 
resembling adaptations to the human host 186. Both the clofibrate and the XBP1 KO mice provide 
in vivo conditions to examine whether changes to the transcriptional profile of P. berghei 
parasites are occurring in low lipid environments. 
 
For the future use of these models systems, we recommend the use of clofibrate treated mice 
over XBP1 KO mice. XBP1, as mentioned before, has a wide range of activities in vivo. XBP1 is 
also involved in the production of dendritic cells (DCs) 224. Although lethal forms of 
Plasmodium, like P. berghei ANKA, are unable to generate DCs that prime CD8 T cells 225, it 
does raise a caveat to the data we have produced, and should be taken into future consideration. 
The levels of clofibrate used in this study were lower than other published reports in determining 
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the impact of clofibrate on fatty acid and triglyceride levels in mice. The results we have 
produced even at this low level dosage of clofibrate suggest that we would demonstrate a more 
significant arrest in Plasmodium growth in mice treated with higher levels of clofibrate. Other 
studies have published clofibrate levels as 500 mg/kg that were safe to be administered to 
Swiss/Webster mice 226. The significant impact on blood-stage growth kinetics that we have 
demonstrated with the 0.5 mg/kg and the 5.0 mg/kg dosages demonstrate how sensitive 
Plasmodium parasites are to their host conditions. The administration of higher dosages of 
clofibrate on mice inoculated with sporozoites will likely have a significant impact on the pre-
patent period. In order to reduce lipid content within the liver to demonstrate a significant impact 
on parasite replication, higher concentrations of clofibrate are required. Clofibrate treatment 
remains an easy and safe method to reliably decrease the fatty acid and triglyceride content in 
mice, therefore testing a wide range of dosages will open new avenues for determining the 
impact of host environment on Plasmodium liver-stages.   
 
Other methods to reliably reduce the levels of cholesterol species in mice include the use of the 
group of the statins. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase in order to suppress cholesterol biosynthesis 214. The family of statins shares similar 
chemical characteristics by containing the aromatic ring structure and an aliphatic fatty acid side 
chain.  
 
Another possible approach would be to use diets that are low in fatty acids or other lipid species, 
which could mimic the effects of clofibrate. For example, synthetic low fat diets have been used 
for the study of atherosclerosis in mice 227. Recently it has been shown the importance of omega-
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3 fatty acids and their potential in reducing the levels of circulating non-esterified fatty acids and 
triglycerides in mice228. These specific diets also offer the potential to modify in vivo the levels 
of circulating lipids to monitor the progression of Plasmodium infections. It would be interesting 
to test their alternate ways to reduce fatty acid and triglyceride contents in the host to determine 
whether we find the same phenotype with P. berghei parasites. Further exploration of these 
model systems would advance the our understanding of parasite’s need for fatty acid and 



















4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
THE MALARIAL LIFE-CYCLE IS COMPLEX AND ENCOMPASSES 
DEVELOPMENT IN DIFFERENT ENVIRONMENTAL CONDITIONS. 
Plasmodium parasites replicate within a number of different environments to complete its life-
cycle and transmit between different hosts. These environments vary widely, therefore the 
parasite has evolved mechanisms to thrive in each of these conditions, to remain pathogenic and 
evade host immunity. A key question in malaria biology is how parasites alter their metabolic 
processes to adapt to constantly changing environmental conditions. Also, do parasites modify 
their metabolism within the same stage of the life-cycle to respond to changes within that stage? 
Like most pathogenic infections, Plasmodium must generate a balance between synthesis and 
scavenge from their host. Identifying which metabolites the parasite requires is important for 
understanding the disease. It could also potentially lead to the development of new therapeutics 
that block either the synthesis or salvage processes. Finally, knowing the impact the host 
environments has on parasite replication can lead to a better understanding of disease severity 
and clinical outcome 186, 229. 
 
In this study, we have addressed these two questions independently. In Chapter 2, we have 
outlined the role of synthesis of the metabolite lipoic acid in Plasmodium berghei parasites. In 
our second aim, in Chapter 3, we have examined the role of host lipids on the pathogenesis of 





KEY QUESTIONS CONCERNING MALARIA PATHOGENESIS 
CHAPTER 2: WHEN IS LIPOIC ACID SYNTHESIS REQUIRED FOR PLASMODIUM PATHOGENESIS? 
Lipoic acid is an important metabolite for eukaryotic cells, including many pathogenic species 
197, 230. Lipoic acid, when attached to enzymatic complexes, serves as their “swinging arm” to 
shuttle intermediates among active sites. Its attachment to these complexes is critical for the 
function of these enzymes. Lipoic acid is introduced into the cells through either the synthesis or 
the scavenge pathways and Plasmodium parasites generate lipoic acid through both.  
 
In this study, we have specifically targeted LipB for disruption in Plasmodium berghei parasites 
and demonstrated that lipoic acid synthesis is critical for normal liver-stage development. We 
demonstrated both in vivo infections and in vitro development assays, the importance of PbLipB 
during liver stages. We observed that disruption of lipoic acid synthesis in the P. berghei 
parasites did not confer any change in virulence during the blood or mosquito stages of 
development. However, it had an increased dependence on scavenging of lipoic acid from the 
environment. Furthermore, PbΔLipB parasites demonstrated reduced virulence in blood-stages 
under fatty acid limiting conditions. This work demonstrates that the lipoic acid synthesis 
pathway is of critical importance during liver stage development of Plasmodium parasite 
 
This life-cycle specific need for the lipoic acid synthesis pathway is most likely due to a greater 
metabolic need during this stage of development than during the mosquito or blood stages. In the 
work we have presented, we confirmed that disruption of lipoic acid synthesis by the parasite 
reduces the levels of lipoylated proteins, the pyruvate dehydrogenase and the branched-chain 
dehydrogenase (PDH and BCDH). PDH is responsible for transforming pyruvate into acetyl-
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CoA by pyruvate decarboxylation. Its role in Plasmodium metabolism has also been determined 
to be within the liver stages of development 205. BCDH is responsible for the degradation of 
branched-chain amino acids. Its role during the Plasmodium life-cycle has not yet been 
determined. It’s likely that is also critical for liver stage development as well, due to its 
expression pattern 104.  
 
CHAPTER 3: DO CHANGES IN FATTY ACID AND TRIGLYCERIDE LEVELS OF THE HOST IMPACT 
PLASMODIUM PATHOGENESIS? 
As discussed in Chapter 1, Plasmodium parasites require the uptake of exogenous lipids from the 
host for blood-stage replication and different host conditions can change the disease severity and 
clinical outcome of Plasmodium infections. How the content of host lipids impacts the 
pathogenesis of Plasmodium parasites remains to be fully characterized.  
 
In this study, we have used two approaches to study the pathogenesis of Plasmodium berghei in 
mice with different fatty acid levels. In the first approach, we used a lipid-lowering agent, 
clofibrate. Clofibrate, by stimulating beta-oxidation of fatty acids in the liver, reduced the lipid 
levels of the serum and liver. We measured a reproducible reduction in the rate of blood-stage 
growth for Plasmodium berghei parasites. The impact on blood-stage growth was more severe 
for the development of ΔpbLipB parasites, in comparison to the wild-type and ΔpbFabI 
parasites. Clofibrate treatment of mice also impacted the development of sporozoites in the liver. 
P. berghei parasites required a slightly longer time for liver stage development in the treated 




In our second approach, we used a genetic approach to modify the levels of fatty acids in mice. 
We employed mice that were deleted for XBP1, a transcription factor that is involved in de novo 
fatty acid synthesis in the liver. XBP1 knock-out mice are conditionally deleted for the XBP1 
gene through CRE-mediated excision. As a result, XBP1 mice were significantly reduced in the 
serum fatty acid content. We demonstrated a similar reduction in the blood-stage growth kinetics 
for the XBP1 knock-out mice versus the wild-type controls. Plasmodium berghei parasites grew 
significantly slower in these mice, supporting our findings from the clofibrate treated mice and 
demonstrating that serum fatty acid content is a major contributing factor in the rate of 
Plasmodium blood-stage replication.  
 
THE FUTURE DIRECTIONS FOR THIS PROJECT 
The work presented in this thesis demonstrates the importance of the host environment on 
malaria pathogenesis as well as demonstrated stage specific needs for the metabolite, lipoic acid. 
Remaining questions on these research topics could be addressed by the following investigations 
and experiments.  
 
The work presented in Chapter 2 focused on the role of lipoic acid synthesis during the 
Plasmodium life-cycle by disrupting the lipoic acid protein ligase LipB. We identified a 
reduction in the levels of lipoylated proteins, however it would be interesting and important to 
determine whether we see the same phenotype by mutating the acceptor domains of these 
proteins. For instance, the PDH and BCDH proteins have annotated domains within the E2 
subunits that receive the lipoic acid attachment. It would be a good complement to our study to 
see the phenotype we saw in liver-stage development would be replicated by specifically 
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mutating these domains in Plasmodium berghei so that they could not accept lipoic acid and the 
multi-subunit complexes would be non-functional. Since we identified a reduction in both levels 
of lipoylated BCDH and PDH proteins, it would be beneficial for future experiments to 
understand the impact of each enzyme has separately on the life-cycle. 
 
Furthermore, investigation into the role of BCDH during Plasmodium development is important. 
Disruption of BCDH in Plasmodium berghei would enable us to investigate when it plays a role 
during the life-cycle. It is highly expressed during liver-stage, leading us to hypothesize that it 
has an important function during this stage. However, there currently is no published information 
about the needs for this protein in Plasmodium biology. BCDH-E2 is one of the proteins that are 
lipoylated in the mitochondria by scavenged lipoic acid. Since lipoic acid scavenging is essential 
to blood-stage replication of Plasmodium falciparum parasites191 yet neither the P. falciparum or 
the P. berghei ΔpbLipB parasites demonstrated loss of blood-stage replication with reduced 
levels of lipoylated BCDH protein 202. Therefore, investigation into the role of BCDH could 
reveal a need for this protein during liver stages of Plasmodium parasites.   
  
Finally, the findings from this study presented new questions into the potential exchange of 
lipoic acid species between the synthesis and the salvage pathways. It is important to further 
study the impact of the lipoic acid analogue, 8-BOA. The data presented in this work showed 
that ΔpbLipB parasites had reduced rates of blood-stage growth after treatment with 8-BOA. This 
result implies that wild-type parasites import lipoic acid from the apicoplast to the mitochondria 
to meet their metabolic needs, whereas in ΔpbLipB parasites this import is absent. It would be 
interesting to see which proteins are lacking lipoylation after treatment with 8-BOA. This type of 
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experiment could be done though western blot analysis of parasite extracts after over-night 
incubation with 8-BOA. We predict that there would be a reduction in the levels of lipoylated 
proteins within the mitochondria, the KGDH and the BCDH, but not the PDH. We also 
hypothesize that ΔpbLipB parasites when treated in the same conditions would have an even 
greater reduction in the levels of lipoylated mitochondrial proteins in comparison to the wild-
type parasites.   
 
In Chapter 3, we presented work in which fatty acid species were reduced in mice through the 
use of clofibrate treatment. Future studies using these methods include identification of the lipoic 
acid levels in the serum of mice treated with lipoic acid. As stated within that chapter, we think 
that ΔpbLipB parasites are more attenuated in blood-stage replication than wild-type parasites 
because lipoic acid is typically attached to albumin as it migrates through the serum. We think 
they are more attenuated during blood-stage replication than the ΔpbFabI parasites because of 
LipB’s role in the lipoylation of mitochondrial proteins. In addition to the possibility of 
clofibrate binding to albumin and inhibiting lipoic acid transport in the serum, we demonstrated 
that clofibrate treatment reduces the levels of circulating albumin. This is another reason why we 
are seeing a dramatic reduction in blood-stage growth kinetics in ΔpbLipB parasites. It is 
generally difficult to measure the levels of lipoic acid in the circulation of humans or mice 
because they are so low. In order to measure the level of lipoic acid in the circulation, we would 
need to give additional lipoic acid to the serum of mice and measure whether or not there is a 
substantial change between the clofibrate treated and untreated mice. Lipoic acid can be 




Follow-up studies with the XBP1 knock-out mice would help to confirm the unique phenotype of 
the ΔpbLipB parasites in clofibrate treated mice. XBP1 knock-out mice have similar levels of 
reduced non-esterified fatty acids and triglycerides as the clofibrate-treated mice, even though 
the two mice models decrease lipids through different pathways. It is important to confirm that 
the phenotype of blood-stage growth kinetics is replicated in the XBP1 knock-out mice. Future 
experiments would consist of inoculating these mice with ΔpbLipB and ΔpbFabI parasites lines 
to determine their blood-stage growth rates. We expect a similar result to the clofibrate-treated 
mice. These results would provide further support that the lipid levels of the host serum make a 
significant impact on parasite replication, independent of how the lipid levels are reduced in vivo.  
 
The data presented in this work demonstrated a subtle impact on liver-stage development in 
clofibrate-treated mice and XBP1 knock-out mice as determined by the pre-patent period. An 
important addition to this data-set would be to inoculate clofibrate-treated and XBP1 knock-out 
mice with ΔpbLipB and ΔpbFabI sporozoites. We predict that these parasites completely arrest 
in liver-stage development, since both parasite strains are significantly attenuated in untreated 
and wild-type mice. In addition, a more sensitive way to detect changes in liver-stage 
development would be to determine the transcript levels of 18s by quantitative reverse 
transcription (qRT-PCR). 18s was used in Chapter 2 to control for detection of liver-stage 
infection by RT-PCR. Detection of 18s by qRT-PCR is regularly used to determine the liver-
stage burden during in vivo infections232. The transcript for the 18 small ribosomal subunit is 
commonly used to detect parasite transcript from the total RNA of the sample. This method is 
very sensitive to differences in parasite burden in the host and might elucidate a more significant 
phenotype during liver-stage development in the two mouse models. 
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As mentioned in Chapter 3, clofibrate treatment of mice has been demonstrated to vary in the 
concentrations administered, with the highest reported dosage of 500 mg/kg 226. The dosages 
used in this study are on the low-end of the range used within clofibrate-literature. Therefore, the 
phenotypes we are seeing in both blood and liver stage demonstrate how sensitive Plasmodium 
parasites are to their environments. To further probe into the fatty acid needs of Plasmodium 
during liver-stage development in particular, future experiments include increasing the dosage of 
clofibrate administered to mice before their inoculation with Plasmodium sporozoites. Since 
dosages up to 500 mg/kg are safe for administration into mice, we recommend using this dosage 
to try to significantly arrest parasites during liver-stage development in vivo. In addition, the 
combination of higher clofibrate dosages with attenuated parasite strains, such as ΔpbLipB and 
ΔpbFabI sporozoites, will likely lead to full attenuation in mice. Comparing how the ΔpbLipB 
and ΔpbFabI sporozoites respond in the lipid-reduced host environments would provide us 
greater insight into how these proteins function during liver-stage development.  
 
Since clofibrate induces beta-oxidation of fatty acids in hepatocyte cells and results in a 
decreased lipid-content within the liver, we also propose elaborating this area of research to 
replicate our results in vitro. Possible experiments would include pre-treatment of cultured 
hepatocytes (such as HepG2 cells used in Chapter 2) with clofibrate and subsequent inoculation 
with sporozoites. Read-outs to determine whether the clofibrate treatment has a significant 
impact on parasite liver-stage replication would include quantifying the size of the developing 
parasite, like the use of fluorescent parasites as illustrated in Chapter 2. Other quantitative 
determinations could include the total number of developing parasites and the number of 
detached cells at different time-points of liver-stage development. Adjusting the use of clofibrate 
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to in vitro hepatocyte conditions would allow for better determination of the reduction in fatty 
acid content upon treatment. Certain methods, such as Folch extraction, could be employed. This 
is also a model system to test for the in vitro activity of antimalarial compounds that inhibit liver-
stages. As briefly discussed in the introduction, the lipid content of the host serum impacts the 
efficacy of blood-stage antimalarias. Liver-stage specific drugs might also demonstrate 
significant differences in their efficacies when changes the lipid content of the host. Clofibrate 
administration of cultured hepatocyte cells is an attractive method to test this hypothesis.  
 
Finally, we identified a reduced rate of parasite replication for both blood and liver-stage 
development and a valuable future experiment would be to determine whether gene expression 
patterns are altered in these conditions. As mentioned in the introduction, one group 186 described 
unique transcriptional profiles in Plasmodium parasites taken directly from human patients. 
These profiles had never been seen before from in vitro parasite cultures, suggesting that 
Plasmodium parasites respond to their environmental conditions by up-regulating certain 
metabolic pathways. A pilot study would be to determine the expression levels of known fatty 
acid metabolism genes in parasites removed from clofibrate or XBP1 knock-out mice with 
parasites in untreated or wild-type mice as a control. If there are differences in this initial gene 
set, a complete understanding the genomic transcriptional patterns could be identified by a 
microarray. Support for the hypothesis that Plasmodium berghei parasites are transcriptionally 
responding to changes in fatty acid levels is provided by data presented in Chapter 3 in which the 
ΔpbLipB parasites are more significantly impacted in their blood-stage replication versus wild-
type. These findings suggest that lipoic acid synthesis, although not essential with normal serum 
fatty acid levels, is necessary under limiting conditions. It is likely there are other metabolic 
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pathways that are similarly needed in the fatty-acid limited conditions we have created.  
 
Although the research we presented in this work did not touch upon the role of lipoic acid as a 
potent antioxidant, it is another future direction for this project. Lipoic acid has the ability to 
form a redox couple that can quench reactive oxygen species 233, Packer, 2011 #528. Other infections 
that replicate in the liver, in particular Hepatitis C virus, induce oxidative stress in the liver of 
patients and play a key role in pathogenesis of the virus 234. Additionally, Plasmodium-infected 
hepatocytes up regulate their redox pathways 235. Redox-perturbing agents would be useful for 
future studies in investigation of the redox pathways of the host. In particular, dithiothreitol 
decreases the oxidative state within the endoplasmic reticulum of the cell. It has also been 
demonstrated to result in increased splicing of XBP1 transcripts, leading to an up regulation of 
genes controlled by this transcription factor 236. It would be very interesting to use this redox 
agent on mice and see whether there are any changes to the liver stage development of wild-type 
and ΔpbLipB sporozoites. It would also be a useful control to verify our results generated with 
the ΔXBP1 mice.  
 
RESULTS FROM THIS RESEARCH RELATE TO GENERAL 
PLASMODIUM BIOLOGY 
The work stated in this thesis examine the fatty acid and lipoic acid needs of the malaria parasite 
Plasmodium berghei, which causes malaria in mouse species. We used this species of malaria as 
a model system to probe unanswered questions in Plasmodium biology. There are several aspects 




The main impetus for generating a P. berghei strain disrupted for LipB was because it was 
shown to be non-essential for blood-stage development in P. falciparum 202. The P. falciparum 
LipB knock-out strain showed that although lipoic acid synthesis was not required during in vitro 
blood-stage replication, the modification generated a replication rate faster than the wild-type 
control. We did not find the same results for in vivo blood-stage growth with P. berghei LipB 
knock-out strains. Our results showed similar blood-stage growth rates when mice were 
inoculated with either 10,000 or 1,000 parasites. Currently, we do not have an explanation for 
this difference between the LipB knock-out strains in different species. Both sets of experiments 
were done with clonal parasite populations. Perhaps the difference is because P. falciparum 
replication rates are determined with in vitro conditions and P. berghei blood-stage replication 
occurs in vivo. Removing P. falciparum from its natural environmental conditions when 
examining blood-stage growth kinetics might amplify small changes that are not seen when 
parasites are replicating in vivo 202. There were no other significant differences between the 
knock-out parasites in different species. Similar to our results identifying the lipoylated proteins 
by Western blot, the P. falciparum LipB knock-out parasites showed reduced levels of PDH and 
BCDH proteins and no change in the levels of KGDH protein.  
 
P. falciparum LipB knock-out parasites were treated with Triclosan, an antibiotic known to 
target the FAS-II pathway. Although it was later determined that PfFabI is not the target of 
Triclosan 105, an earlier publication showed Triclosan as a potent antimalarial 237. However, P. 
falciparum LipB knock-out parasites did not have any significant change in their sensitivity to 
Triclosan treatment. We did not replicate this study with the ΔpbLipB parasites since the target of 




The study also localized the protein Pf LplA2 in P. falciparum by both fusion to GFP and 
immunofluorescence. LplA2 is another lipoate protein ligase that was found to target to both the 
apicoplast and the mitochondria in P. falciparum parasites 204. The authors hypothesized that 
LplA2 is capable of compensating for the loss LipB, leading to a residual amount of PDH 
lipoylation. Our study did not venture into whether or not LplA2 is compensating for the loss of 
LipB in P. berghei although we had similar levels of residual PDH lipoylation. This study 
instead localized PbBCDH since its not predicted to be lipoylated by LipB 204.We found that 
PbBCDH localized to the mitochondria, as predicted. A more detailed understanding of how 
LipB is contributing to the lipoylation of this protein is needed, for both parasite species. Neither 
study localized LipB since it has a strong apicoplast targeting motif and anti-LipB antibodies are 
not available for immunofluorescence.  
 
P. falciparum LipB knock-out parasites were not treated with 8-BOA, unlike this study. 8-BOA 
inhibits lipoic acid scavenging by acting as a competitive inhibitor. This understanding is based 
on work in P. falciparum and we have assumed the same mechanism of action in P. berghei 
parasites 191. It would be interesting to see if there is also increased sensitivity to 8-BOA 
treatment during in vitro conditions with P. falciparum LipB knock-out parasites.  
 
A large portion of the work presented in this document focused on lipoic acid as a component of 
the larger fatty acid metabolism pathway in Plasmodium. However, lipoic acid is unique in 
comparison to the other longer fatty acids that are synthesized by the FAS-II pathway or 
scavenged from the environment. As mentioned previously, Plasmodium utilizes the fatty acids 
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palmitic and oleic acids scavenged from its host environment 176. These fatty acids are 
metabolized into more complex lipid species; including phosphatidylcholine, 
phosphatidylethanolamine, diacylglycerol and triacylglycerol. These complex lipid species are 
known constituents of the membranes and lipid bodies 177. Whereas, lipoic acid is not known to 
be incorporated into complex lipid species or into the cell membrane 191. Therefore, changes in 
the contents of the cellular membrane witnessed in ΔpbLipB parasites are a down-stream effect 
of the reduced capacity of enzymatic components that require lipoic acid modification; PDH-E2 
activity would be limited within the apicoplast, leading to decreased generation of acetyl-CoA as 
FAS-II intermediates. Similarly, 8-BOA treatment to Plasmodium parasites inhibits lipoic acid 
scavenging and is toxic to parasites because the multi-subunit enzymes that require its 
attachment cannot function. Therefore, although lipoic acid is similarly an essential short-chain 
fatty acid that is scavenged from the environment, like the longer chain fatty acids, it plays a 
unique role in parasite metabolism. In most cells, lipoic acid, like long chain fatty acids, can also 
be reduced into shorter chain metabolites via beta-oxidation, however the genes required for 
beta-oxidation of fatty acids have not been found in the Plasmodium genome.  
 
Lipoic acid is also known as a potent antioxidant. This is a unique function that distinguishes it 
from other fatty acid chains. LA is capable of scavenging reactive oxygen and reactive nitrogen 
species in vitro. The antioxidant needs of Plasmodium parasites remain uncharacterized. The 
essential role of lipoic acid in Plasmodium biology could be related to this capacity, but further 




Here we’ve demonstrated that the synthesis of lipoic acid is only required during liver-stage but 
scavenging of lipoic acid is essential in liver and blood-stage. Plasmodium parasites balance their 
metabolic needs through either synthesis or salvage processes. Certain metabolic pathways in 
Plasmodium are completely dependent on scavenging, including amino acid and purine 
nucleotides209. Scavenging of fatty acids is essential for blood-cycle replication of Plasmodium 
falciparum parasites 176. Fatty acid components from human serum, in particular serum albumin 
and purified bovine serum albumin, are essential for P. falciparum growth in vitro 176. Since the 
parasite’s fatty acid composition reflects that of the medium, it implies that the parasite is 
incredibly dependent on scavenging from its environment 177. The parasite has demonstrated the 
capacity to modify scavenged fatty acids, specifically to elongate and desaturate radioactive fatty 
acids provided in the serum. Similarly, lipoic acid from the environment is attached to proteins to 
function as a cofactor in mitochondrial keto-dehydrogenase enzymes, BCDH and KGDH191.  
 
The mechanisms of scavenging and import of lipoic acid and other longer chain fatty acids have 
not been demonstrated on a molecular level. However, several lipid import genes have been 
annotated in the Plasmodium genome 187. Due to the wide range of host environments 
Plasmodium infects, it is likely that it has developed different mechanisms of scavenging. The 
large family of acyl-CoA synthases and acyl-CoA binding proteins demonstrate unique patterns 
of expression that may function in a stage-specific manner180. This family of fatty acid 
scavenging proteins appears to be necessary for both blood and liver-stage 104. Stage-specific 





The unique nature of the Acyl-CoA synthease (ACS) family leads to the potential for the 
development of chemotherapeutics to block fatty acid import from the host. There are twelve 
ACS genes in the P. falciparum genome, the most of any known organism. The duplicity of the 
gene family suggests an essential need for ACS proteins 179. Furthermore, they are located within 
epigenetically repressed centers on the genome commonly associated with genes involved in 
immune evasion (i.e. var, rifin and steavor) 180. Data from our group found the expression all 
four P. berghei ACS genes in mixed blood-stages but only PbACS-9 was expressed in the oocyst 
stage and PbACS-10 during liver stages. We were also unable to disrupt PbACS-10 and PbACS-
11, suggesting essentiality of these proteins during blood-stages. These results demonstrate a 
stage-specificity for the P. berghei gene family and we hypothesize an even more complex 
pattern of the gene expression in P. falciparum. Finally, Triacsin is a known chemical inhibitor 
of ACS enzymes in other cell types and had an IC50 value within the nanomolar range for P. 
falciparum cultures 238. Data from our group could not replicate such a low IC50 value however if 
the published values are true, it is an interesting new method to target the fatty acid scavenge 
pathway in Plasmodium.  
 
The mechanisms for lipoic acid scavenging in Plasmodium are currently unknown. Lipoic acid is 
naturally occurring in red blood-cells and is attached non-covalently to albumin in human 
serum239. Lipoic acid may be imported directly into the parasite, as attached to albumin, into the 
parasite cytosol or may require uptake through a small molecule transporter, such as the H+-
coupled transporter that transports pantothenate 240. Further study is required to identify the 




Several critical synthesis pathways in Plasmodium have been localized to the apicoplast 
organelle 187. Synthesis pathways such as the lipoic acid, fatty acid, isoprenoid and heme 
synthesis pathways have been identified in the Plasmodium genome. The lipoic acid synthesis 
pathway requires an active FAS-II pathway, to generate the octanoyl-ACP precursor. The fact 
that both the FAS-II and the lipoic acid synthesis pathway are both non-essential for blood-stages 
but are critical for liver-stage development, confirms the interdependence of the pathways. FAS-
II intermediates are generated by the Pyruvate Dehydrogenase enzyme (PDH). FAS-II generates 
the ocantoyl-ACP precursor that is used by the lipoic acid synthesis pathway for attachment to 
the PDH complex. PDH degrades pyruvate, generating acetyl-CoA, which feeds back into the 
FAS-II synthesis pathway. These synthesis pathways occur in the apicoplast organelle. 
Fosmidomycin is an apicoplast specific inhibitor of P. falciparum blood-stage growth. Treatment 
of blood-stage cultures could be rescued with isoprenoid precursors 241. Based on these findings, 
the isoprenoid pathway appears to be the only essential synthesis pathway in the apicoplast 
during blood-stage development. This complements our study if we propose that other metabolic 
pathways targeted to the apicoplast would serve their function during non-blood-stages of the 
life-cycle. It would be interesting to follow-up this hypothesis by determining the mosquito and 
liver-stage needs of isoprenoid and heme synthesis. 
 
The majority of the work presented in Chapters 2 and 3 examined the phenotypes of parasites 
during the blood and liver-stage of development. As the data has demonstrated, these stages have 





ΔpbLipB parasites were significantly arrested during liver-stage development however showed 
no significant difference in blood-stage replication unless treated with the lipoic acid scavenge 
inhibitor 8-BOA or in mice with measurably lower circulating lipids. Blood-stage replication 
occurs after Plasmodium parasites have completed replication in the liver and invade red-blood 
cells of the host. In Plasmodium falciparum, parasites multiply within the confines of the red 
blood cell host, lysing the cell when the cycle of replication completes. Plasmodium falciparum 
parasites take 48 hours to complete their development within the red blood cell and upon release 
triggers the immune response that generates the classical waves of fevers and chills. These 
symptoms are the earliest indications that a patient is infected. Blood-stage is also critical for the 
transmission of the disease, since an infected person will generate a certain percentage of 
gametocytes in the blood. These parasite forms when taken up by the mosquito will mature and 
continue the life-cycle. Therefore the development of antimalarials for this life-cycle stage is 
ideal to generate drugs that block both blood stage asexuals and gametocytes, to prevent 
transmission. Plasmodium gametocytes can be tested for their sensitivity to particular 
chemotherapies 68. 
 
In this study, we demonstrated a significantly reduced rate of blood-stage growth of Plasmodium 
parasites in mice with lower circulating fatty acids and triglycerides. However we did not 
identify whether these conditions lead to an increased amount of gametocytemia. From in vitro 
work with P. falciparum, its been identified that low fatty acid conditions promote 
gametocytemia. However more research would help to clarify whether this is a general stress 
response or a particular response to the lipid content of the environment. This would be an 




We examined the replication of Plasmodium berghei parasites in mice as a model system for 
human disease. Liver-stage of development is clinically silent in patients. This stage begins when 
an infected mosquito releases sporozoites that migrate to the liver, invade and start to replicate. 
This period of development yields thousands of merozoites, which escape the infected 
hepatocyte and are released into the blood-stream to infect red blood cells. The amount of 
replication during liver-stage is much higher than during blood-stage. Liver-stage development is 
critical for the life-cycle of Plasmodium parasites; without this stage of development parasites 
are not capable of invading red blood cells. Because this stage is clinically silent, most patients 
do not yet know they are infected. Therefore, therapies that target liver-stage are taken as 
prophylaxis treatments. Liver-stage drugs would need to be taken on a consistent basis to prevent 
Plasmodium infections.  
 
The work we’ve shown here has focused on genetically attenuated Plasmodium berghei strain 
that arrests during liver stage development for the generation of a genetically attenuated 
sporozoite vaccine. Literature presented in the introduction has shown that parasites that arrest 
during liver stage, in both mice and humans, can provide protective immunity to subsequent 
challenge. Liver-stage vaccines would provide protection to Plasmodium infections without 
experiencing any of the symptoms that occur during blood-stage development.  
 
All of the experiments presented in Chapters 2 and 3 were done using the mouse species of 
malaria, Plasmodium berghei ANKA. We decided to use this parasite strain based on the similar 
pathology to P. falciparum since both are lethal strains when they infect mammals. P. berghei 
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has been commonly used as a model to represent cerebral malaria and severe malarial anemia 242. 
We chose to use the mouse strains of C57/Bl6 and Swiss/Webster for the series of liver-stage or 
blood-stage experiments, respectively. Mouse strains of malaria are of particular importance in 
understanding the elements of liver stage development. However, like for all model systems, the 
data presented in this work require the replication of these findings in P. falciparum and the 
other human infective species. There have been many caveats in applying the findings from the 
mouse malaria strains to different aspects of the human disease. For instance, within the field of 
human cerebral malaria a point of contention has been the extent of parasite sequestration in the 
brain and whether the rodent species have the same amount of sequestration 95.  
 
Even within the field of rodent parasites, there has typically been more arrest with the P. yoelli 
versus P. berghei strains when disrupted for the same genes. For example, the disruption of fab 
b/f in Plasmodium berghei resulted in incomplete attenuation, whereas in P. yoelii it completely 
arrests 243. However several studies that have translated genetically attenuated rodent strains into 
P. falciparum strains have demonstrated similar outcomes. P. falciparum parasites disrupted for 
p52 gene, an ortholog of P. berghei p36p, when tested for development with primary human 
hepatocytes demonstrated similar attenuation to the rodent strain 244. Also, when P. falciparum 
parasites were generated for a double-knock out of p52 and p36, it resulted in no observable 
parasites after 4 days of inoculation into hepatocyte in vitro cultures 243. Disruption of either of 
these genes in rodent malaria strains causes complete arrest in vivo, similar to the phenotype 
witness for their corresponding rodent models. However, in clinical trial with P. falciparum 
disrupted of p52 and p36 caused a breakthrough blood-stage infection in one volunteer. These 
results indicate that we might have different phenotypic outcomes at each stage of vaccine 
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development and that all GAP rodent models require complete testing before jumping forward to 
stages of vaccine development. These steps would include thorough testing in both P. yoelii and 
P. berghei strains and in different strains of mice (i.e. BALB/c and C57/Bl6). And finally, a 
corresponding analysis of GAP P. falciparum development in hepatocyte cultures would be 
required.  
 
Initial investment into research with rodent malaria strains has proven to be a worthwhile pursuit. 
In the field of vaccine development, mouse malaria models have successfully predicted vaccine 
failures, although not always effective vaccines 245. They have a useful amount of predictive 
value for vaccines. Drug treatment studies of mouse malaria have demonstrated inconsistent 
results in comparison to their human malaria counterparts. One major reason is that mice might 
be treated before the onset of symptoms in certain cases, which is irrelevant to their counterpart 
human studies. This is just an indication that mouse studies are useful and powerful tools when 
experiments are conducted in a manner close to the natural pathogenesis of the disease as 
possible. The work presented here was conducted with this mind. All of the experiments were 
replicated on independent occasions with control studies run in parallel. Both blood and liver 
stage phenotypes that we present should however be replicated with P. falciparum parasites, if 
possible. The use of the humanized mouse models would offer the best of both worlds 117. Future 
experiments with genetically attenuated P. falciparum parasites should take advantage of this 
model system. The arrest we demonstrated in the ΔpbLipB parasites was significant that we 




TRANSLATING THESE FINDINGS INTO TREATMENTS AND CURES 
FOR MALARIA 
The results from this study demonstrated how lipoic acid synthesis is required in liver-stage and 
during blood-stages in lipid-limiting environments. This implies that lipoic acid is a critical 
factor for Plasmodium pathogenesis in both developmental stages. The levels of circulating 
lipoic acid are typically below the levels of detection in humans. Lipoic acid levels are reportedly 
between 33-145 ng/ml bound to serum albumin in human serum 246. Free lipoic acid is present at 
millimolar levels and administration of 200 to 600mg of lipoic acid will only show a less than 50 
µM accumulation in blood plasma 192. Since its levels in circulation are naturally so low, it is not 
commonly a measurement of malnutrition.  
 
Lipoic acid is a well-promoted dietary supplement. It is absorbed from dietary sources and 
transiently accumulates in many tissues. Its role as a powerful antioxidant is well studied and 
supplemental lipoic acid treatment has a protective effect on several diseases, including 
cardiovascular disease, liver disease, insulin resistance and diabetic polyneuropathy 247. 
However, based on the data presented in this work, it would be recommended to not take lipoic 
acid supplements in malarial-endemic areas. Limiting the amount of free lipoic acid in the 
environment reduces the parasite burden in blood and liver-stages, demonstrated in both P. 
falciparum and P. berghei parasites. There is no recommended way to reduce the natural level of 
lipoic acid from humans. Since many malarial-endemic areas typically have high levels of 




Results from Chapter 3 raise questions into the relationship between Plasmodium pathogenesis 
and malnutrition. The data we have presented show how the levels of fatty acids and 
triglycerides have a significant impact on the virulence of Plasmodium infections. Based on this 
data, one could recommend reducing the intake of lipid species to prevent cases of severe 
malaria. However, it has been well documented that malnutrition leads to a lower functioning 
immune system 38. There is likely a balance between the loss of immune function due to 
undernourishment and the possibility of reducing the malarial-burden with less pathogenic forms 
of Plasmodium in low fatty acid conditions. This balance would exist on a region-specific basis, 
depending on the species of Plasmodium present, the age of the patent and the normal diet of the 
region. However, there are severe consequences to malnourished young children, especially 
children under five. Not only does stunting pose an enormous problem for human development, 
malnutrition is also associated with cognitive impairment and decreased school performance 248. 
Therefore, any benefits from maintaining a low lipid diet for the purpose of combating malaria is 
likely overweighed by their downsides. 
 
Finally, it is very important to have a comprehensive understanding of the relationship between 
the effectiveness of antimalarials and the levels of serum lipids in the host. As mentioned in the 
introduction, arteminisin is one of the most commonly used antimalarials yet it has a short 
plasma half-life of 1-3 hours. This can lead to failure rates since it is metabolized so quickly. 
There have been a number of publications in addressing whether high fat diets lead to more 
bioavailability of antimalarials with high levels of lipid solubility 249, 250 71. It is clear that the 
administration of a single high-fat meal would not significantly impact the bioavailability of 
piperaquine,  yet long-term effects of high fat versus low fat diets on antimalarial activities has 
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yet to be addressed. The mouse models we presented in Chapter 3 would be useful tools in 
discovering whether a long-term reduction in fatty acids impacts the absorption of antimalarials. 
It would also be useful to determine whether there is a correlation between antimalarial activity 
and cases of malnutrition. Further investigation into the fatty acid and other lipid levels impact 
has on antimalarial therapies will have significant consequences on antimalarial treatment 
regimens.   
 
FUTURE DIRECTIONS FOR THE FIELD OF LIPID BIOLOGY IN 
PLASMODIUM PARASITES 
The future of work in the field of fatty acid and lipid metabolism in Plasmodium parasites should 
take advantage of the stage specificity of the pathways. Data from this work and other 
publications from the field have indicated the necessity of scavenging fatty acids from the 
environment for the pathogenesis of Plasmodium parasites during blood stage replication. These 
findings imply an essential role for genes involved in the scavenge pathway during this stage of 
replication. Furthermore, many of these genes are expressed to a higher degree at blood-stage 
and are even specifically regulated for expression within the intraerythrocytic period 181. 
 
We suggest using this knowledge of the importance of scavenging of host lipids during blood-
stage for the development of chemotherapies that can treat Plasmodium infections after the 
demonstration of clinical symptoms. We suggest targeting the Acyl-CoA Synthase gene family 
as these genes failed to be disrupted in Plasmodium berghei (data from our lab, not shown). 
Other proteins involved in the fatty acid scavenge pathway include the Acyl-CoA Binding 
proteins. The considerable polymorphism and redundancy in these gene families make them 
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likely essential in parasite development and unique in structure which make the good drug 
targets.   
 
Other Plasmodium blood-stage lipid synthesis pathways that are also candidates for 
chemotherapeutics include the synthesis of major phospholipids, phosphatidylcholine and 
phosphatidylethanolamine 172. The parasite completes a major amount of modification to 
imported fatty acids, which may also be essential for parasite development. The Plasmodium 
phosophlipid pathway has already shown to be targeted during blood-stage with compounds that 
mimic the structure of membrane precursors, such as ethanolamine, serine or choline 251. 
Compounds that target these pathways inhibit parasite proliferation in the micromolar range.  
 
In addition, targeting the lipoic acid scavenge pathway offers new potential for the development 
of malarial chemotherapies. The potency of 8-BOA treatment for both P. falciparum and P. 
berghei parasites demonstrates that inhibition of lipoic acid salvage pathway would be lethal to 
parasites. Although our studies with 8-BOA showed remaining amount of lipoylated protein in 
the human hepatocyte cells (HepG2) after treatment, 8-BOA is still active against mammalian 
lipoylated proteins. Other parasite specific chemical inhibitors to the lipoic acid scavenge 
pathway should be developed.  
  
Other Plasmodium lipid synthesis pathways we recommend targeting for disruption and the 
generation of the genetically attenuated parasite (GAP) vaccine. The critical difference between 
genes that have the potential for GAP development and pathways we recommend for targeting 
by chemotherapies, is whether they can be disrupted in blood-stage Plasmodium parasites. Genes 
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that can be disrupted through genetic modifications of P. falciparum or other human malarial 
strains, enable further testing for their arrest in liver-stage and ability to stimulate the immune 
response. If genes are unable to be disrupted in blood-stages, in P. falciparum or rodent malaria 
models, they are essential and offer potential for chemotherapeutic development.  
 
As shown in this work, lipoic acid synthesis pathway is not essential for blood-stages, however it 
has a critical role in Plasmodium liver-stage development. Similar to components of the FAS-II 
pathway, we suggest targeting these pathways for the generation of GAP vaccines to combat 
malaria.   
 
The lipid and fatty acid pathways of Plasmodium parasites offer potential for generating GAPs 
by design. Part of the attraction of using genes involved in the fatty acid and lipoic acid synthesis 
pathways for the development of GAPs is that they arrest later than other known genetically 
attenuated parasite strains. Parasites developing into the later stages of liver-stage development 
provide superior antimalarial immunity 107. Parasites that are disrupted for FAS-II genes develop 
later than radiation attenuated sporozoites and also other knock-out parasites tested. FAS-II 
knock-outs also generate a larger memory CD8+ T cell population than the other parasites, 
which confers greater level of protection to challenge. However, as mentioned earlier, there can 
be discrepancies between the mouse models of GAPs and disrupting the orthologous gene in 
human malaria. Mouse models of genetically attenuated parasites offer great potential for their 
design and testing, but validation in human malarial species should always be a consistent branch 
of the experimental procedure. The new developments of the humanized mouse provide great 




Finally, the future directions in the field of lipid biology of Plasmodium should include further 
investigation into how the fatty acid content of the host impacts the disease. Data we have shown 
in Chapter 3 demonstrated how changes in the fatty acid content of the host impact the rates of 
Plasmodium replication. However, the model systems presented in Chapter 3 to reproducibly 
lower fatty acids during Plasmodium replication in vivo should be further explored in the areas 
of transmission and drug solubility. The lipid content of the host can have a significant impact on 
how drugs are absorbed and their effectiveness in clearing infections. The nutritional status of 
the host also has a major impact on whether the immune system can successfully respond to 
infection. The interconnection that exists between nutrition, immunity, severity of disease and 
treatment outcome should be addressed in a multi-factorial manner. For instance, future work on 
malaria chemotherapeutic treatment should take into account the host’s nutritional status, in 
particular the fatty acid and triglyceride content. Likewise, the effectiveness of GAP vaccines 
may vary widely depending upon the nutritional status of the host and their ability to generate a 
protective immune response. Understanding interdependence between the host and pathogen 
fatty acid and lipid profiles in a detailed, molecular level is fundamental to understanding the 
disease and providing the best recommendations for antimalarial therapies and preventative 
treatments. The lipid metabolism of Plasmodium parasites and their hosts is a critical component 
in the design of new drugs, the administration of existing treatments, and the development of 
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